[
 {
  "document": {
   "authors": "Sonali Vaidya, Dhruv Rathod, Diana Imhof, Negin Babaiha, Martin-Hofmann-Apitius, Ulrich StÃ¶lzel",
   "contact_info": "Dhruv Chetanbhai Rathod",
   "copyright": "Copyright \u00a9 2023 Fraunhofer Institute SCAI, All rights reserved.",
   "description": "HemeKG",
   "licences": "MIT License",
   "name": "SHERPA-manual-curation",
   "version": "1.0.0"
  }
 },
 {
  "definitions": [
   {
    "namespace": {
     "keyword": "CHEBI",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20230925.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "DO",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "MESHD",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-diseases/mesh-diseases-20190128.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "HGNC",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20230925.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "GO",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "GOBP",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20190128.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "MESHPP",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20190128.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "MESH",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh/mesh-names-20181007.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "MGI",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-20230925.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "RGD",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-20230925.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "INTERPRO",
     "type": "URL",
     "value": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "MIRBASE",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "CONSO",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/conso/master/export/conso.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "FPLX",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "PFAM",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "HGNCGENEFAMILY",
     "type": "URL",
     "value": "https://raw.githubusercontent.com/pharmacome/terminology/73688d6dc24e309fca59a1340dc9ee971e9f3baa/external/hgnc.genefamily-names.belns",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "PUBCHEM",
     "type": "PATTERN",
     "value": "^\\d+$",
     "value_list": []
    }
   },
   {
    "namespace": {
     "keyword": "CL",
     "type": "PATTERN",
     "value": "^\\d+$",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "Score",
     "type": "PATTERN",
     "value": "0.\\d+",
     "value_list": []
    }
   },
   {
    "annotation": {
     "keyword": "DataSource",
     "type": "LIST",
     "value": null,
     "value_list": [
      "SHERPA-manual-curation"
     ]
    }
   },
   {
    "namespace": {
     "keyword": "PKG",
     "type": "PATTERN",
     "value": ".*",
     "value_list": []
    }
   }
  ]
 },
 {
  "statements_and_sets": [
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In AIP, there is a decreased function of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase (IDO) that forms the first and rate-limiting enzymatic step in kynurenine generation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "TDO2"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In AIP, there is a decreased function of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase (IDO) that forms the first and rate-limiting enzymatic step in kynurenine generation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "IDO1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Three porphyrias; acute intermittent porphyria (AIP), hereditary coproporphyria (HCP) and variegate porphyria (VP) are commonly labelled acute porphyrias (AP) since they can all present with episodic acute neurovisceral attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table: Classifications and principal clinical features"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 17-year-old woman with acute intermittent porphyria presented with seizures, coma, and visual disturbance."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 17-year-old woman with acute intermittent porphyria presented with seizures, coma, and visual disturbance."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "coma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 17-year-old woman with acute intermittent porphyria presented with seizures, coma, and visual disturbance."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "visual disturbances"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Second, the concurrent occurrence of AIP with PRES is exceptionally rare."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The patient also presented with PRES, an uncommon clinical syndrome characterized by reversible changes in the posterior white matter of the brain, and often associated with hypertension, immunosuppressive therapy, or other causes"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Finally, AIP is a rare differential diagnosis of acute motor axonal neu ropathy and should be suspected when associated with abdominal pain in young women."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "GBS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Finally, AIP is a rare differential diagnosis of acute motor axonal neu ropathy and should be suspected when associated with abdominal pain in young women."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria is not a single disease but a group of nine disorders: acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), variegate porphyria (VP), deltaaminolevelunic acid dehyratase deficiency porphyria (ADP), porphyria cutanea tarda (PCT), hepatoerythropoetic porphyria (HEP), congenital erythropoetic porphyria (CEP), erythropoetic protoporphyria (EPP), and X-linked protoporphyria (XLP)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute intermittent porphyria (AIP) has been associated with schizophrenia in some studies, but prior research is limited by the absence of comparison populations"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Latent AIP mutations may be responsible for the finding that first-degree relatives of individuals with AIP, without manifest AIP themselves, also were at increased risk of being diagnosed with schizophrenia or bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AIP is an unusual autosomal dominant disorder resulting in neurovisceral attacks, occurring mostly in women."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute Disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Psychosis may also occur."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Psychotic Disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute intermittent porphyria (AIP) is a rare inherited metabolic disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "metabolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AIP is a rare hereditary metabolic disorder, one of the porphyrin metabolic disorders."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "metabolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus nephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Takayasu arteritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Conclusions: Methotrexate and actinomycin D did not induce acute porphyric attacks in this patient with acute intermittent porphyria; however, severe adverse effects were noted with methotrexate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Methotrexate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "(2) showed in vitro the porphyrinogenic quality of lamotrigine (LTG), tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tiagabine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of \u00c3\u017d\u00c2\u00b4-aminolevulinic acid synthase."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tiagabine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "(2) showed in vitro the porphyrinogenic quality of lamotrigine (LTG), tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "felbamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of \u00c3\u017d\u00c2\u00b4-aminolevulinic acid synthase."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "felbamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "(2) showed in vitro the porphyrinogenic quality of lamotrigine (LTG), tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "lamotrigine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# Eslicarbazepine for focal epilepsy and acute intermittent porphyria* Tamara Herrera-Fortin, Raluca Pana, Ewa Wesolowska, Josiane Bourr\u00c3\u0192\u00c2\u00a9-Tessier, Dang K. Nguyen University of Montreal Hospital Center, Montreal, Quebec, Canada Received January 6, 2020; Accepted March 12, 2020 #### Abstract porphyrias are rare genetic disorders which cause a deficiency in the enzymes involved in the biosynthesis of heme."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Eslicarbazepine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Combining the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s clinical symptoms (epileptic seizures, intermittent abdominal pain, and muscle atrophy), imaging fndings (reversible abnormal signals on cranial MRI), and the detection of a heterozygous c.445C>T mutation in the HMBS gene, our hospital de fnitively diagnosed AIP complicated by PRES."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In this case, the patient presented initially with epilepsy, accompanied byPRES.It is relatively rare for AIP patients to present epilepsy as the frst symptom."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The patient also presented with PRES, an uncommon clinical syndrome characterized by reversible changes in the posterior white matter of the brain, and often associated with hypertension, immunosuppressive therapy, or other causes"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute Intermittent porphyria With Epilepsy as the Initial Symptom and Posterior Reversible Encephalopathy Syndrome: A Case Report"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The diagnosis and treatment of a young patient with AIP who showed epilepsy and posterior reversible encephalopathy syndrome (PRES) as the frst symptoms, who was admitted to our department, are reported."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Given the several atypical features for GBS, the diagnosis of acute intermittent porphyria (AIP) was finally suspected with significant delay."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "GBS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "First, it presents an atypical initial manifestation of AIP: epilepsy, which is rarely reported as the frst symptom in AIP patients, who more commonly present with abdominal pain or neuropsychiatric symptoms"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Combining the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s clinical symptoms (epileptic seizures, intermittent abdominal pain, and muscle atrophy), imaging fndings (reversible abnormal signals on cranial MRI), and the detection of a heterozygous c.445C>T mutation in the HMBS gene, our hospital de fnitively diagnosed AIP complicated by PRES."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute intermittent porphyria (AIP) is a rare hereditary metabolic disorder, manifesting in a series of neuropsychiatric symptoms andabdominalpain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In 1939, Waldenstr\u00c3\u0192\u00c2\u00b6m ^2 noted that schizophrenia was common in families with AIP, but no statistical support was provided."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Combining the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s clinical symptoms (epileptic seizures, intermittent abdominal pain, and muscle atrophy), imaging fndings (reversible abnormal signals on cranial MRI), and the detection of a heterozygous c.445C>T mutation in the HMBS gene, our hospital de fnitively diagnosed AIP complicated by PRES."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition, there seemed to be an overrepresentation of women among those who had both AIP and bipolar disorder, but the small number of observations did not allow formal testing of this potentially important finding."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "population"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Women"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We confirmed AIP by the change in urine color when exposed to light and by high urinary porphobilinogen titration."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, elevated serum, urinary and faecal porphyrins as well as urinary porphobilinogen and D-aminolevulinic acid (table 1) suggested a diagnosis of acute intermittent porphyria (AIP), later supported by the identification of a mutation in the hydroxymethylbilane synthase (HMBS) gene (p. R167W c.499C \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 T)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute intermittent porphyria (AIP) is a rare hereditary metabolic disorder, manifesting in a series of neuropsychiatric symptoms andabdominalpain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mental illness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "First, it presents an atypical initial manifestation of AIP: epilepsy, which is rarely reported as the frst symptom in AIP patients, who more commonly present with abdominal pain or neuropsychiatric symptoms"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mental illness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "First, it presents an atypical initial manifestation of AIP: epilepsy, which is rarely reported as the frst symptom in AIP patients, who more commonly present with abdominal pain or neuropsychiatric symptoms"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In this case, the patient presented initially with epilepsy, accompanied byPRES.It is relatively rare for AIP patients to present epilepsy as the frst symptom."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The presence of epilepsy in patients with AIP may indicate a broader neurological impact, requiring further detailed neurological evaluation and monitoring."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute Intermittent porphyria With Epilepsy as the Initial Symptom and Posterior Reversible Encephalopathy Syndrome: A Case Report"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The diagnosis and treatment of a young patient with AIP who showed epilepsy and posterior reversible encephalopathy syndrome (PRES) as the frst symptoms, who was admitted to our department, are reported."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two and a half years after she was diagnosed with AIP, she was diagnosed with PSS based on dryness of the eyes and mouth, the elevation of immunoglobulins (IgG and Ig A ) and positive results on an anti-SS-A antibody test, an anti-SS-B antibody test, Schirmer's test and a labial gland biopsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "IgG"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Combining the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s clinical symptoms (epileptic seizures, intermittent abdominal pain, and muscle atrophy), imaging fndings (reversible abnormal signals on cranial MRI), and the detection of a heterozygous c.445C>T mutation in the HMBS gene, our hospital de fnitively diagnosed AIP complicated by PRES."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Muscular Atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, elevated serum, urinary and faecal porphyrins as well as urinary porphobilinogen and D-aminolevulinic acid (table 1) suggested a diagnosis of acute intermittent porphyria (AIP), later supported by the identification of a mutation in the hydroxymethylbilane synthase (HMBS) gene (p. R167W c.499C \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 T)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Atypical imaging of the lesions extension: A 17-year-old woman with acute intermittent porphyria presented with seizures, coma, and visual disturbance."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "visual disturbance"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyria was initiated by oxybutynin, precipitated by Bactrim, and became full-blown after metronidazole administration."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Case presentation: In this report, we present a case of an invasive mole with lung metastasis in a 49-year-old Japanese woman who had previously been diagnosed with acute intermittent porphyria at 27 years of age but had no recent history of acute intermittent porphyria attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "invasive mole"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "She was subsequently diagnosed with a acute intermittent porphyria hydatidiform mole via dilatation and curettage (D C)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hydatidiform mole"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Possible GI signs include ileal infarction in acute intermittent porphyria and villous atrophy in variegate porphyria (49,50)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "infarction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyria was considered only after the patient mani fested neuropsychiatric abnormalities with GBS on the differ ential list. Acute porphyria can mimic GBS clinically and is an important differential diagnosis of GBS"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "GBS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Symptoms of AIP typically manifest during acute attacks and may include severe abdominal cramps, a com mon initial symptom often leading to misdiagnosis as acute abdominal conditions, as observed in this case where the patient had intermittent abdominal pain without timely medical consultation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Epilepsy is a neurological disorder, with symptoms that difer from those of AIP, such as abdominal pain and neuropsychiatric symp toms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Individuals with AIP had a fourfold increased risk of schizophrenia or bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "individuals with AIP had double the risk of schizophrenia or bipolar disorder, suggesting that these associations may be as a result of common genetic influences."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Symptoms of AIP typically manifest during acute attacks and may include severe abdominal cramps, a com mon initial symptom often leading to misdiagnosis as acute abdominal conditions, as observed in this case where the patient had intermittent abdominal pain without timely medical consultation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute Disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s electromyographic fndings of neurogenic damage), seizures (consistent with the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The biochemical activity of acute intermittent porphyria was assessed using recorded maximal urinary porphobilinogen (U-PBG)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Initial diagnostic evaluations yielded no significant abnormalities; however, subsequent analysis revealed elevated urinary porphobilinogen, corroborating a diagnosis of acute intermittent porphyria (AIP)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid [\u00c3\u017d\u00c2\u00b4-ALA]) in the body [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Epilepsy is a neurological disorder, with symptoms that difer from those of AIP, such as abdominal pain and neuropsychiatric symp toms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mental illness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s electromyographic fndings of neurogenic damage), seizures (consistent with the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Muscular Atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1. Levels of Heme intermediates upon diagnosis and response to Hemin treatment."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Heptacarboxylporphyrin I"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Pentacarboxylporphyrin I"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Coproporphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s electromyographic fndings of neurogenic damage), seizures (consistent with the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Peripheral neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid [\u00c3\u017d\u00c2\u00b4-ALA]) in the body [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In using chick-embryo hepatocyte culture, Reynolds and Miska (2) developed an animal model for acute intermittent porphyria and analyzed the influence of certain AEDs on hepatic enzyme induction of \u00c3\u017d\u00c2\u00b4-aminolevulinic acid synthase."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s electromyographic fndings of neurogenic damage), seizures (consistent with the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscle weakness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s electromyographic fndings of neurogenic damage), seizures (consistent with the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neurological symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s electromyographic fndings of neurogenic damage), seizures (consistent with the patient\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Muscular Denervation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thus, PRES should be suspected when patients with SLE have acute headache and seizures, especially in those patients who have high blood pressure and are on immunosuppressive treatments."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Seizures may be due to hyponatremia or represent a neurological manifestation of porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": ", 1995 | Study in rat model Bolus dose safe | The relationship of seizures to porphyria is complex."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "B1-B4 are cranial Flair-MRI of a 20-year-old-woman with renal artery stenosis who presented headache and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal artery stenosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Pulmonary infections"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Seizures may be due to hyponatremia or represent a neurological manifestation of porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Atypical imaging findings involving basal ganglia and cerebellum: A 17-year-old woman with Takayasu arteritis developed headache and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "B1-B4 are cranial Flair-MRI of a 20-year-old-woman with renal artery stenosis who presented headache and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tachycardia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscle weakness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the following two years, the patient's epilepsy deteriorated with focal unaware seizures occurring every two to three months and eight episodes of convulsive status epilepticus despite optimizing dosages and replacing lacosamide with pregabalin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "status epilepticus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "While regarding quetiapine, the main restriction for its use lies in the gastrointestinal effects that could lead to a decrease in carbohydrate intake."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "coma"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "visual disturbances"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "visual disturbances"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "steroids"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "visual disturbances"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "immunosuppressant"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Early recognition of PRES is vital for the prompt management of hypertension, the correction of renal dysfunction and the withdrawal of the offending agents."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Therefore, the diagnosis of AIP should be considered when epilepsy is associated with PRES."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Therefore, the diagnosis of AIP should be considered when epilepsy is associated with PRES."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the renin\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153angiotensin system, increased blood pressure, water\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153sodium retention, metabolite accumulation, and damage to the blood\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153brain barrier."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Arterial Pressure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the renin\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153angiotensin system, increased blood pressure, water\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153sodium retention, metabolite accumulation, and damage to the blood\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153brain barrier."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Endothelium, Vascular"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Therefore, PRES should be suspected whenever patients develope headache or seizure after being given cyclosporine A. Prompt withdrawal of the offending drug is very important in such cases."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Therefore, PRES should be suspected whenever patients develope headache or seizure after being given cyclosporine A. Prompt withdrawal of the offending drug is very important in such cases."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The typical neuroimaging presentation of PRES is vasogenic edema predominantly involving the posterior white matter of the cerebral hemispheres, especially the bilateral parietooccipital lobes; the calcarine and paramedian occipital-lobe are usually spared."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vasogenic edema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Posterior reversible encephalopathy syndrome (PRES) is also an uncommon clinical syndrome characterized by localized cerebral edema in the posterior part of the brain, accompanied by abnormal signal changes in white matter areas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cerebral Edema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Apart from the known risk factors, such as hypertension, immunosuppressants, and renal failure of various etiologies may be the precipitants of PRES."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The patient also presented with PRES, an uncommon clinical syndrome characterized by reversible changes in the posterior white matter of the brain, and often associated with hypertension, immunosuppressive therapy, or other causes"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Apart from the known risk factors, such as hypertension, immunosuppressants, and renal failure of various etiologies may be the precipitants of PRES."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "immunosuppressant"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "SLE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Apart from the known risk factors, such as hypertension, immunosuppressants, and renal failure of various etiologies may be the precipitants of PRES."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This case report presents the case of a 20-year-old female patient who sought emergency medical attention for severe abdominal pain, nausea and vomiting, tachycardia, hypertension, and discolored urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The co-morbidities in those patients with high blood pressure included eclampsia, primary renal disease and lupus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tachycardia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This case report presents the case of a 20-year-old female patient who sought emergency medical attention for severe abdominal pain, nausea and vomiting, tachycardia, hypertension, and discolored urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tachycardia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The co-morbidities in those patients with high blood pressure included eclampsia, primary renal disease and lupus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A high proportion of patients had comorbidities, including peripheral neuropathy, hypertension, liver and kidney disease, and psychiatric disorders (Fig. 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with AHP had a higher risk of kidney cancer (0.8 % vs. 0.2 %, p<0.001), hypertension, and chronic kidney disease but no increase in risk for cardiovascular disease, except for cerebrovascular disease in patients with elevated U-PBG, (aHR =1.40 [95% CI:1.06-1.85])."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "kidney cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the renin\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153angiotensin system, increased blood pressure, water\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153sodium retention, metabolite accumulation, and damage to the blood\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153brain barrier."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Other Risk Factors for Development of Type II Diabetes Mellitus and Screening Interval There are several other risk factors increasing the risk of having/ developing type II DM; these include obesity, inactivity, high blood pressure, a family history of DM, and age."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Type II Diabetes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "autonomic dysfunction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "kidney cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153residual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ischaemic heart disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disorders include hypertension, arrhythmia, and respiratory arrest."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The diagnosis is simple and cost-effective, so measurement of urinary porphobilinogen should be routinely obtained in patients with axonal GBS."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "GBS"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As a differential diagnosis of Guillain Barr\u00c3\u0192\u00c2\u00a9 syndrome, acute porphyria was then considered and ultimately proved to be the diagnosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "GBS"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Another study showed a near fourfold increase in the risk of being diagnosed with schizophrenia (RR = 3.6) and bipolar disorder (RR = 3.7) in patients diagnosed with AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Borderline personality disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "First-degree relatives of these individuals have almost twice the risk of presenting schizophrenia (RR = 1.6) and bipolar disorder (R = 1.8) [10\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Borderline personality disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "More evidence is needed to establish the porphyria-precipitating effect of oxybutynin and metronidazole."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, all these drugs are available as oral preparations only and the treatment of status epilepticus in these patients therefore warrants the use of a rapidly acting drug which can be given parenterally and is safe in porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "status epilepticus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The difference between porphyria patients and the general population reached statistical significance for nervous system disorders, gastrointestinal disorders, renal disorders, mental disorders and pain (gastrointestinal diseases 22.2 % vs. 29.9 % p=.013, cardiovascular diseases 36.8 % vs. 41.7 % p=.150, renal diseases 6.4 % vs. 10.6 % p=.032, diseases of the nervous system 11.6 % vs. 20.5 % p=.0006, mental diseases 18.0% vs. 30.4% p = <.0001, pain 4.2% vs. 15.6% p = .0003)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "nervous system disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria may be categorized clinically as acute hepatic, blistering cutaneous, or nonblistering cutaneous depending on clinical features."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria may be categorized clinically as acute hepatic, blistering cutaneous, or nonblistering cutaneous depending on clinical features."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "F female, M male, A I P acute intermittent porphyria, H C P hereditary coproporphyria, A D H D attention deficit hyperactivity disorder, B I D bis in die, T I D ter in die ^a Diagnosis not confirmed ^b Although not a core symptom in porphyria, it was the reason that triggered the porphyria workup ^c Doses given daily unless stated otherwise."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mental illness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In one long-term study on a cohort of selected patients with symptomatic AIP, >50 % developed porphyria associated kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Based on the recorded causes of death, AHP patients had a higher risk of death related to renal disease ( n=12[1.0 %] vs. ref, n=37[0.3 %], p<0.001 ), PLC ( n=54[4.3 %] vs. ref, n=20[0.2 %], p<0.001 ) and porphyria ( n=10[0.8 %] vs. ref, n=0 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Seizures may be due to hyponatremia or represent a neurological manifestation of porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also review symptoms and pathologies of lead intoxication that affect enzymes that mediate heme synthesis and share features with porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The porphyrias are a group of rare metabolic diseases related to altered functions in the eight enzymatic steps in the heme synthesis pathway."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Genetic or acquired defects of one of the eight enzymes involved in the biosynthesis of heme can result in neurovisceral symptoms, cutaneous symptoms, or a combination of the two."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "skin disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The porphyrias are highly relevant to hepatologists since patients can present with symptoms and complications that require liver transplantation (LT), and some porphyrias are associated with a high risk for primary liver cancer (PLC)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "primary liver cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "primary liver cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Genetic or acquired defects of one of the eight enzymes involved in the biosynthesis of heme can result in neurovisceral symptoms, cutaneous symptoms, or a combination of the two."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neuralgia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "High\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090PLC risk and the need for LT assessment are among several reasons why hepatological expertise often is essential in the management of porphyria patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PLCD1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The heme biosynthetic pathway showing intermediates, enzymes and types of porphyria associated with each enzyme."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PPOX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Diagnosis should be suspected when there is prolonged and recurrent episodes of unexplained abdominal pain-particularly when it is associated with neurological complications such as peripheral motor neuropathy, convulsions, coma or bulbar paralysis, hyponatremia or prompted by fasting, diets, or exposure to certain medications [5]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Psychiatric symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Diagnosis should be suspected when there is prolonged and recurrent episodes of unexplained abdominal pain-particularly when it is associated with neurological complications such as peripheral motor neuropathy, convulsions, coma or bulbar paralysis, hyponatremia or prompted by fasting, diets, or exposure to certain medications [5]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "somatoform disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Table I. Use of antiepileptic drugs in porphyria | | | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | | Study | Study type | Result | | Gabapentin | | | | Krauss et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antiepileptic drugs"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Table I. Use of antiepileptic drugs in porphyria | | | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | | Study | Study type | Result | | Gabapentin | | | | Krauss et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Gabapentin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our current knowledge about AHP-related nonhepatic cancer risk, cardiovascular, and psychiatric comorbidity is limited, and it is unknown whether AHP-type or biochemical porphyria activity are associated with differences in risk."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "cancer risk"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The difference in cardiovascular disease between porphyria patients and the general population was not significant ( 41.73 % vs. 36.79 % p=.150 ).All diseases except renal diseases were more frequent in the reference group with fibromyalgia compared to the porphyria patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The difference between porphyria patients and the general population reached statistical significance for nervous system disorders, gastrointestinal disorders, renal disorders, mental disorders and pain (gastrointestinal diseases 22.2 % vs. 29.9 % p=.013, cardiovascular diseases 36.8 % vs. 41.7 % p=.150, renal diseases 6.4 % vs. 10.6 % p=.032, diseases of the nervous system 11.6 % vs. 20.5 % p=.0006, mental diseases 18.0% vs. 30.4% p = <.0001, pain 4.2% vs. 15.6% p = .0003)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseasess"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lead intoxication causes a 10 -fold increase in urine levels of ALA and normal or only slight increases in urine levels of PBG, as in ALADP porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead intoxication"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As in other acute porphyrias, the mechanism of neurological damage is not well understood."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, considering both the well-known role of kidney impairment in increasing plasma Hcy and the possible association between acute porphyrias and progressive impairment of kidney function (Table 1) (especially in patients presenting high ALA/PBG urinary excretion), in order to minimize this possible confounding factor, we controlled all our results for creatine clearance [1-2,8,10]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, MedicAlert (www.medicalert.org) provides bracelets and wallet cards that contain information on acute porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The metabolic (and clinical) activity of the acute porphyrias and the efficacy of therapy can be monitored by assessing metabolite excretion."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Chlorpromazine | Clonazepam, 1 mg BID, Nortriptyline 10 mg gradually increased to 50 mg ."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The porphyrias are a group of at least eight metabolic disorders caused by alterations in enzymes involved in heme biosynthesis (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two young adults, ages 21 and 23 years, with severe HEP developed generalized seizures and had neuroimaging evidence of cerebral cortical atrophy and calcifications in the frontal lobes, presumably related to hypoxic injury as in other porphyrias (Berenguer et al. 1997)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypoxic injury"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, considering both the well-known role of kidney impairment in increasing plasma Hcy and the possible association between acute porphyrias and progressive impairment of kidney function (Table 1) (especially in patients presenting high ALA/PBG urinary excretion), in order to minimize this possible confounding factor, we controlled all our results for creatine clearance [1-2,8,10]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney impairment"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also review symptoms and pathologies of lead intoxication that affect enzymes that mediate heme synthesis and share features with porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lead intoxication"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "He was diagnosed as having porphyria during an episode of status epilepticus 1 year previously based on a positive urinary test for porphobilinogen and had been receiving gabapentin and levetiracetam ever since."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "status epilepticus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is the most prevalent porphyria disease worldwide, with a prevalence in Denmark of approximately 1 / 10000,^2 yet little is known about its prognosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The term PCT was first suggested by Waldenstr\u00c3\u0192\u00c2\u00b6m ^10 in 1937 to distinguish this form of porphyria from the rare photomutilating congenital erythropoetic porphyria (Gunther's Disease)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ein Beispiel f\u00c3\u0192\u00c2\u00bcr die symptomatische, exogene Form einer PCT ist die durch Hexachlorbenzol ausgel\u00c3\u0192\u00c2\u00b6ste porphyria turcica."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Its maximal activity in hepatocytes is limited, such that, when ALA syn-thase-1 is induced, it becomes secondarily rate-limiting for porphyrin and heme synthesis, with marked accumulations of PBG and ALA, the biochemical hallmarks of active acute hepatic porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Some porphyrias are caused by processes in the liver,3 some can damage the liver, some can lead to primary liver cancer (PLC)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "primary liver cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The terms porphyrin and porphyria are derived from the Greek word porphyrus, meaning purple."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Some women have cyclic menstrual attacks, progesterone increases heme catabolism, and synthetic estrogens and progesterones induce porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "menstrual"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The annual incidence of PLC was 0.52 % when restricted to those with selfreported manifest porphyria disease only, and 0.86 % when further restricted to individuals with manifest AHP disease and aged 50 years or older."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PLCD1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Think of porphyria when a patient presents with unexplained abdominal and neuropsychiatric symptoms and/or photosensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropsychiatric symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most AEDs such as carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), and lamotrigine (LTG) may precipitate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phenytoin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Some porphyrias are caused by processes in the liver,3 some can damage the liver, some can lead to primary liver cancer (PLC)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Figure 1).4, 5, 6 Furthermore, a plasma fluorescence scan can discriminate the characteristic emission maxima of the metabolites and support the biochemical diagnosis (Table 1).6 Beside the hepatic and erythropoietic porphyrias, secondary elevation in porphyrins have been found in patients with other diseases\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009despecially in patients with chronic liver diseases (Supplementary Table 1).7, 8, 9, 10, 11, 12, 13 We review the pathogenesis, symptoms, and treatment of the most frequent porphyrias (PCT, AIP, and EPP) (Table 2).5, 6, 14 We present typical cases, diagnoses, and treatments and discuss therapeutic strategies in development."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "fluorescence"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Microabscesses formed under the stratum corneum, with neutrophilic and eosinophilic invasion, and neutrophilic exocytosis was observed in the epidermis (hematoxylin and eosin staining, \u00c3\u0192\u00e2\u20ac\u201d20 and \u00c3\u0192\u00e2\u20ac\u201d40 magnification) Table 3 porphyria classification | Type of porphyria | Enzyme inheritance | Inheritance | Clinical manifestation | | Urine concentration | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | | | | Skin | Neuropsychiatric | | | Plumboporphyria | Porphobilinogen synthase | AR, 9q34 | - | + | ALA COPRO-gen III | | Acute intermittent porphyria | Hydroxymethylbilane synthase | AD, 11q23 | - | + Abdominal pain, neuropathy, mental changes, and tachycardia | PBG \u00c3\u008f\u00c6\u2019-ALA | | Congenital erythropoietic | Uroporphyrinogen III synthase | AR, 10q26 | + | - Skin lesion and hepatopathy in early childhood | UPG I COPRO-gen I | | porphyria cutanea tarda | Uroporphyrinogen decarboxylase | AD, 1q34 | ++ | - Dark urine, occurring after middle age | UPG | | Hereditary coproporphyria | Coproporphyrinogen oxidase | AD, 9 | + | + Abd"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "exocytosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The porphyrias are a group of disorders of heme biosynthesis, each characterized by an enzymatic defect in the heme biosynthetic pathway."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "heme biosynthetic process"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias are characterized by attacks of neurovisceral manifestations such as seizures, neuropathy, and psychosis (Solinas and Vajda, 2004; Kauppinen, 2005)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Urine from porphyria patients may be dark or reddish in color due to the presence of excess porphyrins and related substances, and may darken further after exposure to light."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In PCT, a number of different liver diseases may precipitate into the liver disease, whereas, in EPP, it is the porphyria itself which leads to liver disease, due to progressive deposition and accumulation of insoluble protoporphyrinIX in hepatocytes and bile canaliculi."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It should be emphasized that our case report presents a patient with partial and secondarily generalized seizures within the scope of a cryptogenic focal epilepsy since childhood, and that no porphyria-induced generalized seizures as seen in a porphyric crisis were reported."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "generalized seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Recurrent attacks of porphyria may lead to progressive or irreversible neuropathy and prolonged debilitation [2, 11]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias are characterized by attacks of neurovisceral manifestations such as seizures, neuropathy, and psychosis (Solinas and Vajda, 2004; Kauppinen, 2005)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients can develop cirrhosis due to accu- mulation of porphyria in the hepatocytes and subsequent parenchymal damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our analysis corroborates some of the \u00c3\u00a2\u00e2\u201a\u00ac\u00c5\u201cred flags\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u009d identified in the EXPLORE Study (prospective, multinational, natural history study characterizing disease activity).9 As gastrointestinal disorders, pain, and neurological disorders are more common in porphyria patients than in the general population, it can be assumed that the combination of abdominal or back pain with at least one additional symptom, mainly of a neurological nature, is also applicable to this cohort and is expected to be encountered predominantly by the specified medical specialties."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastrointestinal disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our analysis corroborates some of the \u00c3\u00a2\u00e2\u201a\u00ac\u00c5\u201cred flags\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u009d identified in the EXPLORE Study (prospective, multinational, natural history study characterizing disease activity).9 As gastrointestinal disorders, pain, and neurological disorders are more common in porphyria patients than in the general population, it can be assumed that the combination of abdominal or back pain with at least one additional symptom, mainly of a neurological nature, is also applicable to this cohort and is expected to be encountered predominantly by the specified medical specialties."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neurological disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The major clinical manifestations of the porphyrias are either neurologic, usually in the form of acute attacks, or cutaneous, resulting from phototoxicity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MP",
         "name": "phototoxicity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "erythropoietic protoporphyrias (EPP and XLEPP) can develop a severe cholestatic liver disease that is often fatal without a liver transplantation. In AP, some patients have severe recurrent attacks that do not respond to treatment and LT is a curative treatment option. Hence, the treatment aims for LT in porphyrias can be quite different."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cholestatic liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "To our knowledge, this is the first study to explore the association between AIP and bipolar disorder and the largest to date to test the association between AIP and schizophrenia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Bipolar disorder was also included, due to its genetic overlap with schizophrenia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^3 Interestingly, the PBGD MspI 2.2 kb allele was subsequently associated with schizophrenia, ^4 but later studies failed to replicate this finding."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Current thinking is that decreased GABAergic neurons' activity in conjunction with increased glutamate release [25], increased oxidative stress [26\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2], and increased metabolites of kynurenine pathway [27] leads to disease pathology."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "tryptophan metabolic pathway"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intriguingly, the kynurenine pathway has been implicated in both schizophrenia ^13 and bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "tryptophan metabolic pathway"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Complicating matters further, some literature suggests individuals with porphyria are more likely to have anxious and obsessive personalities [11, 15].Additionally, somatoform disorders, in particular factitious disorder; a condition that if not identified, exposes the patient to unnecessary risks such as inadequate procedures and treatments, including potentially addictive drugs [12, 16]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "individuals with AIP had double the risk of schizophrenia or bipolar disorder, suggesting that these associations may be as a result of common genetic influences."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# Acute intermittent porphyria: comorbidity and shared familial risks with schizophrenia and bipolar disorder in Sweden"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In sum, we found strong associations between AIP and schizophrenia and bipolar disorder that merit further attention in research and clinical practice."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^12 Because our study is based on a considerably larger cohort of individuals with AIP as compared with prior studies, and because we were able to assess a matched unexposed cohort, it lends strong support for the idea that AIP is linked to schizophrenia and bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AIP can be seen as a natural model of psychotic and affective illness, as the signs and symptoms in many respects are similar to schizophrenia and bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intriguingly, the kynurenine pathway has been implicated in both schizophrenia ^13 and bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Recent Findings Recent literature begins to clarify associations between AP, schizophrenia, bipolar disorder, and other psychopathology."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intriguingly, the kynurenine pathway has been implicated in both schizophrenia ^13 and bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "tryptophan metabolic pathway"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 shows the most common psychiatric disorders implicated in acute porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Individuals with manifest AIP (exposure) and individuals with diagnoses of schizophrenia and bipolar disorder (outcomes) were identified through their first diagnoses of the respective disorder in the Swedish Patient Register."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "To assess risks of schizophrenia and bipolar disorder in individuals with manifest AIP (and their relatives) compared with individuals without manifest AIP (and their relatives), we estimated risk ratios (RRs) and 95 % confidence intervals using conditional logistic regressions."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Because shared familial risks, including genetic and environmental factors, are indicated when relatives of individuals with AIP have schizophrenia or bipolar disorder but not manifest AIP, ^11 we specified the analyses according to these conditions."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Compared with individuals without manifest AIP, individuals with AIP had fourfold increased risks of being diagnosed with schizophrenia ( RR=3.6,95 %CI 2.0-6.4 ) or bipolar disorder ( RR=3.7,95 %CI 2.1-6.7 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "First-degree relatives of individuals with AIP had double the risk of schizophrenia ( RR=1.6,95 % CI 1.0-2.7 ) and bipolar disorder ( RR=1.8,95 %CI 1.0-3.2, online Table DS1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We observed that individuals with manifest AIP had a fourfold excess risk of being diagnosed with schizophrenia or bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, first-degree relatives of individuals with AIP had double the risk of both schizophrenia and bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Here, we linked Swedish registers to examine the risk of schizophrenia and bipolar disorder in 717 individuals diagnosed with AIP and their first-degree relatives, compared with matched individuals without AIP and their first-degree relatives."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Individuals with AIP had a fourfold increased risk of schizophrenia or bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "individuals with AIP had double the risk of schizophrenia or bipolar disorder, suggesting that these associations may be as a result of common genetic influences."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# Acute intermittent porphyria: comorbidity and shared familial risks with schizophrenia and bipolar disorder in Sweden"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Therefore, PRES should be suspected whenever patients develope headache or seizure after being given cyclosporine A. Prompt withdrawal of the offending drug is very important in such cases."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cyclosporine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Despite having undergone several AED treatments [PHT, carbamazepine (CBZ), valproate (VPA), lamotrigine (LTG), primidone (PRM), and GBP] over the years, no seizure-free interval had been observed."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbamazepine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "After hematin administration and intense rehabilitation, the patient slowly recovered from the full-blown acute porphyria attack."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gastrointestinal diseases include abdominal pain, appendicitis, nausea and vomiting, constipation, diarrhoea and ileus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastrointestinal disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Six years ago, in the fifth week of pregnancy, the woman developed acute and severe diffuse abdominal pain, accompanied by nausea, vomiting, constipation, persistent chest, back, and lower back pain, and red urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Case Report A 24-year-old woman was admitted with generalized abdominal pain, constipation, and recurrent vomiting for 6 days."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We concluded that the attacks of acute porphyria occurred over a 2-month span, characterized by abdominal pain, constipation, autonomic neuropathy, peripheral neuropathy, psychosis, delirium, and metabolic disturbances."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Arnold Chiari malformation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This is often accompanied by constipation, nausea, vomiting, and symptoms of ileus and paresthesia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ileus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This is often accompanied by constipation, nausea, vomiting, and symptoms of ileus and paresthesia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "paresthesia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The diagnosis of porphyria was confirmed by a positive urine porphobilinogen on three consecutive samples."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The occurrence of PRES in AIP patients may be due to the abnormal accumulation of porphyrin metabolites in the body caused by AIP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias (APs) are inherited disorders caused by deficiencies in one of the enzymes involved in haem biosynthesis, leading to overproduction of potentially neurotoxic porphyrin precursors (delta-aminolaevulinic acid [ALA] and porphobilinogen [PBG]) in the liver when the rate-limiting enzyme, ALA synthase 1 (ALAS1), is activated."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Pulmonary infections"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cerebral Edema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Resultant overproduction of the neurotoxic intermediates \u00c3\u017d\u00c2\u00b4-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Coronary Artery Spasm"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In this case, the patient presented initially with epilepsy, accompanied byPRES.It is relatively rare for AIP patients to present epilepsy as the frst symptom."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The occurrence of epilepsy with PRES in AIP patients is relatively rare, suggesting that the neu rological efects of AIP may be more complex."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Consequently, there is only a limited range of alternative seizure treatments for patients with porphyria and coexisting epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two population studies from Canada reported a higher prevalence of stroke, diabetes, heart disease, high blood pressure, asthma, chronic bronchitis, stomach/intestinal ulcers, arthritis, thyroid conditions, migraine, Alzheimer's disease and cancer in persons with a history of epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "high blood pressure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two population studies from Canada reported a higher prevalence of stroke, diabetes, heart disease, high blood pressure, asthma, chronic bronchitis, stomach/intestinal ulcers, arthritis, thyroid conditions, migraine, Alzheimer's disease and cancer in persons with a history of epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "heart disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The second session addressed different aspects of brain development implicated in epileptogenesis, Renzo Guerrini presented data on genetic disorders of cortical development associated with epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "brain development"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The second session addressed different aspects of brain development implicated in epileptogenesis, Renzo Guerrini presented data on genetic disorders of cortical development associated with epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "genetic disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^70 Preliminary data from recent and small clinical series indicate that PGB and ZNS may represent valid alternatives as add-ons in brain tumour-related epilepsy, although larger studies are needed."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "brain tumour"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two population studies from Canada reported a higher prevalence of stroke, diabetes, heart disease, high blood pressure, asthma, chronic bronchitis, stomach/intestinal ulcers, arthritis, thyroid conditions, migraine, Alzheimer's disease and cancer in persons with a history of epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "asthma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two population studies from Canada reported a higher prevalence of stroke, diabetes, heart disease, high blood pressure, asthma, chronic bronchitis, stomach/intestinal ulcers, arthritis, thyroid conditions, migraine, Alzheimer's disease and cancer in persons with a history of epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "migraine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hematin therapy was eventually discontinued as the patient was convinced it worsened her epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Hematin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Nervous system disorders cover e.g. epilepsy, polyneuropathy, convulsions, paranesthesia, and motor weakness."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Nervous system disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A mutation in the HMBS gene was detected in the patient and her cousin, but the patient had more severe AIP and more severe symptoms (such as epilepsy and a limp), which may be related to the co-morbidity of PSS."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A mutation in the HMBS gene was detected in the patient and her cousin, but the patient had more severe AIP, more frequent seizures, and more severe symptoms (such as epilepsy and a limp), which may be related to the co-morbidity of PSS."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On the other hand, there were typical clinical manifestations of PSS such as dry eyes and a dry mouth, the elevation of immunoglobulins (IgG and IgA) and the results of Schirmer's test, an anti-SS-A antibody test, an anti-SS-B antibody test, and a labial gland biopsy were all positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "IgG"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry eyes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On the other hand, there were typical clinical manifestations of PSS such as dry eyes and a dry mouth, the elevation of immunoglobulins (IgG and IgA) and the results of Schirmer's test, an anti-SS-A antibody test, an anti-SS-B antibody test, and a labial gland biopsy were all positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "IgG"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry mouth"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Peripheral neuropathy causing pain and weakness can progress to quadraparesis and respiratory embarrassment."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Peripheral neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "quadraparesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of \u00c3\u017d\u00c2\u00b4-aminolevulinic acid synthase."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tiagabine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "glutamate reuptake"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "synaptic transmission, GABAergic"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The occurrence of PRES in AIP patients may be due to the abnormal accumulation of porphyrin metabolites in the body caused by AIP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cerebral Edema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Resultant overproduction of the neurotoxic intermediates \u00c3\u017d\u00c2\u00b4-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "response to oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Coronary Artery Spasm"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "Positive Glutamate Release"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neurotoxicity Syndromes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heme synthesis requires condensation of glycine and succinyl-CoA into 5-aminolevulinic acid (5-ALA) and the subsequent enzymatic conversion of 5-ALA into heme."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscle weakness"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscle weakness"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neuropathy, mostly muscle weakness, develops when contraindicated drugs are used."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscle weakness"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscle weakness"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hallucinations"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscle weakness"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "urinary retention"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients treated with givosiran may have normal excretion of porphyrin precursors, as levels usually normalise before chronic neurological symptoms subside.27 All comorbidities should be excluded in any patient with AP who has chronic symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neurological symptoms"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal artery stenosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal artery stenosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal artery stenosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus nephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal artery stenosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The co-morbidities in those patients with high blood pressure included eclampsia, primary renal disease and lupus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The co-morbidities in those patients with high blood pressure included eclampsia, primary renal disease and lupus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thus, PRES should be suspected when patients with SLE have acute headache and seizures, especially in those patients who have high blood pressure and are on immunosuppressive treatments."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "B1-B4 are cranial Flair-MRI of a 20-year-old-woman with renal artery stenosis who presented headache and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal artery stenosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Clinical Presentations and Prognosis Seizures and headache were the most common symptoms and occurred in 22 ( 91.7 % ) and 20 ( 83.3 % ) patients, respectively."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This case report presents the case of a 20-year-old female patient who sought emergency medical attention for severe abdominal pain, nausea and vomiting, tachycardia, hypertension, and discolored urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tachycardia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tachycardia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tachycardia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the following two years, the patient's epilepsy deteriorated with focal unaware seizures occurring every two to three months and eight episodes of convulsive status epilepticus despite optimizing dosages and replacing lacosamide with pregabalin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "status epilepticus"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "One patients was misdiagnosed during the initial stage because of atypical imaging findings, and 2 patients were diagnosed with lupus encephalopathy and given steroid and immunosupressant treatments."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "immunosuppressant"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Before the onset of neurological symptoms, 10 patients used steroids or immunosuppressants."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "immunosuppressant"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "steroids"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus nephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "connective tissue diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A1-A4 are cranial MRIs of a 23-year-old woman with eclampsia who presented with headache."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus nephritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A high proportion of patients had comorbidities, including peripheral neuropathy, hypertension, liver and kidney disease, and psychiatric disorders (Fig. 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association of CKD with AIP has been suggested since the 1990s. The clinical entity can be classified as porphyria- associated kidney disease (PAKD), as CKD is more likely to occur in symptomatic patients with PBG and ALA excess."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus nephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "connective tissue diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "SLE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lymphoma, renal disease, neuropathy, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association of CKD with AIP has been suggested since the 1990s. The clinical entity can be classified as porphyria\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090associated kidney disease (PAKD),23 as CKD is more likely to occur in symptomatic patients with PBG and ALA excess."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^39 HCP and VP can also cause skin photosensitivity that in AIP only occurs when severe renal disease leads to further accumulation of plasma porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal diseases are defined as renal insufficiency, renal colic and interstitial nephritis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "interstitial nephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "connective tissue diseases"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thrombocytopenic"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute renal failure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute renal failure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ten patients ( 41.7 % ) used steroids or immunosuppressants, three ( 12.5 % ) had acute renal failure before the symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute renal failure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "immunosuppressant"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thus, PRES should be suspected when patients with SLE have acute headache and seizures, especially in those patients who have high blood pressure and are on immunosuppressive treatments."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "SLE"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Die Therapie der ersten Wahl ist Chloroquin, das aber im Gegensatz zur Behandlung bei Malaria oder systemischem Lupus erythematodes (SLE) nur 2-mal/Woche in einer Dosis von 125 mg gegeben wird."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "SLE"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Malaria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Epilepsy, AIP, and SLE can also coexist independently, which was most likely the case with our patient who had a long-standing history of focal epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "SLE"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additional manifestations of HH include hyperpigmentation, cardiomyopathy, diabetes mellitus, hypogonadism, hypothyroidism, and arthropathy due to pseudogout."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiomyopathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# Chapter 1 Diagnosis of Dermatologic Cutaneous Diseases Review ## Diagnosing diabetes mellitus in patients with porphyria cutanea tarda Anne L. Christiansen ^1, MD (D), Anette Bygum ^2, DMSc, Ole Hother-Nielsen ^3, DMSc, and Lars M. Rasmussen ^1, DMSc ^1 Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense C, Denmark, ^2 Department of Dermatology and Allergy Centre, Odense University Hospital, Odense C, Denmark, and ^3 Department of Endocrinology, Odense University Hospital, Odense C, Denmark ## Correspondence Anne Lindegaard Christiansen, MD Department of Clinical Biochemistry and Pharmacology Odense University Hospital Kloevervaenget 47, Indgang 40 5000 Odense C Denmark E-mail: anne.lindegaard@rsyd.dk [^0] ## Abstract The prevalence of diabetes mellitus is increased in patients with porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Besides increased risk of developing hepatocellular carcinoma, these patients also have an augmented risk of developing diabetes mellitus (DM)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Takayasu arteritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Takayasu arteritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Takayasu arteritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus nephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Takayasu arteritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "purpura"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "purpura"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal artery stenosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "purpura"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "purpura"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus nephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "purpura"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "purpura"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Takayasu arteritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Methotrexate is commonly used to alleviate the symptoms of arthritis (11) and skin lesions (12) in patients with PSS."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Methotrexate"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "arthritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Methotrexate is commonly used to alleviate the symptoms of arthritis (11) and skin lesions (12) in patients with PSS."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Methotrexate"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "skin lesions"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A porphyrinogenic capacity has also been shown in in vitro studies on LTG and TGB."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tiagabine"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of \u00c3\u017d\u00c2\u00b4-aminolevulinic acid synthase."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "felbamate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "\u00c3\u017d\u00c2\u00b4-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A porphyrinogenic capacity has also been shown in in vitro studies on LTG and TGB."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "lamotrigine"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "visual disturbance"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "visual disturbance"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALAS1 overexpression may result in intra-hepatic PLP deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Pyridoxal-phosphate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, patients in the decompensated groups show also higher mean levels of Hcy/Cys ratio, suggesting a greater de rangement of Hcy trans-sulfuration pathway in these groups, which may result from PLP absolute/relative deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Pyridoxal-phosphate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe abdominal pain is the most common symptom and other symptoms may include: nausea, vomiting, constipation, muscle weakness, urinary retention, palpitation (due to a rapid heart rate and often accompanied by hypertension), confusion, hallucinations, and seizures pain in the back, arms and legs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Psychotic Disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Many studies show an association between acute por phyria and severe mental illness ["
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mental illness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It has become increasingly evident that AP is associated with a sig nificant risk of PLC."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "An association between PLC and AP was first reported in 1984 by Lithner and Wetterberg who identified 11 patients with PLC in a cohort of 206 patients with AIP in the north of Sweden between 1960 and 1981.4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Recent Findings Recent literature begins to clarify associations between AP, schizophrenia, bipolar disorder, and other psychopathology."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "psychiatric symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Psychiatric symptoms associated with porphyria can be difficult to identify."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "psychiatric disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The majority of PLC in patients with AP are hepatocellular carcinoma (HCC), but cholangiocarcinoma and mixed HCC- cholangiocarcinoma tumours have also been reported"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "catatonia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Mania"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depressive symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Suicide ideation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Anxiety"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Phobias"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Obsessive-compulsive"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Somatoform disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Insomnia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Restlessness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Impulsive Behavior"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Delirium"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cognitive Dysfunction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Agitation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Histrionic Personality Disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Mental disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Chronic fatigue"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Mental Disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Conclusions: This study's findings, collected before the introduction of givosiran, as the first approved preventive therapy for acute porphyria in Europe, highlight the need for healthcare strategies and policies tailored to the complex needs of acute porphyria patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neuropathy is common in acute porphyria attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Psychiatric diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias (AP) are characterized by heme deficiency and induction of hepatic 5-aminole vulinate synthase (ALAS1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "heme deficiency"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The majority of PLC in patients with AP are hepatocellular carcinoma (HCC), but cholangiocarcinoma and mixed HCC- cholangiocarcinoma tumours have also been reported"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Cholangiocarcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The majority of PLC in patients with AP are hepatocellular carcinoma (HCC), but cholangiocarcinoma and mixed HCC- cholangiocarcinoma tumours have also been reported"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "mixed HCC-cholangiocarcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gastrointestinal diseases include abdominal pain, appendicitis, nausea and vomiting, constipation, diarrhoea and ileus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastrointestinal disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "After hematin administration and intense rehabilitation, the patient slowly recovered from the full-blown acute porphyria attack."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The second day after undergoing a Cesarean section, the woman had severe abdominal pain, accompanied by headaches, dizziness, blurred vision, and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "More evidence is needed to establish the porphyria-precipitating effect of oxybutynin and metronidazole."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyria was diagnosed, with acute intermittent porphyria as the working diagnosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "One telltale clinical pearl is that psychiatric symptoms favor acute porphyria over GBS [2]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Autonomic dysfunction of the gastrointestinal system, including constipation and abdominal pain, is frequently present in acute porphyria [9]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neurological symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Case Report A 24-year-old woman was admitted with generalized abdominal pain, constipation, and recurrent vomiting for 6 days."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyria needs to be ruled-out in patients with recurrent constipation and other abdominal symptoms, particularly after initiation of new medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In fact, this is the first reported case of acute porphyria in a patient with Arnold Chiari malformation, which are 2 separate genetic disorders."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Arnold Chiari malformation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We report an unusual case of acute porphyria in a patient with Arnold Chiari syndrome."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Arnold Chiari malformation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patient: Female, 33 Final Diagnosis: Acute porphyria Symptoms: Abdominal pain \u00c3\u201a\u00c2\u00b7"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "autonomic neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We concluded that the attacks of acute porphyria occurred over a 2-month span, characterized by abdominal pain, constipation, autonomic neuropathy, peripheral neuropathy, psychosis, delirium, and metabolic disturbances."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "delirium"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Case Report: A women with Arnold Chiari malformation type II who was treated with oxybutynin and antibiotics, including Bactrim for neurogenic bladder and recurrent urinary tract infection, presented with non-specific abdominal pain, constipation, and diarrhea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "psychiatric symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "psychiatric disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastrointestinal disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neuropathy is common in acute porphyria attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "skin disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "behavioural symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with AP are at risk of developing PLC"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "primary liver cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid (ALA)]"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neuralgia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscular pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscular weakness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatigue"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common manifestation is abdominal pain (often accompanied by constipation and signs of ileus), mimicking a surgical emergency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ileus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Six years ago, in the fifth week of pregnancy, the woman developed acute and severe diffuse abdominal pain, accompanied by nausea, vomiting, constipation, persistent chest, back, and lower back pain, and red urine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lower back pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The second day after undergoing a Cesarean section, the woman had severe abdominal pain, accompanied by headaches, dizziness, blurred vision, and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headaches"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The second day after undergoing a Cesarean section, the woman had severe abdominal pain, accompanied by headaches, dizziness, blurred vision, and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dizziness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with AP, mainly acute intermittent porphyria, have a significantly increased risk for PLC that warrants surveillance and adequate follow-up of high-risk groups."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Long- term complications of acute porphyria include chronic hypertension with renal impairment,10 liver damage and liver carci noma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We then seriously considered acute porphyria given her recurrent abdominal symptoms, medication history, and man ifestations of acute porphyria overlapping with GBS"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "GBS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We then seriously considered acute porphyria given her recurrent abdominal symptoms, medication history, and man ifestations of acute porphyria overlapping with GBS"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Symptomatic AP patients had significantly higher urinary ALA and PBG levels, plasma Hcy, HHcy prevalence and Hcy/Cys ratio when compared to asymptomatic carriers of AP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid (ALA)]"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid (ALA)]"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Symptomatic AP patients had significantly higher urinary ALA and PBG levels, plasma Hcy, HHcy prevalence and Hcy/Cys ratio when compared to asymptomatic carriers of AP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Clinicians should therefore be aware of the long-term complications of AP, which typically include chronic neuropathy and encephalopathy, high blood pressure and porphyria-associated kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "encephalopathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In acute porphyria (AP), neurotoxic porphyrin precursors are produced in the liver and LT is a curative treatment option in patients with recurrent severe neuropathic attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neuralgia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Long- term complications of acute porphyria include chronic hypertension with renal impairment,10 liver damage and liver carci noma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Anxiety disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Long- term complications of acute porphyria include chronic hypertension with renal impairment,10 liver damage and liver carci noma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal impairment"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depression"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "asthenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "palpitation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Photosensitivity Disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Symptomatic AP patients had significantly higher urinary ALA and PBG levels, plasma Hcy, HHcy prevalence and Hcy/Cys ratio when compared to asymptomatic carriers of AP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Symptomatic AP patients had significantly higher urinary ALA and PBG levels, plasma Hcy, HHcy prevalence and Hcy/Cys ratio when compared to asymptomatic carriers of AP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "homocysteine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mean plasma homocysteine was significantly higher in patients with biochemical signs of decompensated disease"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "homocysteine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias (AP) are characterized by heme deficiency and induction of hepatic 5-aminole vulinate synthase (ALAS1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid (ALA)]"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In acute porphyria (AP), neurotoxic porphyrin precursors are produced in the liver and LT is a curative treatment option in patients with recurrent severe neuropathic attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "porphyrin precursors"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Clinicians should therefore be aware of the long-term complications of AP, which typically include chronic neuropathy and encephalopathy, high blood pressure and porphyria-associated kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Clinicians should therefore be aware of the long-term complications of AP, which typically include chronic neuropathy and encephalopathy, high blood pressure and porphyria-associated kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "high blood pressure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The doctors at Saitama Medical Center told me that methotrexate (MTX) was most commonly used to treat my disease (invasive mole with lung metastasis) but had not been implicated as either porphyrinogenic or nonporphyrinogenic, and therefore, they carefully treated me with MTX."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "invasive mole"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methotrexate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with AP, mainly acute intermittent porphyria, have a significantly increased risk for PLC that warrants surveillance and adequate follow-up of high-risk groups."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Liver cirrhosis, which is found in over 80 % of patients with PLC in the general population [13], is typically not observed in AHP patients with PLC [6, 8, 12].Although leading theories regarding the pathogenesis linking AHP and PLC suggest that AHP could increase the risk of cancers in general [14-16], currently there is not, to our knowledge, any published evidence that persons with AHP are at an increased risk of any other cancers."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The initial diagnosis and differential diagnosis of porphyrias continue to rely on biochemical, quantitative determinations of the porphyrin precursors and porphyrins in urine, stool, plasma and heparinized blood."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Clinical features of CEP\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009dThe phenotype can vary depending on the severity of the inherited UROS mutations and levels of porphyrins in plasma and erythrocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Light that corresponds to the Soret band that maximally photoactivates porphyrins passes through window glass; therefore porphyric patients are not fully protected from skin photosensitivity by remaining indoors or in automobiles."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "Light"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Because of their ability to absorb electromagnetic radiation from sunlight and their similarity to chlorophyll, which captures energy for photosynthesis, porphyrins are important pigments of life."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chlorophyll"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Physical stress, menstruation, pregnancy, alcohol, pork bacon, and selected foods that contain porphyrins were found to increase urinary porphyrin concentrations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "menstruation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal failure with loss of urinary excretion requires porphyrin analysis in serum or plasma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Phlebotomy is first-line treatment and mitigates the presence of iron overload, and hydroxychloroquine serves to inhibit porphyrin formation and promote urinary excretion of the porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Figure 1).4, 5, 6 Furthermore, a plasma fluorescence scan can discriminate the characteristic emission maxima of the metabolites and support the biochemical diagnosis (Table 1).6 Beside the hepatic and erythropoietic porphyrias, secondary elevation in porphyrins have been found in patients with other diseases\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009despecially in patients with chronic liver diseases (Supplementary Table 1).7, 8, 9, 10, 11, 12, 13 We review the pathogenesis, symptoms, and treatment of the most frequent porphyrias (PCT, AIP, and EPP) (Table 2).5, 6, 14 We present typical cases, diagnoses, and treatments and discuss therapeutic strategies in development."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Figure 1).4, 5, 6 Furthermore, a plasma fluorescence scan can discriminate the characteristic emission maxima of the metabolites and support the biochemical diagnosis (Table 1).6 Beside the hepatic and erythropoietic porphyrias, secondary elevation in porphyrins have been found in patients with other diseases\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009despecially in patients with chronic liver diseases (Supplementary Table 1).7, 8, 9, 10, 11, 12, 13 We review the pathogenesis, symptoms, and treatment of the most frequent porphyrias (PCT, AIP, and EPP) (Table 2).5, 6, 14 We present typical cases, diagnoses, and treatments and discuss therapeutic strategies in development."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "fluorescence"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most porphyriarelated drugs are thought to induce cytochrome P450 activity and thus increase the demand for hepatic heme biosynthesis, leading to increased porphyrin formation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias (APs) are inherited disorders caused by deficiencies in one of the enzymes involved in haem biosynthesis, leading to overproduction of potentially neurotoxic porphyrin precursors (delta-aminolaevulinic acid [ALA] and porphobilinogen [PBG]) in the liver when the rate-limiting enzyme, ALA synthase 1 (ALAS1), is activated."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, PCT is also a less common cause of ESRD due to the accumulation of porphyrin, which damages the kidneys upon excretion. This accumulation of porphyrin is further exacerbated once the kidneys fail, leading to an increase in skin mani festations such as blistering of skin when exposed to sunlight and infections."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "They lead to the accumulation of porphyrins that cause skin photosensitivity and occasionally severe liver damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, PCT is also a less common cause of ESRD due to the accumulation of porphyrin, which damages the kidneys upon excretion. This accumulation of porphyrin is further exacerbated once the kidneys fail, leading to an increase in skin mani festations such as blistering of skin when exposed to sunlight and infections."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ESRD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute hepatic porphyrias (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and aminolevulinic acid dehydratase deficient porphyria) manifest in attacks and are characterized by overproduction of porphyrin precursors, producing often serious abdominal, psychiatric, neurologic, or cardiovascular symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In most cutaneous porphyrias, porphyrin-induced photosensitivity causes chronic skin fragility and formation of vesicles or bullae on light-exposed skin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bullae"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "When used, they should be used in lower than typical doses due to the rapid removal of accumulated porphyrin from the hepatocytes potentially causing necrosis and acute hepatitis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "necrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although some of these conditions, such as membranous glomerulonephritis or vasculitis, may instead have been coded as renal failure/chronic kidney disease (23 ICD-9 codes for the diagnosis of viral hepatitis have been tested and validated in the Veterans Administration healthcare system, and have demonstrated high specificity and positive predictive value in the identification of HCV-infected persons [13]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal failure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "J Clin Invest 56:661-667 11.Lee PK, Abrahams I, Bickers DR (1999) porphyria cutanea tarda occurring in a patient with renal failure, systemic lupus erythematosus and chronic hepatitis C infection treated with hemodialysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal failure"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a prolonged attack, acute peripheral neuropathy (PNP) and signs of central nervous system (CNS) involvement may occur. The prevalence of acute intermittent porphyria (AIP) has been estimated at 1:2000 based on likely pathogenic variations identified in the HMBS (hydroxymethylbilane synthase) gene in Caucasians, but the estimated risk of clinical symptoms in them is low, ~1%."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscle weakness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "insomnia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^57 Sufficient caloric support (carbohydrates, protein) is essential for treatment of AHP-especially when attacks are induced or amplified by low caloric intake, nausea, and vomiting, which are usually present in these patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "To date, there is no robust pathophysiological element to support a role for porphyrin precursors in renal cancer."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "kidney cancer"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "kidney cancer"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "autonomic dysfunction"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "autonomic dysfunction"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "kidney cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, different ICD-code distinctions between the ICD-9 (1987-1998) and ICD-10 (1997-2015) eras makes capture and labeling of some conditions such as atrial fibrillation and advanced stage chronic kidney disease (CKD) different between time periods."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrial fibrillation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with AHP had a higher risk of kidney cancer (0.8 % vs. 0.2 %, p<0.001), hypertension, and chronic kidney disease but no increase in risk for cardiovascular disease, except for cerebrovascular disease in patients with elevated U-PBG, (aHR =1.40 [95% CI:1.06-1.85])."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "kidney cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although some of these conditions, such as membranous glomerulonephritis or vasculitis, may instead have been coded as renal failure/chronic kidney disease (23 ICD-9 codes for the diagnosis of viral hepatitis have been tested and validated in the Veterans Administration healthcare system, and have demonstrated high specificity and positive predictive value in the identification of HCV-infected persons [13]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "membranous glomerulonephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In various conditions associated with PCT, such as chronic HCV and alcohol use, hepcidin levels are low compared with controls."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT results from the inhibition of hepatic UROD, a cytoplasmic housekeeping enzyme that converts uroporphyrinogen to coproporphyrinogen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda is the result of absent or defective uropor phyrinogen III decarboxylase (UROD), the enzyme responsible for the conversion of uroporphyrinogen III into coproporphyrinogen III."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is caused by reduced ( <50 % ) activity of uroporphyrinogen decarboxylase (Uro-D)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT, the most common of the human porphyrias, is caused by deficiency in activity of hepatic uroporphyrinogen decarboxylase, the enzyme responsible for the stepwise decarboxylation of uropor phyrinogen to coproporphyrinogen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## DISCUSSION porphyria cutanea tarda is the most common form of porphyria and is caused by a deficiency of uroporphyrinogen decarboxylase in the liver (1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda (PCT) is a metabolic disease where the fifth enzyme in the heme synthesis, uroporphyrinogen decarboxylase (UROD), has reduced activity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of porphyria cutanea tarda involves deficiency and inhibition of uroporphyrinogen decarboxylase."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT results from the inhibition of hepatic UROD, a cytoplasmic housekeeping enzyme that converts uroporphyrinogen to coproporphyrinogen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Coproporphyrinogen III"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda is the result of absent or defective uropor phyrinogen III decarboxylase (UROD), the enzyme responsible for the conversion of uroporphyrinogen III into coproporphyrinogen III."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Coproporphyrinogen III"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Conclusions: These results indicate that ESRD patients with PCT are actually at decreased risk of some infections compared with ESRD patients without comorbid disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "infections"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Results: PCT was associated with a significantly decreased risk for 3 out of the 5 outcomes: bacterial infections (adjusted odds ratio: 0.50 ; 95 % confidence interval: 0.43-0.58 ), cellulitis ( 0.61 ; 0.53-0.71 ), and bacteremia (0.44 ; 0.38-0.52)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bacteremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Urine porphobilinogen is normal in PCT, and ALA is normal or only mildly increased."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 2"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 2"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients have an increased risk of developing hepatocellular carcinoma14 and diabetes mellitus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pitfalls in the different tests along with the interfering comorbidities and treatments concerning patients with porphyria cutanea tarda complicate diagnosing these patients with diabetes mellitus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15031049.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Irrespective of whether the increased risk of hepatocellular carcinoma in patients with PCT simply results from sporadictype PCT being a marker for common causes of liver cirrhosis, or whether the explanation for the association is more complex, ^2 one of the reasons why the recognition of PCT is important is that it is a marker for potentially treatable risk factors for hepatocellular carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients have an increased risk of developing hepatocellular carcinoma14 and diabetes mellitus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association of liver disease, particularly alcoholic liver disease, and PCT was recognized by Brunsting et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Also, most have reported relatively static estimates of cumulative prevalence and have not included some of the serious, but less commonly encountered, extrahepatic manifestations of HCV infection (e.g., mixed cryoglobulinaemia, membranous glomerulonephritis, porphyria cutanea tarda)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 2"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "glomerulonephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association of liver disease, particularly alcoholic liver disease, and PCT was recognized by Brunsting et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "SSTIs are char acterized by erythema, edema, warmth, and pain or tenderness, and the severity of the infection is highly dependent on comorbidities, critical illness, advanced age, immunocompromised status, hepatic or renal disease, and vascular insufficiency"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "erythema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "SSTIs are char acterized by erythema, edema, warmth, and pain or tenderness, and the severity of the infection is highly dependent on comorbidities, critical illness, advanced age, immunocompromised status, hepatic or renal disease, and vascular insufficiency"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Kynurenic acid, a product of tryptophan metabolism, is believed to contribute to the neuroregulation of glutamate and dopamine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Glucose Intolerance"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Kynurenic acid, a product of tryptophan metabolism, is believed to contribute to the neuroregulation of glutamate and dopamine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperinsulinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron overload can impact disease progression and treatment options for patients with comorbid conditions, such as porphyria cutanea tarda, hepatitis C virus, and coronary artery disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most patients with PCT have evidence of siderosis on liver biopsy, and the disease resolves with iron deple tion."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "siderosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In contrast, there is little experience concerning antiepileptic drug (AED) treatment in patients with porphyria cutanea tarda (PCT)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antiepileptic drug"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic hepatitis C is another risk factor for porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The results were interpreted to indicate that the effect of ethanol to produce a porphyria cutanea tarda phenotype is mediated by effects of alcohol on iron metabolism, specifically an effect to increase iron within hepatocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ethanol"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Commonly seen SSTIs include ab scesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cellulitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Commonly seen SSTIs include ab scesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abscess"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Commonly seen SSTIs include ab scesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "folliculitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "SSTIs are char acterized by erythema, edema, warmth, and pain or tenderness, and the severity of the infection is highly dependent on comorbidities, critical illness, advanced age, immunocompromised status, hepatic or renal disease, and vascular insufficiency"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "edema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Dark urine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT can be further complicated by skin and soft tissue infections (SSTIs)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "soft tissue infections"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Commonly seen SSTIs include ab scesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Methicillin Resistant Staphylococcus aureus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 2"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cystic Kidney"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This study, comprising 108 patients with PCT, was intended to define the role of hemochromatosis gene (HFE) mutations in the expression of PCT and to determine the contribution of acquired factors including alcohol, hepatitis C virus (HCV), and estrogen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, pa tients with PCT also have an increased prevalence of impaired glucose tolerance and diabetes mellitus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with PCT are at increased risk for liver cancer and may benefit from surveillance, especially if they have advanced fibrosis or cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Consequently, these characteristics are common among patients with PCT and may explain why they have an increased risk of liver cancer and, possibly, other cancers"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with PCT are at increased risk for liver cancer and may benefit from surveillance, especially if they have advanced fibrosis or cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HIV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There is also a strong association between PCT and chronic HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other common cutaneous manifesta tions seen include hypertrichosis, hyperpigmentation, and a thickened appearance of the skin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other common cutaneous manifesta tions seen include hypertrichosis, hyperpigmentation, and a thickened appearance of the skin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperpigmentation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We defined the biochemical diagnosis of PCT as either urine urocarboxylporphyrin/creatinin greater than 6\u00c3\u201a\u00c2\u00b5mol/mol creatinine, plasma fluorescence emission peak at 615 to 620 nm, or fecal heptacarboxylporphyrin greater than 2 nmol/g (dry weight)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis C"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute myocardial infarction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Stroke"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neoplasms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Chronic obstructive pulmonary disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with PCT are at increased risk for liver cancer and may benefit from surveillance, especially if they have advanced fibrosis or cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is a known complication of ESKD, possibly due to iron over load resulting from a number of factors such as erythropoietin deficiency and the administration of exogenous iron."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "End Stage kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Urine porphobilinogen is normal in PCT, and ALA is normal or only mildly increased."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Individuals with end-stage renal disease (ESRD), a potential complication of PCT, also exhibit an increased risk of infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, PCT is also a less common cause of ESRD due to the accumulation of porphyrin, which damages the kidneys upon excretion. This accumulation of porphyrin is further exacerbated once the kidneys fail, leading to an increase in skin mani festations such as blistering of skin when exposed to sunlight and infections."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Reduced enzyme activity results in accumulation of porphyrins, heme intermediates, primarily in the liver and skin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Conclusions: Patients with PCT have increased mortality, primarily explained by an increased mortality from gastrointestinal diseases and from cancers of the gut, liver/gallbladder, and lungs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastrointestinal disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Manifestations of PCT include blistering of sun-exposed skin and liver disease due to the accumulation of porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association between PCT and impaired glucose metabolism is not fully understood but possibly implicates iron overload; a previous study showed that patients with PCT with persistently high ferritin levels were more likely to develop impaired glucose metabolism and diabetes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association between iron and PCT is well established. Siderosis is detected in up to 90% of patients who undergo liver biopsy, and a reduction in total body iron content by therapeutic phlebotomies leads to disease remission"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "siderosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT manifests as skin fragil ity, blistering cutaneous lesions on sun-exposed areas, dark urine, and elevated plasma and urine porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Dark urine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Dark urine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of PCT is thought to involve iron-generated free oxygen radicals that oxidize uroporphyrinogen, leading to the formation of a uroporphomethene inhibitor of UROD."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association between PCT and impaired glucose metabolism is not fully understood but possibly implicates iron overload; a previous study showed that patients with PCT with persistently high ferritin levels were more likely to develop impaired glucose metabolism and diabetes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Ferritins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Reduced enzyme activity results in accumulation of porphyrins, heme intermediates, primarily in the liver and skin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Manifestations of PCT include blistering of sun-exposed skin and liver disease due to the accumulation of porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT manifests as skin fragil ity, blistering cutaneous lesions on sun-exposed areas, dark urine, and elevated plasma and urine porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In all types of PCT, por phyrin accumulation and clinical symptoms of PCT do not occur unless UROD enzymatic activity falls below approxima tely 20% in the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "When hepatic UROD activity is reduced to less than 20% of normal activity, uroporphyrinogen and the porphyrinogens that are intermediates in its 4-step decarboxylation accumulate in the liver and are auto-oxidized to their corresponding porphyrins. After considerable accumulation in the liver, these porphyrins appear in plasma and bile and are excreted in the urine and stool."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastrointestinal disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neoplasms, Stomach"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Gallbladder Neoplasms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lung Neoplasms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Manifestations of PCT include blistering of sun-exposed skin and liver disease due to the accumulation of porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT manifests as skin fragil ity, blistering cutaneous lesions on sun-exposed areas, dark urine, and elevated plasma and urine porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The predominant clinical manifestations of PCT are skin fragility and blistering skin lesions."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The predominant clinical manifestations of PCT are skin fragility and blistering skin lesions."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT manifests as skin fragil ity, blistering cutaneous lesions on sun-exposed areas, dark urine, and elevated plasma and urine porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Due to the increased photosensitivity and skin fragility, PCT patients are more susceptible to infections."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "infections"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Manifestations of PCT include blistering of sun-exposed skin and liver disease due to the accumulation of porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Photosensitivity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Photosensitivity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Photosensitivity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is diagnosed biochemically by high levels of porphyrins in the plasma and urine, with a predominance of uroporphyrinogen and hepta- and hexa- and pentacarboxyl porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Uroporphyrinogen III"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is diagnosed biochemically by high levels of porphyrins in the plasma and urine, with a predominance of uroporphyrinogen and hepta- and hexa- and pentacarboxyl porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heptacarboxylporphyrin III"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heptacarboxylporphyrin III"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is diagnosed biochemically by high levels of porphyrins in the plasma and urine, with a predominance of uroporphyrinogen and hepta- and hexa- and pentacarboxyl porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "SNOMED",
         "name": "Hexacarboxylporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Uroporphyrin III"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, PCT is also a less common cause of ESRD due to the accumulation of porphyrin, which damages the kidneys upon excretion. This accumulation of porphyrin is further exacerbated once the kidneys fail, leading to an increase in skin mani festations such as blistering of skin when exposed to sunlight and infections."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ESRD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical manifestations of PCT are dermatological only and include increased skin fragility, bruising, vesicles, and bullae that may become hemorrhagic in the sun-exposed areas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bullae"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical manifestations of PCT are dermatological only and include increased skin fragility, bruising, vesicles, and bullae that may become hemorrhagic in the sun-exposed areas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bruising"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical manifestations of PCT are dermatological only and include increased skin fragility, bruising, vesicles, and bullae that may become hemorrhagic in the sun-exposed areas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemorrhagic"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHP",
         "name": "Blood Transfusion"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHP",
         "name": "Blood Transfusion"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHP",
         "name": "Blood Transfusion"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eclampsia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHP",
         "name": "Blood Transfusion"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "corticosteroids"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cyclosporine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "corticosteroids"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tacrolimus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "corticosteroids"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sirolimus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "corticosteroids"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "corticosteroids"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tacrolimus"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cyclosporine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "9"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sirolimus"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cyclosporine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sirolimus"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tacrolimus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thrombocytopenic"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thrombotic"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "One patients was misdiagnosed during the initial stage because of atypical imaging findings, and 2 patients were diagnosed with lupus encephalopathy and given steroid and immunosupressant treatments."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "encephalopathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, two cases in our study were diagnosed with lupus encephalopathy and were given steroid and immunosuppressant treatments that could increase blood pressure and aggravate endothelial injury."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "encephalopathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "encephalopathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "One patients was misdiagnosed during the initial stage because of atypical imaging findings, and 2 patients were diagnosed with lupus encephalopathy and given steroid and immunosupressant treatments."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "steroid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, two cases in our study were diagnosed with lupus encephalopathy and were given steroid and immunosuppressant treatments that could increase blood pressure and aggravate endothelial injury."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "steroid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lupus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In chronic antiepileptic treatment, carbamazepine (CBZ), oxcarbazepine (OXC) and PHT should be used with caution in patients with heart disease, and they should be avoided in the event of atrioventricular conduction dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbamazepine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "heart disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most AEDs such as carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), and lamotrigine (LTG) may precipitate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbamazepine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most AEDs such as carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), and lamotrigine (LTG) may precipitate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbamazepine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbamazepine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although some of these conditions, such as membranous glomerulonephritis or vasculitis, may instead have been coded as renal failure/chronic kidney disease (23 ICD-9 codes for the diagnosis of viral hepatitis have been tested and validated in the Veterans Administration healthcare system, and have demonstrated high specificity and positive predictive value in the identification of HCV-infected persons [13]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vasculitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In general, the patient with SLE often had underlying endothelial injury caused by vasculitis and/or its associated complications such as vessel spasm and angiopathy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vasculitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "spasm"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Pulmonary infections"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Blood chemistry revealed hyponatremia and persistent acute renal failure despite rehydration."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Attacks may be complicated by neurologic findings (mental changes, convulsions, and peripheral neuropathy that may progress to respiratory paralysis), and hyponatremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "An inappropriately high secretion of antidiuretic hormone (Schwartz-Bartter syndrome) leads to a potentially lifethreatening severe hyponatremia, another diagnostic feature of acute porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Laboratory analysis revealed a striking hyponatremia ( 117 mEq / L; normal >133 mEq / L ) with increased urine level of sodium ( 154 mEq / L )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sodium"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In this case, a comprehensive diagnostic evaluation was undertaken, which included analyzing biochemical assays, including those from her previous medical records to affirm the presence of SIADH characterized by hyponatremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "SIADH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Diagnosis should be suspected when there is prolonged and recurrent episodes of unexplained abdominal pain-particularly when it is associated with neurological complications such as peripheral motor neuropathy, convulsions, coma or bulbar paralysis, hyponatremia or prompted by fasting, diets, or exposure to certain medications [5]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "paralysis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "paralysis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "paralysis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "visual disturbance"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Visual disturbance occurred in 15 patients ( 62.5 % ), mental status change was found in 7 patients ( 29.2 % ), and paralysis was present in 2 patients ( 8.3 % )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "paralysis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "visual disturbance"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20572911.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 57-year-old man with focal segmental glomerulosclerosis presented with headache, hemiplesia, and visual disturbances."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "focal segmental glomerulosclerosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "headache"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AIP was controlled by administering high doses of human hemin, avoiding all contraindicated medications, controlling infections, and optimizing nutrition via a jeju nostomy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The treatment strategy for our patient, including intravenous hemin administration, discontinuation of so dium valproate (a known AIP exacerbant), and initiation of a high-carbohydrate diet, is consistent with the recom mendations in the Chinese Expert Consensus on Diagnosis and Treatment of AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and \u00c3\u017d\u00c2\u00b4-ALA), and alleviate symptoms"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and \u00c3\u017d\u00c2\u00b4-ALA), and alleviate symptoms"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Heptacarboxylporphyrin I"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Pentacarboxylporphyrin I"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Coproporphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and \u00c3\u017d\u00c2\u00b4-ALA), and alleviate symptoms"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "After hematin administration and intense rehabilitation, the patient slowly recovered from the full-blown acute porphyr ia attack."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients presenting with hyponatremia should receive heme therapy because hyponatremia can worsen with glucose infusions."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hemin is thought to work by decreasing levels of ALAS1, thereby reducing the production of toxic heme precursors [22\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u015324]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intravenous heme (Normosang; Orphan Europe, Puteaux, France, in Europe and some other regions, and Panhematin; Recordati Rare Diseases, Lebanon, NJ, in the United States, Mexico, and elsewhere) acts as a transcription factor that reduces expression of the ratelimiting hepatic enzyme ALAS1."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intravenous hemin administration (4mg/kg once daily for 7 consecutive days) to inhibit \u00c3\u017d\u00c2\u00b4-ALA synthase (ALAS) activity and reduce porphyrin precursor accumulation; discontinuation of sodium valproate (which may exacerbate AIP) and replacement with levetiracetam (500mgtwicedaily) for seizure control; and maintenance of acid-base balance, correction of electrolyte disturbances, and a high-carbohydrate diet (daily intake \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a5 300g) to stabilize metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and \u00c3\u017d\u00c2\u00b4-ALA), and alleviate symptoms"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nicillin, cephalosporins, imipenem, gentamicin, amikacin, vancomycin | | Physiotherapeutic measures from the very beginning | | of attacks resolved with supportive care, whereas the other two-thirds required heme therapy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "imipenem"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intravenous hemin administration (4mg/kg once daily for 7 consecutive days) to inhibit \u00c3\u017d\u00c2\u00b4-ALA synthase (ALAS) activity and reduce porphyrin precursor accumulation; discontinuation of sodium valproate (which may exacerbate AIP) and replacement with levetiracetam (500mgtwicedaily) for seizure control; and maintenance of acid-base balance, correction of electrolyte disturbances, and a high-carbohydrate diet (daily intake \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a5 300g) to stabilize metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and \u00c3\u017d\u00c2\u00b4-ALA), and alleviate symptoms"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Consistently, the metabolic task 'heme synthesis' was blocked in the porphyria models (Fig. 3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In porphyria patients, Hcy accumulation is likely to result from reduced hepatic CBS and CBL activity secondary to low heme availability and to possible intra-hepatic depletion of PLP due to the ALAS1 induction [10,25-27]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The porphyrias are a group of inherited disorders causing a deficiency in the heme synthesis pathway and consequently an accumulation of heme precursors (Solinas and Vajda, 2004; Kauppinen, 2005)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The porphyrias are a group of eight recognized diseases, mostly inherited, in which there are defects in normal porphyrin and heme synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In AP, a reduced hepatic trans-sulfuration activity, resulting from either a low heme availability (in case of CBS) and/or depletion of PLP due to ALAS1 induction, may be responsible for Hcy accumulation [10,25-27]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "PLP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The liver synthesizes 20 % of heme, which regulates its own production via interaction with 5-aminolevulinate synthase 1 (ALAS1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "regulates"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most anticonvulsants can aggravate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Many anticonvulsants can cause exacerbation of clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-5)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Each porphyria results from overproduction of heme precursors secondary to partial deficiency or, in XLP, increased activity of one of the enzymes of heme biosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most anticonvulsants can aggravate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Many anticonvulsants can cause exacerbation of clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-5)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HSCT corrects the defective heme pathway and should be considered early in patients with severe erythropoietic porphyrias to minimize end-organ damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "nan",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Etiology and pathogenesis of ADP\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009dALAD (ALA dehydratase; PBG synthase [EC 4.2.1.24]) catalyzes the formation of the monopyrrole PBG from two molecules of ALA, a precursor committed to synthesis of porphyrins, heme, and other tetrapyrroles."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Classification, inheritance and prevalence of the porphyrias Heme precursors in the various types of porphyria initially accumulate in either the liver or bone marrow, which are the tissues most active in heme biosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Heme synthesis | Prosthetic part of hemoglobin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hemoglobin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition, these patients may present psychiatric conditions secondary to the disease, such as adjustment disorder and substance use disorders."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "catalysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heme is essential for life and is often referred to as 'pigment of life' (48)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "pigment"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We empirically used high doses over several months as repeated tapering attempts were associated with rebounds of urinary porphobilinogen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Triggers such as drugs, fasting, or hormonal changes induce the first and rate limiting enzyme of the heme synthesis pathway, aminolevulinic acid synthase 1 (ALAS1), in the liver and cause downstream accumulation of 5-aminolevulinic acid (ALA) and porphobilinogen (PBG), cytotoxic porphyrin precursors associated with acute porphyria attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA is further metabolized to other heme precursors, and as a result coproporphyrin III is excreted in urine in large amounts and protoporphyrin IX is increased in erythrocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "coproporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients known to have a hepatic porphyria should not receive drugs such as carbamazepine (CBZ), VPA, PHT, CZP, DZP, and phenobarbital (PB), which are known to cause exacerbation of clinical symptoms by inducing hepatic heme synthesis ( 1-3,6,7 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^66 A 4.4-fold increase of reported AIP patients with recurrent attacks since the introduction of heme therapy (from 4 of 230 in 1985 to 40 of 536 in 2008) may be due to several reasons, including induction of heme oxygenase 1 , but also improved survival by heme therapy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "CBS and CGS activities require vitamin B6 (as PLP) and CBS also depends on heme as a cofactor [9,10,24]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "PLP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We concluded that the attacks of acute porphyria occurred over a 2-month span, characterized by abdominal pain, constipation, autonomic neuropathy, peripheral neuropathy, psychosis, delirium, and metabolic disturbances."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Arnold Chiari malformation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diarrhea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Autonomic dysfunction of the gastrointestinal system, including constipation and abdominal pain, is frequently present in acute porphyria [9]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Arnold Chiari malformation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gastrointestinal motility testing and electrogastrography (EGG) may provide a better understanding of the pathogenesis of chronic nausea and elucidate the potential role of chronic autonomic neuropathy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "autonomic neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Chronic pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Clinical manifestations of AIP are broad and include neurovisceral crises, neuropathy and a range of psychiatric symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "psychiatric symptoms"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A high proportion of patients had comorbidities, including peripheral neuropathy, hypertension, liver and kidney disease, and psychiatric disorders (Fig. 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "psychiatric disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A high proportion of patients had comorbidities, including peripheral neuropathy, hypertension, liver and kidney disease, and psychiatric disorders (Fig. 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "psychiatric disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Neuropathy is common in acute porphyria attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Psychiatric diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15031049.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In any patient who presents with photoexposed unilocular blisters and skin fragility, the diagnosis should be considered."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "skin disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "35193623.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Diagnostic reasons for disability pension that were increased compared to matched controls were PCT or skin disease in 11 of 199 cases (PCT: n=7, incident rate ratios [IRR] = 49.2, Cl=38.8,62.4; diseases of the skin and subcutaneous tissue, n=4, IRR=4.2, Cl=1.6,11.0 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "skin disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Due to the increased photosensitivity and skin fragility, PCT patients are more susceptible to infections."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "skin disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "infections"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mortality risk during follow-up was higher among patients with AHP ( 21 % vs. 18 %, p=0.001 ), and associated with primary liver cancer, female sex, and biochemical activity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "primary liver cancer"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "elevated peak PBG lev els were strongly associated with PLC risk while none of the gene carriers with only normal PBG (n = 345) developed PLC"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "primary liver cancer"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This was confirmed in a case\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153control study that also identified increasing ALA and PBG levels after age 65 as an indicator of increased risk of PLC."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "primary liver cancer"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALAS1 activity is dependent on vitamin B6 (Pyridoxal-phosphate, PLP) as cofactor [6,7]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Pyridoxal-phosphate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This hypothesis that porphyrins are toxic is supported by a study from 1992 that showed that patients with PCT who developed hepatocellular carcinoma had a longer untreated symptomatic period."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron as risk factor for hepatocellular carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Another minor risk factor is aflatoxin B1 consumption, which is responsible for most cases of hepatocellular carcinoma in Africa, where the consumption of contaminated foods is common."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "aflatoxin B1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The incidence of hepato-cellular carcinoma (HCC) in acute hepatic porphyria and the prevalence of patients with recurrent acute attacks of porphyria were also investigated (Innala and Andersson, 2011)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute hepatic porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Estrogens"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15031049.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009dI found Josep Llovet and colleagues\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2 Seminar on hepatocellular carcinoma (Dec 6, p 1907)1 helpful. Regarding risk factors, it is perhaps worth adding mention of porphyria cutanea tarda (PCT)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepatocellular carcinoma is currently one of the most frequently occurring tumors worldwide and it has a highly negative prognosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tumor"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heme groupcontaining proteins have essential and diverse functions in the body including oxygen transport, electron transfer, and catalysis and heme synthesis occurs in all nucleated cells [2]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depressive symptoms"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depressive symptoms"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Catatonia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depressive symptoms"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depressive disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Suicide ideation"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Suicide ideation"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depressive symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Suicide ideation"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Catatonia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Suicide ideation"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depressive disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Phobias"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Somatoform disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Insomnia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Restlessness"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Delirium"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Agitation"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We evaluated the AHP disease burden in patients aged \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a5 12 years in a post hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled ENVISION trial of givosiran (NCT03338816), an RNA interference (RNAi) therapeutic that targets the enzyme ALAS1 to decrease ALA and PBG production."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Givosiran therapy (siRNA for hepatic ALAS1) dramatically reduced plasma ALA levels within a few weeks. The drug has subsequently prevented attacks and reduced the severity of pain in AP patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Givosiran is a small interfering RNA that neutralizes excess ALAS1 mRNA in hepatocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Since givosiran prevents the accumulation of ALA and PBG and in theory, it could reduce the risk of PAKD if porphyrin precursor levels were normal in severely affected patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "These results showed that the RNAi therapeutic givosiran is effective in patients with recurrent AHP regardless of prior hemin use, and that it reduces analgesic use and pain both during and between porphyria attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In ENVISION, the number of porphyria attacks and attack severity were both reduced in patients receiving givosiran compared with those receiving placebo, regardless of prior hemin use."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, the current study highlights the severe disease burden associated with AHP, even in patients with a relatively low rate of attacks, and supports the effectiveness of givosiran for the management of certain acute and chronic porphyria symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^69 An interim analysis from a phase 3 trial (Envision) in 94 randomized patients with AHP and at least 2 attacks within 6 months before enrollment has been made public in April 2019, showing a significant reduction in the annualized rate of porphyria attacks, days of administered heme, and urinary ALA levels with Givosiran."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^68 The phase 1 trial with once monthly Givosiran demonstrated high efficacy in reducing acute attacks in 6 patients with AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We analyzed baseline AHP severity via chronic symptoms between attacks, comorbidities, concomitant medications, hemin-associated complications, and quality of life (QOL) and evaluated givosiran ( 2.5 mg / kg monthly) in patients with and without prior hemin prophylaxis on number and severity of attacks and pain scores during and between attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Conclusions: Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may partly be alleviated with givosiran."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "These results showed that the RNAi therapeutic givosiran is effective in patients with recurrent AHP regardless of prior hemin use, and that it reduces analgesic use and pain both during and between porphyria attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "analgesic"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Givosiran reduced the number and severity of attacks, days with worst pain scores above baseline, and opioid use versus placebo."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "opioid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Givosiran, an RNA interference therapy, is approved for the treatment of frequent recurrent attacks of AIP. Givosiran reduces the frequency of attacks, and the need for heme\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090infusion therapy, and improves the quality of life in many patients with severe forms of AP. Long\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090term outcomes and real\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090life studies of this relatively new treatment are promising but still limited. The introduction of givosiran will probably reduce the need for LT in AIP, but LT remains an important curative option when all other treatments fail."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "RNA interference"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Givosiran therapy (siRNA for hepatic ALAS1) dramatically reduced plasma ALA levels within a few weeks. The drug has subsequently prevented attacks and reduced the severity of pain in AP patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "severity of pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Of note, givosiran can cause transient deterioration in renal function, usually within the first 3 months of use, possibly related to local haem depletion. Long- term renal failure has also been reported in a few patients with pre- existing PAKD on givosiran. In addition, other GalNAc- conjugated siRNAs have caused mild nephropathy and hepatopathy in animal models. This is likely due to RNAi- mediated off- target effects rather than chemical modifications or perturbation of RNAi pathways, suggesting an inflammatory or immune response to these drugs. Longer and systematic nephrological follow- up is needed to assess which AP patients are at risk of developing CKD."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Autosomal recessive defects in ferrochetalase (FECH) cause erythropoietic protoporphyria (EPP), where accumulation and photoactivity of protoporphyrin mediate both skin and liver damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Autosomal recessive defects in ferrochetalase (FECH) cause erythropoietic protoporphyria (EPP), where accumulation and photoactivity of protoporphyrin mediate both skin and liver damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The liver damage is characterized by cholestasis due to protoporphyrin precipitation within hepatocytes and the intrahepatic biliary tree."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The liver damage is characterized by cholestasis due to protoporphyrin precipitation within hepatocytes and the intrahepatic biliary tree."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cholestasis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Symptomatic treatment for fatigue and nausea There is currently no validated treatment for fatigue."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatigue"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic pain, often moderately severe and mainly neuropathic in origin, is common in patients with severe recurrent attacks and is associated with fatigue and nausea, often resulting in poor quality of life."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatigue"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic pain, often moderately severe and mainly neuropathic in origin, is common in patients with severe recurrent attacks and is associated with fatigue and nausea, often resulting in poor quality of life."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Chronic pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Anxiety disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Kidney disease In patients with renal impairment, AEDs which are mainly eliminated by the kidneys will have a longer half life and tend to accumulate in the blood because of the reduced glomerular filtration rate and tubular secretion."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal impairment"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Antiepileptic treatment | | Psychiatric treatment | | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | | Recommended | To be avoided | Recommended | To be avoided | | Depression | CBZ, GBP, LTG, OXC, PGB, VPA | PB, PHT, PRM, TGB, TPM | Citalopram Escitalopram Sertraline Trazodone Venlafaxine | Amoxapine Maprotiline Bupropion | | Anxiety | BZD, GBP, PGB, VPA | LEV | BZD SSRIs | - | | Psychosis | LTG, OXC, VPA | ESM, LEV, TPM | Olanzapine Quetiapine Risperidone | Chlorpromazine Clozapine | Conversely, rifampicin reduces the plasma concentration of CBZ, LTG, PB, PHT and VPA."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depression"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Antiepileptic"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute abdominal pain"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Due to the increased photosensitivity and skin fragility, PCT patients are more susceptible to infections."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Photosensitivity Disorders"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "infections"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, patients in the decompensated groups show also higher mean levels of Hcy/Cys ratio, suggesting a greater de rangement of Hcy trans-sulfuration pathway in these groups, which may result from PLP absolute/relative deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hyperhomocysteinemia (HHcy) is associated with endothelial damage, neurotoxicity and increased risk for vascular diseases."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "endothelial damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "hyperhomocysteinemia (HHcy), has been related to neuro logical and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "endothelial damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hyperhomocysteinemia (HHcy) is associated with endothelial damage, neurotoxicity and increased risk for vascular diseases."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Neurotoxicity Syndromes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "hyperhomocysteinemia (HHcy), has been related to neuro logical and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Neurotoxicity Syndromes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hyperhomocysteinemia (HHcy) is associated with endothelial damage, neurotoxicity and increased risk for vascular diseases."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vascular disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "hyperhomocysteinemia (HHcy), has been related to neuro logical and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vascular disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 2 summarizes homocysteine-related vitamin status and C677T polymorphism status for MTHFR gene in the studied groups."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "homocysteine"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "MTHFR"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "During follow-up none of the study patients were taking vitamin supplements or drugs known to interfere with homocysteine metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "homocysteine"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin supplements"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^2 Xenobiotics also directly induce ALAS1."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Xenobiotics"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | porphyria ('ALASm')/ sideroblastic anemia | 5-aminolevulinate synthase ( A L A S 2, Gene ID: 212, E.C. 2.3.1.37)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sideroblastic anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HHcy may represent an indirect marker of ALAS1 induction and its prevalence may be suggestive of a role of HHcy in the pathogenesis and/or comorbidities of AP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HHcy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALAS1 activity is dependent on vitamin B6 (Pyridoxal-phosphate, PLP) as cofactor [6,7]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | porphyria ('ALASm')/ sideroblastic anemia | 5-aminolevulinate synthase ( A L A S 2, Gene ID: 212, E.C. 2.3.1.37)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although ALA loading combined with iron enhanced the reduction of UROD activity in mice, factors that induce hepatic ALAS1 are seldom implicated in human PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine \u00c3\u017d\u00c2\u00b2 synthase (CBS) and cystathionine \u00c3\u017d\u00c2\u00b3-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Induction of ALAS1 in AHPs leads to an exaggerated accumulation of the neuropharmacologic active porphyrin precursors."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This might account for the ability of intravenous glucose and other nutritional carbohydrates or gluconeogenic amino acids to attenuate signals of a fasting state, resulting in increased expression of ALAS1."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "amino acids"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscular pain"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscular weakness"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of fatigue is probably multifactorial. It could include direct or indirect consequences to brain regions involved in cognition by ALA, sequels of autonomic dysfunction, low\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090grade inflammation in the liver and brain, and chronic stress caused by the disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatigue"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "autonomic dysfunction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic pain, often moderately severe and mainly neuropathic in origin, is common in patients with severe recurrent attacks and is associated with fatigue and nausea, often resulting in poor quality of life."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatigue"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Chronic pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of fatigue is probably multifactorial. It could include direct or indirect consequences to brain regions involved in cognition by ALA, sequels of autonomic dysfunction, low\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090grade inflammation in the liver and brain, and chronic stress caused by the disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatigue"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of fatigue is probably multifactorial. It could include direct or indirect consequences to brain regions involved in cognition by ALA, sequels of autonomic dysfunction, low\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090grade inflammation in the liver and brain, and chronic stress caused by the disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatigue"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "cognition"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatigue"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatigue"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "muscular pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "coproporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For example, in 32 members of an Australian family, 14 (including 10 adults) were determined to have HCP on the basis of a high fecal coproporphyrin III/I ratio and/or low lymphocyte CPOX enzyme activity, but only one had clinical symptoms of porphyria (Blake et al. 1992)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "coproporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ADP is assumed to be a hepatic porphyria, although liver transplantation was not beneficial in a child with severe disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As epileptic seizures usually occur in the acute forms of hepatic porphyria, it is not surprising that there is more experience in the management and AED treatment for these cases than for those of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epileptic seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^32 The overexpression of heme oxygenase-1 under conditions of inflammation, fasting, or physical or oxidative stress increases heme degradation and thereby removes feedback inhibition of ALAS1, promoting disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALAS1 activity is dependent on vitamin B6 (Pyridoxal-phosphate, PLP) as cofactor [6,7]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "PLP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The authors suggested that ALAS1 has a higher affinity for PLP when compared to other PLP-dependent enzymes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "PLP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, PLP is in important co-factor for Glutamate decarboxylase (GAD) activity, the sole enzyme able to synthesize \u00c3\u017d\u00c2\u00b3-aminobutyric acid (GABA), a major inhibitory neurotransmitter, whose reduced effect or availability has also been observed during AP exacerbations [60-61]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "PLP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "4-aminobutyric acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In porphyria patients, Hcy accumulation is likely to result from reduced hepatic CBS and CBL activity secondary to low heme availability and to possible intra-hepatic depletion of PLP due to the ALAS1 induction [10,25-27]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "PLP"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Merk H, Bolsen K, Lissner R, Goerz G (1986) Hexachlorobenzene alteration of benzo[a]pyrene metabolism in porphyric and non-porphyric rats."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Hexachlorobenzene"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thyroid disease Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) influence thyroid hormone metabolism, causing a decrease in total and free thyroxin levels."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Thyroid disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thyroid disease Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) influence thyroid hormone metabolism, causing a decrease in total and free thyroxin levels."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "thyroid hormone"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Antihypertensives | Enzyme-inducing AEDs increase the metabolism of beta-blockers and dihydropyridine calcium antagonists | | | PHT reduces the active metabolite of losartan by up to 63 %."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Antihypertensives"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other antidepressants such as citalopram, escitalopram, sertraline, trazodone and venlafaxine do not have a significant effect on AED metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "trazodone"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other antidepressants such as citalopram, escitalopram, sertraline, trazodone and venlafaxine do not have a significant effect on AED metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "venlafaxine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "To evaluate potential effects of intestinal nutrient absorption on whole body metabolism, we analyzed secretion patterns obtained from the two diets."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "nutrient absorption"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Succinyl-CoA is formed in mitochondria, chiefly by action of the tricarboxylic acid cycle, and it has other pathways for utilization and metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "tricarboxylic acid cycle"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Xenobiotics inhibit the activities of multidrug resistance-associated proteins and/or OATPs and affect the metabolism and disposition of CPs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Xenobiotics"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The model's failure to correctly predict some known elevated reported biomarkers, e.g. citrulline and glycogen (Supplementary Material, Table S7), highlights that enterocyte metabolism is not the only cause for biomarkers but that other tissues, such as liver and muscle, also contribute significantly to plasma biomarkers."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "histidine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Succinyl-CoA is formed in mitochondria, chiefly by action of the tricarboxylic acid cycle, and it has other pathways for utilization and metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Succinyl-CoA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tyrosinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic renal insufficiency"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It has been estimated that approximately forty percent of children with hereditary tyrosinemia type 1 develop the signs and symptoms of ADP (Rank et al. 1987)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary tyrosinemia type 1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Enzyme activities in AIP, HCP and VP are reduced to about 50 % of normal, indicating near or complete haplodeficiency, and are much lower in ADP, in which both alleles are affected (Nordmann et al, 1997; Badminton and Elder, 2005)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^79,80 Hexachlorobenzene, a fungicide that was used in agriculture until 1984, inhibits UROD and causes PCT in humans and animals."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Hexachlorobenzene"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^79,80 Hexachlorobenzene, a fungicide that was used in agriculture until 1984, inhibits UROD and causes PCT in humans and animals."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Hexachlorobenzene"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fungicide"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thyroid disease Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) influence thyroid hormone metabolism, causing a decrease in total and free thyroxin levels."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Thyroid disease"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "thyroxin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thyroid disease Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) influence thyroid hormone metabolism, causing a decrease in total and free thyroxin levels."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "thyroid hormone"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Thyroid disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Succinyl-CoA is formed in mitochondria, chiefly by action of the tricarboxylic acid cycle, and it has other pathways for utilization and metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "tricarboxylic acid cycle"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Succinyl-CoA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "citrullinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to citrulline conversion | For arginine synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "histidine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "histidine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "imino"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "imino"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We concluded that the attacks of acute porphyria occurred over a 2-month span, characterized by abdominal pain, constipation, autonomic neuropathy, peripheral neuropathy, psychosis, delirium, and metabolic disturbances."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oxybutynin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Arnold Chiari malformation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Case Report: A women with Arnold Chiari malformation type II who was treated with oxybutynin and antibiotics, including Bactrim for neurogenic bladder and recurrent urinary tract infection, presented with non-specific abdominal pain, constipation, and diarrhea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oxybutynin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neurogenic bladder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Case Report: A women with Arnold Chiari malformation type II who was treated with oxybutynin and antibiotics, including Bactrim for neurogenic bladder and recurrent urinary tract infection, presented with non-specific abdominal pain, constipation, and diarrhea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oxybutynin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "urinary tract infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyria was initiated by oxybutynin, precipitated by Bactrim, and became full-blown after metronidazole administration."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oxybutynin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "nan",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oxybutynin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "nan",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Bactrim"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The underlying mechanism is that metabolism of certain medications demands more hepatic cytochrome P450 enzymes, which derive from heme [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Bactrim"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oxybutynin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Liver cirrhosis, which is the most common risk factor (>80%) for PLC in general, is less common in patients with AP- associated PLC. Other contributing liver diseases leading to inflammation and fibrosis, such as viral hepatitis, hepatic steatosis or alcoholic liver diseases, are uncommon in AP patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PLCD1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The significant risk of PLC in AP has prompted recommendations for liver cancer surveillance by ultrasound imaging every 6\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u015312 months from the age of 50 in patients with a history of symptomatic AP disease.4 Due to the previous lack of evidence, patients with biochemical activity who never had symptoms are not included in these recommendations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PLCD1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "liver cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Olanzapine 10 mg changed to aripiprazole due to cramping."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropsychiatric symptoms"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phenytoin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epileptic seizure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phenytoin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most AEDs such as carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), and lamotrigine (LTG) may precipitate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phenytoin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phenytoin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phenytoin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "arrhythmias"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phenytoin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypotension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Several antiepileptic drugs (AEDs), through their hepatic metabolism and consequent induction of heme synthesis, may precipitate acute attacks in patients with clinically latent hepatic porphyria (Solinas and Vajda, 2004; Thunell et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antiepileptic drugs"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Table I. Use of antiepileptic drugs in porphyria | | | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | | Study | Study type | Result | | Gabapentin | | | | Krauss et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Gabapentin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antiepileptic drugs"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our main aim was not to establish a precise estimate of the incidence or prevalence of hypertension in patients with AHP, but rather to assess if the high rates of HT and CKD influence the risk of secondary cardiovascular diseases in relation to AHP type and U-PBG status."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseasess"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Looking more closely at the health challenges faced by acute porphyria patients, it was found that these patients were more likely to suffer from nervous system disorders, pain, and mental disorders in the first year before the index compared to the general population."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "nervous system disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Another variable conditioning the natural history of HCC is the severity of the underlying liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Conclusions and recommendations Evidence for a role for hepatic iron as a co-morbid factor in liver disease, particularly in chronic hepatitis C and steatohepatitis (alcoholic or nonalcoholic), continues to mount."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The prevalence of liver disease in patients with lichen planus is reported to be as high as 35 % .^10 Several small studies have suggested that HCV may be related."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lichen planus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "35193623.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a previous study, we found an increased risk of premature death in persons with sporadic PCT, although not familial PCT, due mostly to liver disease and alcohol and substance abuse [17]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "premature death"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On average, patients with XLP have more severe disease, with higher protoporphyrin levels and perhaps a greater risk of liver disease than do those with EPP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Clinical manifestations of AIP are broad and include neurovisceral crises, neuropathy and a range of psychiatric symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lymphoma, renal disease, neuropathy, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lymphoma, renal disease, neuropathy, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As a result, the main triggers for chronic encephalopathy and neuropathy in AP may be the constant excess of ALA and low\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090grade inflammation of hepatic origin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "encephalopathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Worsening neuropathy led to respiratory failure requiring mechanical ventilation and she was transferred to our ICU.Clinical findings on admission included proximal weakness with hypoesthesia, facial diplegia, and abolished tendon reflexes, except for the Achilles reflexes; additional central nervous system signs were present including visual blurring, hallucinations, and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "respiratory failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The natural history of hepatocellular carcinoma is heterogeneous and is influenced by nodule dimension, the mono- or plurifocality of lesions at diagnosis, the growth rate of the tumor, and the stage of the underlying cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with HH and significant alcohol consumption have a higher incidence of cirrhosis and other complications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "alcohol consumption"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In six cohort studies, 26% (range 0%\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u015340%) of the 53 patients with AP- associated PLC had cirrhosis. Of the seven French patients with PLC, two had not only cirrho- sis but also chronic viral hepatitis, which is strongly associated with the development of fibrosis. In the histological samples of the 13 Swedish patients with AP and PLC, mild to moderate fibrosis was common and one- third had cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic viral hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Long-term infection is necessary for the development of most extrahepatic manifestations; many are present primarily in patients with cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Long-term"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Only 30% of alcoholics develop cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholics"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with HH and significant alcohol consumption have a higher incidence of cirrhosis and other complications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "insulin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association of PCT with HCV is strongest in those patients that have cirrhosis (60-90 %)^76,78 In all countries, PCT is an uncommon complication of HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": ", 2002), in 119 consecutive patients with chronic hepatitis C, the H F E mutations commonly associated with hereditary hemochromatosis were significantly more common in these patients in comparison with findings for control subjects ( 48 % vs. 37.9 %, P=.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of H F E, especially in C 282 Y^+1 s homozygotes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The presence of the C282Y mutation was strongly associated with the presence of more advanced degrees of fibrosis or cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The HFE mutations were significantly more common in these patients in comparison with findings for control subjects ( 48 % versus 37.9 %, p=0.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of HFE, especially in C282Y homozygotes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "insulin resistance"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyria was initiated by oxybutynin, precipitated by Bactrim, and became full-blown after metronidazole administration."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "metronidazole"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition, these patients may present psychiatric conditions secondary to the disease, such as adjustment disorder and substance use disorders."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Case Report: A women with Arnold Chiari malformation type II who was treated with oxybutynin and antibiotics, including Bactrim for neurogenic bladder and recurrent urinary tract infection, presented with non-specific abdominal pain, constipation, and diarrhea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hematin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intermittent constipation and vague abdominal pain were considered to be adverse effects of oxybutynin and iron replacement in the first 3 hospital encounters; the patient's neuropsychiatric manifestations were initially thought to be known adverse reactions to metronidazole [5]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "medications"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Among hospitalized persons with HCV infection the prevalence of mental disorders, tobacco use/COPD, alcohol abuse, substance abuse and chronic kidney disease was particularly high (65 Although the tolerability of newer HCV regimens appears to have much improved, recent trials using direct acting antivirals have typically excluded participants with impaired renal function, recent alcohol or substance abuse, malignancy, autoimmune disorders and significant heart disease, for example [23,24]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ferritin plasma concentrations and serological markers of HCV infection were evaluated."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Note that this is an opposite relationship compared with the general population, where complaint of dry eyes (5 %) is more common than finding histological evidence (<0.5 %) .^62 Of patients with Sj\u00c3\u0192\u00c2\u00b6gren syndrome, however, only 5 to 10 % has evidence of HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mixed cryoglobulinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In various conditions associated with PCT, such as chronic HCV and alcohol use, hepcidin levels are low compared with controls."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This viral infection can lead to a reduction in hepcidin levels and generate hepatocyte oxidative damage"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other conditions, considered \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153high priority\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2 for HCV treatment include HBV or HIV coinfection, nonalcoholic fatty liver disease (associated with metabolic syndrome), diabetes mellitus and porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other conditions, considered \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153high priority\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2 for HCV treatment include HBV or HIV coinfection, nonalcoholic fatty liver disease (associated with metabolic syndrome), diabetes mellitus and porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with PCT should be screened for HFE mutations and for HCV."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vasculitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Conclusions: This case report, for the first time, documents acute porphyria attack as a result of a sequential combination of 3 common medications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HBV"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This is the first case report of the concomitant presence of both acute porphyria and Arnold Chiari malformation, 2 genetic disorders with unclear association."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HIV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25697467.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyria is a debilitating disorder caused by accumulation of intermediates of heme as a result of enzyme deficiency in heme synthesis [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nonalcoholic fatty liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cryoglobulinaemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Proteinuria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Nephrotic syndrome"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "glomerulonephritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Contributing environmental factors include alcohol use and hepatitis C virus (HCV) infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^1,2 Unlike other forms of porphyria, PCT usually is an acquired disease precipitated by extrinsic risk factors that commonly include excessive alcohol consumption, smoking, and chronic hepatitis C virus (HCV) infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# INTRODUCTION Approximately 2.7 million noninstitutionalized persons in the United States have chronic hepatitis C virus (HCV) infection [1] and, accordingly, are at risk for development of advanced liver disease and hepatocellular carcinoma [2]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^1,2 Unlike other forms of porphyria, PCT usually is an acquired disease precipitated by extrinsic risk factors that commonly include excessive alcohol consumption, smoking, and chronic hepatitis C virus (HCV) infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This viral infection can lead to a reduction in hepcidin levels and generate hepatocyte oxidative damage"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "response to oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# INTRODUCTION Approximately 2.7 million noninstitutionalized persons in the United States have chronic hepatitis C virus (HCV) infection [1] and, accordingly, are at risk for development of advanced liver disease and hepatocellular carcinoma [2]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "advanced liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Also, most have reported relatively static estimates of cumulative prevalence and have not included some of the serious, but less commonly encountered, extrahepatic manifestations of HCV infection (e.g., mixed cryoglobulinaemia, membranous glomerulonephritis, porphyria cutanea tarda)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinaemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition, HCV infection is associated with an array of nonhepatic conditions, directly or indirectly related to effects of the virus itself, which contribute to overall hepatitis C-related morbidity [3-9]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "At that time, he had an acute HCV infection and jaundice that required a prolonged hospitalization."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Elevated urinary uroporphyrin levels are detected in only 0.5 to 22 % of patients with chronic HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Many are older patients with longstanding HCV infection and symptomatic cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the early 1990s, multiple investigators simultaneously reported that 50 to 90 % of patients with essential MC had HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "MC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Epidemiologic studies associate HBV, as well as HCV, with the development of HCC."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HBV"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HIV infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HIV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HIV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HIV infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, it is currently unresolved whether mild-to-moderate hepatic iron deposition or heterozygosity for the C282Y mutation plays a role in human alcoholic liver disease or in nonalcoholic fatty liver disease or nonalcoholic steatohepatitis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nonalcoholic fatty liver disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Of MC-associated MPGN, 81 % is HCV RNA+ versus 25 % of noncryoglobulinemic glomerulonephritis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "glomerulonephritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "MPGN"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mycophenolate mofetil can inhibit the proliferation of activated B cells and reduce serum immunoglobulin levels (5), and especially in patients with PSS associated with hyperglobulinemia and glomerulonephritis (6)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "glomerulonephritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Mycophenolate mofetil"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Aber auch bei PCT-Patienten ohne Mutationen in HFE findet sich erh\u00c3\u0192\u00c2\u00b6hte Eisenspeicherung bei verminderter Bildung von Hepcidin [20]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "To our knowledge, there are no published data on erythroferrone (ERFE), the main bone marrow-derived regulator of hepcidin, in EPP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ERFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "An important milestone in understanding iron homeostasis was the discovery and characterization of hepcidin, ^115 a 25 -amino acid peptide synthesized mainly in the liver, which acts as a negative regulator of ferroportin, the key iron transporter across the basolateral membrane of duodenal enterocytes, hepatocytes, and macrophages."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC40A1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepcidin causes degradation of the iron export transporter ferroportin in gut enterocytes and macrophages, and low levels of hepcidin result in increased iron absorption in the gut and increased iron export out of cells such as macrophages and hepatocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC40A1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also demonstrated that hepcidin levels were positively associated with ferritin and haemoglobin levels, suggesting normal physiologic iron regulation in patients with EPP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The annual incidence of developing HCC, like that for the HCV, is conditioned by the presence and severity of the underlying liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The annual risk of developing HCC in HCV-infected patients depends on the presence and severity of the underlying liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Fourteen new cases of HCC (11 from Sweden) were reported in patients with acute porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HCC carcinogenesis in AP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "carcinogenesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association of liver disease, particularly alcoholic liver disease, and PCT was recognized by Brunsting et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe alcoholic liver disease is associated with the haemochromatosis gene mutant."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, HFE gene mutations, and alcoholic liver disease Patients with alcoholic liver disease commonly have elevations of serum iron indices (serum ferritin and percent iron saturation) (Bonkovsky & Obando, 1999; Milman et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There are several reasons why hepatic iron overload may occur in patients with alcoholic liver disease, including increased ingestion of iron (as in classical African dietary iron overload), increased intestinal iron absorption [perhaps due to up-regulation of divalent cation (or metal) transporter 1 or to an increase in the maintenance of iron in the reduced [^0]: * Corresponding author."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Etiology and pathogenesis of ADP\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009dALAD (ALA dehydratase; PBG synthase [EC 4.2.1.24]) catalyzes the formation of the monopyrrole PBG from two molecules of ALA, a precursor committed to synthesis of porphyrins, heme, and other tetrapyrroles."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ADP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "coproporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALAD is present in vast abundance in mammalian cells; for example in liver its activity is 80 to 100 -fold greater than that of ALAS, the first and ratelimiting enzyme for hepatic heme biosynthesis (Kappas et al. 1995)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients who are heterozygous for a mutation that reduces ALAD activity by 50 % develop acute porphyria symptoms once they have an even slight increase in lead exposure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The ALAD enzyme activity is reduced in diabetes mellitus (Fernandez-Cuartero et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of hemochromatosis alleles."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Familial PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The disease becomes active when acquired factors, such as iron, alcohol, Hepatitis C Virus (HCV), HIV, estrogens (used, for example, in oral contraceptives and prostate cancer treatment) and possibly smoking, combine to cause a deficiency of UROD in the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogens"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The disease becomes active when acquired factors, such as iron, alcohol, Hepatitis C Virus (HCV), HIV, estrogens (used, for example, in oral contraceptives and prostate cancer treatment) and possibly smoking, combine to cause a deficiency of UROD in the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oral contraceptives"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, HFE gene mutations, and porphyria cutanea tarda porphyria cutanea tarda, the most common of the human porphyrias, is caused by a deficiency in activity of hepatic uroporphyrinogen decarboxylase, the enzyme responsible for the stepwise decarboxylation of uroporphyrinogen to coproporphyrinogen, during the process of heme synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the presence of iron, CyP450 enzymes catalyze the conversion of uroporphyrinogen into uroporphomethene, an inhibitor of UROD, as shown in mice."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The fifth enzyme of the heme synthetic pathway is UROD, which carries out the stepwise conversion of the beta acetate moieties of uro'gen 1 or uro'gen 3 to hepta-, hexa-, penta-, and finally to tetra-carboxyl porphyrinogens, the latter better known as CP'ogens 1 and 3."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrinogens"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Since the UROD enzyme activity is markedly reduced in HEP, it is sufficient to lead to accumulation of highly carboxylated porphyrinogens and porphyrins in liver and possibly other tissues."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrinogens"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The actual intermediate in the biosynthetic pathway to heme is coproporphyrinogen 3 (CP'ogen3) (Figure 1), formed by serial decarboxylations from uroporphyrinogen3 (uro'gen3) by the enzyme uroporphyrinogen decarboxylase (UROD), as shown in Figure 2."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "coproporphyrinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Both PCT and HEP (described in the next section) are due to deficient activity of hepatic uroporphyrinogen decarboxylase, the fifth enzyme in the heme biosynthetic pathway."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## porphyria Cutanea Tarda ## Pathophysiology Low activity ( <20 % ) of hepatic uroporphyrinogen decarboxylase (UROD) underlies all cases of PCT (acquired type 1 or familial type 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "erythema"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "pruritus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Only CBZ could cause a seizure reduction, but this treatment had to be discontinued as an elevation of the transaminases as well as pruritus and erythema were noted."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "erythema"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "pruritus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pain stress contributes to neuroendocrine reactions that activate ALAS1 and exacerbate symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Pain"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Amongst them well recognized are: alcohol abuse, oestrogen replacement therapy, iron overload, haemodialysis, viral infections (hepatitis C, hepatitis B, HIV virus), exposure to polychlorinated hydrocarbons and inherited mutations in the HFE gene concerning classic haemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oestrogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda Zaneta J. Bulaj, John D. Phillips, Richard S. Ajioka, Michael R. Franklin, Linda M. Griffen, Donald J. Guinee, Corwin Q. Edwards, and James P. Kushner Inherited and acquired factors have been implicated in the pathogenesis of porphyria cutanea tarda (PCT), a disorder characterized by a photosensitive dermatosis and hepatic siderosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A possible explanation of our finding is that in our patient population, coexistence of various concomitant precipitat ing factors such as iron overload, oestrogen replacement therapy and HCV infection, seems to facilitate cumulatively the manifesta tion of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda is associated with hepatic iron overload and responds to iron-reduction therapy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is yet unclear whether the pathology of liver disease in patients with HCV is influenced by iron overload or limited to the direct cell damage from replication of the virus and subsequent inflammation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "35193623.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This may be explained in part by PCT itself or treatment for PCT, such as digestive issues as a known side-effect of chloroquine, used for treatment of PCT or related to for example hepatitis C, iron overload or other co-morbidities."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "35193623.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This may be explained in part by PCT itself or treatment for PCT, such as digestive issues as a known side-effect of chloroquine, used for treatment of PCT or related to for example hepatitis C, iron overload or other co-morbidities."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chloroquine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "These data indicate that the most dramatic effect of HFE mutations on the hepatic iron overload seen in PCT occurs when the Cys282Tyr/Cys282Tyr genotype is present."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other HFE mutations associated with iron overload have recently been described, but these occur infrequently."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Nonalcoholic steatohepatitis has been associated with evidence of iron overload (Bacon et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Nonalcoholic steatohepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "TFRC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "alcohol drinking"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron is often implicated in the pathogenesis of sporadic-type PCT because overload facilitates the formation of oxygen-free radicals, which in turn can facilitate the formation of a UROD inhibitor"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition to increased duodenal absorption, other mechanisms have been postulated as causes of portosystemic shuntrelated iron overload, including relative hepatic hypoxia, and associated pancreatic insufficiency with decreased bicarbonate secretion (Grace & Powell, 1974)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "bicarbonate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association between PCT and impaired glucose metabolism is not fully understood but possibly implicates iron overload; a previous study showed that patients with PCT with persistently high ferritin levels were more likely to develop impaired glucose metabolism and diabetes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron is often implicated in the pathogenesis of sporadic-type PCT because overload facilitates the formation of oxygen-free radicals, which in turn can facilitate the formation of a UROD inhibitor"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The generation of uroporphomethene is dependent on the amount of iron in the liver in murine models, and in mice with heterozygous UROD knock out, iron overload is sufficient to cause a PCT phenotype"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is a known complication of ESKD, possibly due to iron over load resulting from a number of factors such as erythropoietin deficiency and the administration of exogenous iron."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thus, heavy iron overload per se can cause serious damage, including cirrhosis and hepatocellular carcinoma in the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heavy iron overload causes serious damage, including cirrhosis and hepatocellular carcinoma in the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition to a mutation in the gene coding for UROD, several factors are known to reduce enzyme activity and thus facilitate porphyrin accumulation: high alcohol intake, smoking, iron overload, hepatitis C, human immundeficiency virus (HIV), and estrogen use in women."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A role for modest iron overload in increasing severity of alcohol-induced liver disease has been well established from results of experimental studies."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thus, heavy iron overload per se can cause serious damage, including cirrhosis and hepatocellular carcinoma in the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heavy iron overload causes serious damage, including cirrhosis and hepatocellular carcinoma in the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The major recognized risk factors for disease development are chronic hepatitis C(CHC), heavy alcohol use, iron overload (which is generally only mild or moderate), and estrogen use."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron is often implicated in the pathogenesis of sporadic-type PCT because overload facilitates the formation of oxygen-free radicals, which in turn can facilitate the formation of a UROD inhibitor"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "beta-Thalassemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Also, iron overload may increase oxidative stress (ROS) which can induce ALA synthase and increase the production of ALA, which in turn, may increase uroporphyrinogen production."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Both HCV infection and alcohol excess have been associated with hepatic siderosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "siderosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "first suggested that hemochromatosis gene mutations were responsible for the hepatic siderosis in many patients with PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "siderosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "siderosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Estrogens"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^4,6 In this respect we believe that bearing in mind the comorbidities of the patients with epilepsy at the time of chosing an antiepileptic drug (AED) should improve overall health and quality of life in those with epilepsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antiepileptic drug"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "J Clin Invest 56:661-667 11.Lee PK, Abrahams I, Bickers DR (1999) porphyria cutanea tarda occurring in a patient with renal failure, systemic lupus erythematosus and chronic hepatitis C infection treated with hemodialysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The Japanese study reported that it takes 13 years from a presumed infection, which was produced by a blood transfusion infected with HCV , to the development of chronic hepatitis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHP",
         "name": "Blood Transfusion"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "(2002), namely, that, in patients who are homozygous for the C282Y mutation and who have chronic hepatitis C , it is extraordinarily likely that cirrhosis will develop, and at a young age."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most patients with chronic hepatitis C , including those with elevated serum ferritin level, elevated serum iron saturation, or both, have not been found to have elevations in hepatic iron concentrations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "(1999) observed an unexpectedly high frequency ( 2.7 % ) of C282Y homozygosity among patients with chronic hepatitis C and biochemical evidence of increased iron in patients with HFE mutations in comparison with findings for those without."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "J Clin Invest 56:661-667 11.Lee PK, Abrahams I, Bickers DR (1999) porphyria cutanea tarda occurring in a patient with renal failure, systemic lupus erythematosus and chronic hepatitis C infection treated with hemodialysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "These favorable effects of iron reduction alone confirmed and extended results of earlier reports, which had shown significant improvements in serum levels of alanine aminotransferase in patients with chronic hepatitis C who previously had not experienced complete or sustained virological responses to interferon and who then were treated by iron-reduction therapy by means of therapeutic phlebotomy (Hayashi et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GPT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Only 1 of 70 (1%) patients with noncirrhotic chronic hepatitis had glucose intolerance, compared with 34 of 165 (21%) patients with cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "glucose intolerance"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter change may well occur due to downregulation by ethanol (actually, its proximate oxidation product, acetaldehyde) of hepatic production of hepcidin, ^11 which, in turn, appears to be the key regulator of expression of ferroportin on the basolateral membrane of duodenal enterocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ethanol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter change may well occur due to downregulation by ethanol (actually, its proximate oxidation product, acetaldehyde) of hepatic production of hepcidin, ^11 which, in turn, appears to be the key regulator of expression of ferroportin on the basolateral membrane of duodenal enterocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ethanol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "acetaldehyde"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Results of a recent study in mice lacking expression of the HFE gene showed that ethanol treatment increased hepatic nonheme iron and hepatic 5-aminolevulinate synthase activity in the H F E^-/-, but not in wild-type, mice (Sinclair et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ethanol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Corresponding to this was higher hepatic hydroxyproline content in animals given ethanol and iron compared with the other three groups (not shown in this figure)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ethanol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxyproline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Results of a recent study in mice lacking expression of the H F E gene showed that ethanol treatment increased hepatic nonheme iron and hepatic 5 -aminolevulinate synthase activity in the H F E-/- mice, but not in wild-type mice."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ethanol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "aminolevulinate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ethanol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "malondialdehyde"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For cellulitis, patients of increasing age, female sex, on hemodialysis, with catheter and graft compared to AVF access, and with diagnoses of tobacco use, alcohol dependence, hepatitis C, or HIV were at increased risk."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cellulitis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Female sex, catheter compared to AVF access, tobacco use, hepatitis C, and HIV were associated with an increased risk of abscess."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abscess"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Increasing age, black and other race compared to white race, Hispanic ethnicity, hemodialysis modality, and alcohol dependence were associated with a decreased risk of abscess."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abscess"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alcohol dependence"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Commonly seen SSTIs include abscesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "folliculitis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cellulitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients have symptoms of burning, itching, pain, erythema, and edema on sun-exposed skin areas, sometimes but not always resembling sunburn."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "edema"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "erythema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients have symptoms of burning, itching, pain, erythema, and edema on sun-exposed skin areas, sometimes but not always resembling sunburn."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "edema"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "itching"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other skin manifestations include hyperpigmentation, hypertrichosis, alopecia due to scaring and purplish heliotrope suffusion of periorbital areas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperpigmentation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Porphyrins are phototoxic, resulting in cutaneous symptoms such as blisters, sores, hyperpigmentation, and hypertrichosis on sun-exposed areas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperpigmentation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Facial hyperpigmentation and hypertrichosis may occur."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperpigmentation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Porphyrins are phototoxic, resulting in cutaneous symptoms such as blisters, sores, hyperpigmentation, and hypertrichosis on sun-exposed areas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Figure 1 Patient with hypertrichosis of zygomatics, hyperpigmentation, scars and bullae of the face and hands."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperpigmentation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other common cutaneous manifestations seen include hypertrichosis, hyperpigmentation, and a thickened appearance of the skin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperpigmentation"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^13-16 A study of 1,930 Finnish men reported that the men with ferritin level \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a5 200 ng / dL had a risk 2.2 times higher of acute myocardial infarction when compared to men with lower serum ferritin level."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute myocardial infarction"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Risk factors of fibrosis in alcohol-induced liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nonalcoholic steatohepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Determining the degree of fibrosis by some means is needed due to the increased risk of hepatocellular carcinoma (HCC) in HH patients with advanced fibrosis and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In most of these patients, cirrhosis is already present ^20 but in a few only some degree of fibrosis is seen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27, 1695-1699."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We were able to grade 84 of the 89 liver biopsies for active inflammation and staging of fibrosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In six cohort studies, 26% (range 0%\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u015340%) of the 53 patients with AP- associated PLC had cirrhosis. Of the seven French patients with PLC, two had not only cirrho- sis but also chronic viral hepatitis, which is strongly associated with the development of fibrosis. In the histological samples of the 13 Swedish patients with AP and PLC, mild to moderate fibrosis was common and one- third had cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, patients with end-stage kidney disease (ESKD) have high levels of hepcidin and are also at risk of developing PCT"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "End Stage kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "End Stage kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, patients with end-stage kidney disease (ESKD) have high levels of hepcidin and are also at risk of developing PCT"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "End Stage kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Excess porphyrins in the skin interact with light of approximately 400 nm -wavelength and are activated and generate reactive oxygen species that cause skin damage and increased fragility (Grossman and Poh-Fitzpatrick, 1980; Lim, 1989)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The harmful effects are related to increased oxidative stress and production of reactive oxygen species causing oxidative damage to lipids, proteins, and nucleic acids."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Yet, as described elsewhere in this issue, excessive iron is toxic to all types of cells because it increases oxidative stress and reactive oxygen species, which in turn cause the oxidation of lipids, proteins, and nucleic acids."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The toxicity of iron is believed to involve increased oxidative stress, with iron-catalyzed production of reactive oxygen species causing oxidative damage to lipids, proteins, and nucleic acids."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A \\'twohit\\' theory has been suggested, which involves accumulation of fat in the liver, especially in the form of free fatty acids (\\'first hit\\'), coupled with a \\'second hit\\' that produces increased oxidative stress and reactive oxygen species."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatty liver"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of PCT is thought to involve iron-generated free oxygen radicals that oxidize uroporphyrinogen, leading to the formation of a uroporphomethene inhibitor of UROD."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "Uroporphomethene"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "his study also found that persistently elevated serum ferritin over time was an independent risk factor for DM"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Ferritins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association between PCT and impaired glucose metabolism is not fully understood but possibly implicates iron overload; a previous study showed that patients with PCT with persistently high ferritin levels were more likely to develop impaired glucose metabolism and diabetes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Ferritins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Porphyrins may be directly neurotoxic and trigger neurologic complications such as seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The occurrence of PRES in AIP patients may be due to the abnormal accumulation of porphyrin metabolites in the body caused by AIP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cerebral Edema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "These por phyrins are activated by light exposure (especially at wavelengths near 400 nm) and generate reactive oxygen species that damage sun-exposed skin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "These por phyrins are activated by light exposure (especially at wavelengths near 400 nm) and generate reactive oxygen species that damage sun-exposed skin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Coronary Artery Spasm"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15031049.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In any patient who presents with photoexposed unilocular blisters and skin fragility, the diagnosis should be considered."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Increasing age, female sex, Hispanic ethnicity, and alcohol dependence were associated with a decreased risk of blisters."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alcohol dependence"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mycophenolate mofetil can inhibit the proliferation of activated B cells and reduce serum immunoglobulin levels (5), and especially in patients with PSS associated with hyperglobulinemia and glomerulonephritis (6)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Mycophenolate mofetil"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "proliferation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The proportion of hospitalizations with an in-hospital death decreased significantly from 3.7 From 2004 to 2011, significant increases were found in the prevalence of obesity, hypertension, diabetes, disorders of lipid metabolism, metabolic syndrome, tobacco use/COPD, mental disorders, renal failure/chronic kidney disease, nonhepatic cancers, connective tissue disease, osteoarthritis and ischaemic heart disease among hospitalized persons with HCV infection (P < 0.0001) (Table 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "obesity"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The comorbidities assessed in this study were obesity, hypertension, diabetes, disorders of lipid metabolism, metabolic syndrome (a composite variable using the presence of at least two of the following: obesity, hypertension, diabetes or disorder of lipid metabolism), tobacco use/chronic obstructive pulmonary disease (COPD), mental disorders (which encompassed affective, thought and anxiety disorders), alcohol abuse, substance abuse except alcohol, renal failure/chronic kidney disease (including dialysis), ischaemic heart disease, nonhepatic cancers (which included head and neck, lung, prostate, oesophageal, breast and non-Hodgkin's lymphoma), osteoarthritis, connective tissue disease, hepatitis B virus (HBV) infection and HIV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "obesity"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Other Risk Factors for Development of Type II Diabetes Mellitus and Screening Interval There are several other risk factors increasing the risk of having/ developing type II DM; these include obesity, inactivity, high blood pressure, a family history of DM, and age."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "obesity"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Type II Diabetes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The proportion of hospitalizations with an in-hospital death decreased significantly from 3.7 From 2004 to 2011, significant increases were found in the prevalence of obesity, hypertension, diabetes, disorders of lipid metabolism, metabolic syndrome, tobacco use/COPD, mental disorders, renal failure/chronic kidney disease, nonhepatic cancers, connective tissue disease, osteoarthritis and ischaemic heart disease among hospitalized persons with HCV infection (P < 0.0001) (Table 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "connective tissue disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The two women with the substantially elevated urinary porphyrin levels had a combination of predisposing factors: they were receiving oestrogen replacement therapy because of amenorrhoea, had markedly elevated plasma ferritin concentration, while one of them was HCV positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oestrogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The two women with the substantially elevated urinary porphyrin levels had a combination of predisposing factors: they were receiving oestrogen replacement therapy because of amenorrhoea, had markedly elevated plasma ferritin concentration, while one of them was HCV positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "They found a significant correlation between hepcidin mRNA expression and HIC and serum ferritin but not with the hepatic activity index, fibrosis stage, or viral load."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "They noted that chronic carriers for hepatitis B had elevated serum iron or ferritin compared with individuals who achieved !"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, HFE gene mutations, and alcoholic liver disease Patients with alcoholic liver disease commonly have elevations of serum iron indices (serum ferritin and percent iron saturation) (Bonkovsky & Obando, 1999; Milman et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Homozygotes for the Cys282Tyr mutation with grade 3 alcohol consumption had higher ferritin values and liver iron content than alcohol abusers who were not homozygotes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "alcohol consumption"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lymphoma, renal disease, neuropathy, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lymphoma, renal disease, neuropathy, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "With the exceptions of cryoglobulinemia, lymphoma, and Sjogren syndrome, no pathogenic mechanism has been proposed for most of these associations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "With the exceptions of cryoglobulinemia, lymphoma, and Sjogren syndrome, no pathogenic mechanism has been proposed for most of these associations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lymphoma, renal disease, neuropathy, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although only 10 % of HCV-infected persons will have symptomatic xerophthalmia or xerostomia, \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a4 77 % will have evidence of Sj\u00c3\u0192\u00c2\u00b6gren syndrome if it is sought with diagnostic tests (Table 6)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "xerophthalmia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Note that this is an opposite relationship compared with the general population, where complaint of dry eyes (5 %) is more common than finding histological evidence (<0.5 %) .^62 Of patients with Sj\u00c3\u0192\u00c2\u00b6gren syndrome, however, only 5 to 10 % has evidence of HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry eyes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Primary Sj\u00c3\u0192\u00c2\u00b6gren's syndrome (PSS) is a chronic inflammatory autoimmune disease that mainly affects exocrine glands such as the lacrimal and salivary glands (2) and that has a definite familial aggregation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjoegren syndrome"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "autoimmune disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mixed cryoglobulinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mixed cryoglobulinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mixed cryoglobulinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, neuropathy, lymphoma, and Sj\u00c3\u0192\u00c2\u00b6gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "With the exceptions of cryoglobulinemia, lymphoma, and Sjogren syndrome, no pathogenic mechanism has been proposed for most of these associations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is essential that future reports of disease associations with hepatitis C contain control groups that are well matched for age, sex, and severity of liver disease, because these are the most common confounding variables."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Amongst them well recognized are: alcohol abuse, oestrogen replacement therapy, iron overload, haemodialysis, viral infections (hepatitis C, hepatitis B, HIV virus), exposure to polychlorinated hydrocarbons and inherited mutations in the HFE gene concerning classic haemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Amongst them well recognized are: alcohol abuse, oestrogen replacement therapy, iron overload, haemodialysis, viral infections (hepatitis C, hepatitis B, HIV virus), exposure to polychlorinated hydrocarbons and inherited mutations in the HFE gene concerning classic haemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alcohol abuse"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "35193623.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This may be explained in part by PCT itself or treatment for PCT, such as digestive issues as a known side-effect of chloroquine, used for treatment of PCT or related to for example hepatitis C, iron overload or other co-morbidities."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chloroquine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Several studies have reported an association between hepatitis C and diabetes mellitus (DM).Problems in interpreting these studies include the frequent failure to account for other variables that predispose to diabetes and the lack of matched control groups."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Amongst them well recognized are: alcohol abuse, oestrogen replacement therapy, iron overload, haemodialysis, viral infections (hepatitis C, hepatitis B, HIV virus), exposure to polychlorinated hydrocarbons and inherited mutations in the HFE gene concerning classic haemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oestrogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alcohol dependence"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE mutations, alcohol and hepatitis C are known to decrease hepcidin levels and thereby increase iron absorption from the intestine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For cellulitis, patients of increasing age, female sex, on hemodialysis, with catheter and graft compared to AVF access, and with diagnoses of tobacco use, alcohol dependence, hepatitis C, or HIV were at increased risk."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alcohol dependence"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Controlling for demographic and clinical covariates the final models (Table 3 and Fig. 2) indicated that: - For bacterial infections, increasing age, female sex, hemodialysis modality, tobacco use, alcohol dependence, and hepatitis C and HIV diagnoses were associated with an increased risk of the infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alcohol dependence"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition to a mutation in the gene coding for UROD, several factors are known to reduce enzyme activity and thus facilitate porphyrin accumulation: high alcohol intake, smoking, iron overload, hepatitis C, human immundeficiency virus (HIV), and estrogen use in women."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The main risk factors of HCC are the hepatitis B (HBV) and the hepatitis C (HCV) viruses, which together account for three quarters of all cases worldwide."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For example, thyroid disease has been frequently reported in persons with hepatitis C. Many of these reports, however, are of persons undergoing interferon treatment for their hepatitis, and \u00c3\u017d\u00c2\u00b1 interferon has been known to unmask thyroid disease in patients with other illnesses."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thyroid disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For systemic bacteremia, ESRD patients of increasing age, female sex, on hemodialysis, with catheter and graft compared to AVF access, and diagnosed with tobacco use, alcohol dependence, hepatitis C, or HIV were at increased risk for bacteremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bacteremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "primary liver cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "About 20% of those with an acute attack report photosensitivity although bullae and skin fragility are much less common than in VP Although disease-causing CPOX mutations occur equally in males and females, acute attacks are much more frequent in women, mainly between ages 16 and 45 years (the years of active ovulation)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CPOX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, the key drugs used in systemic therapy, such as methylprednisolone and cyclophosphamide, can induce the acute onset of AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methylprednisolone"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Resultant overproduction of the neurotoxic intermediates \u00c3\u017d\u00c2\u00b4-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron also induces heme oxygenase, causing depletion of a regulatory heme pool and thus derepression of ALA synthase, which further increases the production of uroporphyrinogen and uroporphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron also induces heme oxygenase, causing depletion of a regulatory heme pool and thus derepression of ALA synthase, which further increases the production of uroporphyrinogen and uroporphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The diagnosis of PCT was based on typical clinical features and was confirmed by increased urine excretion of uroporphyrin (quantified spectrophotometrically) and skin biopsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a study using 130 cases of CEP, dermal deposits of uroporphyrin frequently induced dramatic phototoxic oxygen-dependent skin damage with extensive ulcerations and mutilations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "skin damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Drug eruption is a common adverse effect of various types of nonchemotherapeutic drugs, and it was highly unlikely that there was any relationship between cutaneous symptoms and porphyria in our patient because no changes in her urinary coproporphyrin or uroporphyrin levels were observed throughout her episode."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Drug eruption"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathies"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The risk of other cardiovascular conditions commonly associated with HT such as heart failure, atrial fibrillation, ischemic heart disease, and peripheral artery disease did not differ between the AHP groups and comparators."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjogren syndrome"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Also, most have reported relatively static estimates of cumulative prevalence and have not included some of the serious, but less commonly encountered, extrahepatic manifestations of HCV infection (e.g., mixed cryoglobulinaemia, membranous glomerulonephritis, porphyria cutanea tarda)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrial fibrillation"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "heart failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Among hospitalized persons with HCV infection the prevalence of mental disorders, tobacco use/COPD, alcohol abuse, substance abuse and chronic kidney disease was particularly high (65 Although the tolerability of newer HCV regimens appears to have much improved, recent trials using direct acting antivirals have typically excluded participants with impaired renal function, recent alcohol or substance abuse, malignancy, autoimmune disorders and significant heart disease, for example [23,24]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "membranous glomerulonephritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Among hospitalized persons with HCV infection the prevalence of mental disorders, tobacco use/COPD, alcohol abuse, substance abuse and chronic kidney disease was particularly high (65 Although the tolerability of newer HCV regimens appears to have much improved, recent trials using direct acting antivirals have typically excluded participants with impaired renal function, recent alcohol or substance abuse, malignancy, autoimmune disorders and significant heart disease, for example [23,24]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alcohol abuse"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a previous study, we found an increased risk of premature death in persons with sporadic PCT, although not familial PCT, due mostly to liver disease and alcohol and substance abuse [17]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "substance abuse"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "35193623.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153residual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "substance abuse"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "premature death"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153residual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "osteoarthritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153residual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "osteoarthritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ischaemic heart disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153residual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153residual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ischaemic heart disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^120,121 Erythrocyte concentrates that suppress erythropoiesis and plasma exchange that removes excess metal-free protoporphyrin have been used to treat liver failure or prevent further decompensation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "osteoarthritis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "More often, a rapidly progressive cholestatic liver failure characterizes the symptomatic debut."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "erythropoiesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Alcohol also inhibits other enzymes in the heme pathway, and chronic alcoholism suppresses erythropoiesis and increases dietary iron absorption."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cholestatic"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hypocortisolism, factors related to erythropoiesis and celiac disease, should be excluded."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "erythropoiesis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although some of these conditions, such as membranous glomerulonephritis or vasculitis, may instead have been coded as renal failure/chronic kidney disease (23 ICD-9 codes for the diagnosis of viral hepatitis have been tested and validated in the Veterans Administration healthcare system, and have demonstrated high specificity and positive predictive value in the identification of HCV-infected persons [13]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "erythropoiesis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hypocortisolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Relative risk assessments are also affected by the PLC incidences in the reference populations, which vary with the prevalence of viral hepatitis and other liver diseases."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "viral hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, HFE gene mutations, and viral hepatitis An association between iron and viral hepatitis was first highlighted by Blumberg et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "viral hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PLCD1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Liver cirrhosis, which is the most common risk factor (>80%) for PLC in general, is less common in patients with AP- associated PLC. Other contributing liver diseases leading to inflammation and fibrosis, such as viral hepatitis, hepatic steatosis or alcoholic liver diseases, are uncommon in AP patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "viral hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "viral hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron loading has also been described after portosystemic shunts and in endstage liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "viral hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "beta-Thalassemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron in liver diseases other than hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron accumulation is more likely to occur in subjects with the common HFE mutations associated with hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron is the most important cofactor and hemochromatosis gene mutations (HFE) (mostly heterozygous) are found in up to two-thirds of the patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron accumulation is more likely to occur in subjects with the common HFE mutations associated with hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Multiple studies have examined the complex interplay between iron regulation and haematopoiesis in EPP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^77 Iron does not directly inhibit UROD."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematopoiesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Recognize the central role of iron in PCT pathogenesis"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The association between iron and PCT is well established. Siderosis is detected in up to 90% of patients who undergo liver biopsy, and a reduction in total body iron content by therapeutic phlebotomies leads to disease remission"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is often the result of multiple environmental and inherited factors: UROD pathogenic variants reduce baseline levels of this enzyme, and other factors influence iron and oxidative stress in hepatocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron is central to the pathophysiology of PCT, leading to the formation of a UROD inhibitor, present in the liver, that prevents the decarboxylation of uroporphyrinogen to coproporphyrinogen during heme biosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Notably, due to the potential for iron to increase protoporphyrin levels and light sensitivity in EPP, current guidelines recommend against routine iron supplementation unless there is signifi cant anaemia or iron deficiency"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most patients with PCT have evidence of siderosis on liver biopsy, and the disease resolves with iron deple tion."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Photosensitivity Disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^1,2 Iron can increase reactive oxygen species (ROS), which, in turn, increases the rate of oxidation of uroporphyrinogens."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "siderosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The generation of uroporphomethene is dependent on the amount of iron in the liver in murine models, and in mice with heterozygous UROD knock out, iron overload is sufficient to cause a PCT phenotype"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The generation of uroporphomethene is dependent on the amount of iron in the liver in murine models, and in mice with heterozygous UROD knock out, iron overload is sufficient to cause a PCT phenotype"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron is central to the pathophysiology of PCT, leading to the formation of a UROD inhibitor, present in the liver, that prevents the decarboxylation of uroporphyrinogen to coproporphyrinogen during heme biosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "Uroporphomethene"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Notably, due to the potential for iron to increase protoporphyrin levels and light sensitivity in EPP, current guidelines recommend against routine iron supplementation unless there is signifi cant anaemia or iron deficiency"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "Uroporphomethene"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cytochrome"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On completionof thisarticle, the reader will (1) recognize iron as a risk factor for certain nonhemochromatotic disorders a"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In hepatocytes, alcohol and iron are believed to act synergistically to generate free radicals, which contribute to the forma tion of the uroporphomethene that inhibits hepatic UROD, as well as cause cellular damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "nonhemochromatotic disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Indeed, there is an association between the trait of beta-thalassae mia and PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "free radical"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "According to our results, patients with TM demonstrate an increased prevalence of PCT, in relation to the general population."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "beta-Thalassemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Herein, we evaluate a potential causal relation between PCT and TM, focusing on PCT's predisposing factors."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "beta-Thalassemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Beta thalassaemia major (TM) is a clinical entity with a wide spectrum of clinical manifestations as a result of life-long transfusion-dependent anaemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "beta-Thalassemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The prevalence of cryoglobulinaemia, vasculitis, nephrotic syndrome or membranoproliferative glomerulonephritis and porphyria cutanea tarda among hospitalizations with HCV infection was consistently low during the study period (i.e., <0.5 % )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "beta-Thalassemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "anaemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, it was recently observed that areas that have a high incidence of HCC and high aflatoxin intake correspond to areas in which HBV infection is endemic and that patients at higher risk of developing HCC are those who are exposed to both HBV and AFB1 risk factors."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "membranoproliferative glomerulonephritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinaemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other risk factors include aflatoxin B1 intake, alcohol consumption, and some hereditary diseases, among which are hereditary hemochromatosis, hereditary tyrosinemia, and \u00c3\u017d\u00c2\u00b1_1 anti-trypsin deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "aflatoxin B1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Low-dose hydroxychloroquine (100 mg orally twice weekly) is an alternative option for patients with PCT who do not have access to or cannot tolerate therapeutic phlebotomy, and who do not have marked iron overload. Chloroquine can be used as well, but hydroxychloroquine is preferred because of its superior safety pro file. These 4-aminoquinolines are taken up in hepatocyte lysosomes, which then release large amounts of accumu lated porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "aflatoxin B1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tyrosinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hydroxychloroquine (and chloroquine) in the amounts used for other diseases cause hepatotoxicity in PCT, and this adverse effect is largely avoided with the low-dose regimen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chloroquine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Once patients and control subjects are matched for cirrhosis and other variables known to predispose persons to DM, the association between HCV and DM is weak but still present nevertheless."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chloroquine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatotoxicity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^1 PCT patients are primarily diagnosed and treated by dermatologists, who may not be aware of the association with and the pitfalls in testing for DM in these patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "insulin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Clinicians need to know the pros and cons for each test to be able to properly diagnose PCT patients with possible DM.This article provides an update on the knowledge of DM in PCT patients and the relevant available tests and recommendations for a diagnostic procedure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the largest US retrospective study of 1117 patients with chronic viral hepatitis, the prevalence of type 2 DM was 21 % in patients with HCV versus 12 % in patients with hepatitis B virus (HBV)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Methods to Detect the Level of Glycemia for the Diagnosis and Monitoring of Diabetes Mellitus The definition of diabetes is based on the presence of hyperglycemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic viral hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Diabetes Mellitus - Definition and Clinical Course DM is a serious metabolic disease defined by hyperglycemia and complicated by micro- and macrovascular abnormalities."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperglycemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the largest US retrospective study of 1117 patients with chronic viral hepatitis, the prevalence of type 2 DM was 21 % in patients with HCV versus 12 % in patients with hepatitis B virus (HBV)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperglycemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A possible explanation of our finding is that in our patient population, coexistence of various concomitant precipitat ing factors such as iron overload, oestrogen replacement therapy and HCV infection, seems to facilitate cumulatively the manifesta tion of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "type 2"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oestrogen"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For systemic bacteremia, ESRD patients of increasing age, female sex, on hemodialysis, with catheter and graft compared to AVF access, and diagnosed with tobacco use, alcohol dependence, hepatitis C, or HIV were at increased risk for bacteremia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oestrogen"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE mutations, alcohol and hepatitis C are known to decrease hepcidin levels and thereby increase iron absorption from the intestine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alcohol dependence"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bacteremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pathogenic variants in the HFE gene found in hereditary hemochromatosis are more common than expected in PCT, even in the absence of marked iron over load."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with PCT should be screened for HFE mutations and for HCV."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Others have found that 24 of 113 patients with alcoholic liver disease ( 21 % ) carried the C282Y mutation of HFE, compared with 7 of 92(7.6 %) in the control group ( P=.007 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Correlation of the iron phenotype with the HFE genotype The hepatic iron concentration, transferrin saturation, and the serum ferritin concentration were highest in PCT patients who were homozygous for the Cys282Tyr mutation (Table 3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that 69.4 % of NASH patients carried one of the two mutations of HFE (versus 40.5 % of controls)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most patients with clinically evident hemochromatosis are homozygous for the ancestral Cys282Tyr mutation at the HFE locus, ^27 and it has been estimated that approximately half of the Cys282Tyr homozygotes develop clinically significant iron overload."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "NASH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In contrast, no effect of heterozygosity for HFE mutations (C282Y or H63D) on severity of alcoholic liver disease was observed among 257 patients from the north of England (Grove et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other investigators from Australia ^31 did not report an increased susceptibility to alcoholic cirrhosis in patients with the C282Y HFE mutation, compared with findings for control subjects."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition, HCV infection is associated with an array of nonhepatic conditions, directly or indirectly related to effects of the virus itself, which contribute to overall hepatitis C-related morbidity [3-9]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "morbidity"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "25894392.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of hemochromatosis alleles."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "morbidity"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mutations at the HFE locus, HCV infection, excess alcohol intake, and exposure to estrogens all proved to be risk factors for the development of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Familial PCT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "relative roles of hemochromatosis gene (HFE) mutations, HCV, alcohol, and estrogens as risk factors for disease expression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogens"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Approximately 18 % of American women between the ages of 18 and 44 use oral contraceptives, ^55 and 15 % of postmenopausal American women use medicinal estrogens as hormone replacement therapy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogens"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogens"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oral contraceptives"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "With liver injury or increased oxidative stress in general, more porphyrinogens are nonenzymatically oxidized to the corresponding porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrinogens"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "With liver injury or increased oxidative stress in general, more porphyrinogens are nonenzymatically oxidized to the corresponding porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrinogens"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Decreased UROD leads to increased production of 8- to 5-carboxymethyl substituted porphyrinogens (De Matteis, 1998)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrinogens"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver injury"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, as hepatic MTX metabolism does not involve cytochrome P450, the association between MTX and PCT cannot be explained by this mechanism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrinogens"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with PCT usually carry polymorphic variants of CyP450 genes, leading to higher enzyme activities, whereas patients with familial PCT express a polymorphic variant of glycerol phosphate O acyltransferase that is associated with iron accumulation in HFE-associated hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The cytochrome P450 1A2 has been implicated in PCT pathogenesis in a murine model of PCT24; however, which CYPs might be involved in human PCT has not been conclusively established."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Little is known about the porphyrogenic potentials of newer agents such as levetiracetam, which is reported not to induce the hepatic cytochrome P-450 system."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A liver-specific isozyme of cytochrome P450, P4501A2 (CYP1A2), is essential for chemically-induced porphyria in mice, ^65 but induction of CYP1A2 alone is not sufficient to produce a porphyric response in rats."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "levetiracetam"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALAS1 is induced via induction of cytochrome P450 (CyP450), such as by xenobiotics, smoking, excess alcohol consumption, fasting, and female sex hormones."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "At least in murine models, cytochrome P450 enzyme activity is involved in the generation of this inhibitor."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "Uroporphomethene"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE genotyping DNA was available from 87 patients with PCT ( 64 with S-PCT and 23 with F-PCT) and from 56 clinically normal subjects married to members of well-characterized hemochromatosis pedigrees."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with PCT usually carry polymorphic variants of CyP450 genes, leading to higher enzyme activities, whereas patients with familial PCT express a polymorphic variant of glycerol phosphate O acyltransferase that is associated with iron accumulation in HFE-associated hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with PCT usually carry polymorphic variants of CyP450 genes, leading to higher enzyme activities, whereas patients with familial PCT express a polymorphic variant of glycerol phosphate O acyltransferase that is associated with iron accumulation in HFE-associated hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In human beings with porphyria cutanea tarda, the presence of H F E gene mutations is the major reason for increased hepatic iron, with alcohol perhaps playing a secondary role, as has just been described for the mouse model of human hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The disease always occurs with a normal or increased amount of hepatic iron, and iron deficiency is protective, and the prevalence of HFE (hemochromatosis) mutations is increased."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Alcohol consumption, a history of smoking, prior HIV or hepatitis C infection, hemochromatosis, estrogen exposure, or the combination of two or more of these factors increases the susceptibility to symptomatic PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition to the well-known hepatotoxicity of heavy iron overload, as occurs in hemochromatosis, whether primary (hereditary) or secondary, evidence continues to mount that lesser degrees of hepatic iron loading may worsen liver [^0]injury or hepatic fibrosis in nonhemochromatotic liver diseases."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Regarding the type of AP, most assessments of PLC risk are based on cohorts with a predominance of patients with AIP. Sporadic cases of PLC in patients with VP and HCP have been published,11,15,74\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u015377 but large VP or HCP cohort studies exploring PLC risk are lacking and specific risk estimates for these forms of AP are scarce."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatotoxicity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Two cases of co-existence of variegate porphyria and celiac disease have been reported."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "VP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "VP is an autosomal dominant genetic disorder due to partially deficient activity of the mitochondrial enzyme protoporphyrinogen oxidase (PPOX) (Brenner and Bloomer, 1980; Singal and Anderson, 2013).Enzyme activity is approximately 50 percent of normal in all tissues and mitochondria-containing cells that have been examined, including lymphocytes and cultured fibroblasts (Meissner, Hift and Corrigall, 2003)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "VP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "celiac disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This pattern of porphyrin elevation is characteristic but not completely specific since uroporphyrin elevation occurs in other porphyrias, and a PCT-like pattern occurs in some patients with variegate porphyria (VP)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "VP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PPOX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table: Classifications and principal clinical features"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "VP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Uroporphyrinogen III"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The prevalence of VP is 1 in 300 among the white population of Dutch descent in South African population, due to a founder effect (Eales, Day, and Blekkenhorst, 1980; Meissner et al. 1996; Hift et al. 1997; Meissner, Corrigall and Hift, 2012)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "VP"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the 8th and final step of heme synthesis, the enzyme FECH inserts ferrous iron into PP to form heme."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "founder effect"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "VP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The oxidative process involves CYPs and requires ferrous iron (Phillips et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ferrous iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There is persuasive evidence that iron reduction decreases insulin resistance, and it likely also decreases oxidative stress, two key pathogenic features of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ferrous iron"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYPs"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nonalcoholic fatty liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^32 The overexpression of heme oxygenase-1 under conditions of inflammation, fasting, or physical or oxidative stress increases heme degradation and thereby removes feedback inhibition of ALAS1, promoting disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Increased oxidative stress by liver injury from accumulated iron increases the likelihood that uroporphyrinogen will be oxidized to uroporphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is often the result of multiple environmental and inherited factors: UROD pathogenic variants reduce baseline levels of this enzyme, and other factors influence iron and oxidative stress in hepatocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Future studies should seek to solidify the relationship between porphyria and mental illness with the aim to have evidence-based guidelines."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A \\'twohit\\' theory has been suggested, which involves accumulation of fat in the liver, especially in the form of free fatty acids (\\'first hit\\'), coupled with a \\'second hit\\' that produces increased oxidative stress and reactive oxygen species."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There is growing evidence that only a mild degree of iron overload is sufficient to enhance alco-hol-induced liver injury."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatty liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The relationship between protoporphyrin and platelet count remained similar when adjusting for ferritin and ALT ( \u00c3\u017d\u00c2\u00b2=-0.36, p<0.001, Figure 1A), surrogates for iron status and liver injury, respectively, which can also affect platelet count."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver injury"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "With liver injury or increased oxidative stress in general, more porphyrinogens are nonenzymatically oxidized to the corresponding porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver injury"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Increased oxidative stress by liver injury from accumulated iron increases the likelihood that uroporphyrinogen will be oxidized to uroporphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver injury"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "With liver injury or increased oxidative stress in general, more porphyrinogens are nonenzymatically oxidized to the corresponding porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver injury"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The hepatic UROD protein level remains at its genetically determined level in all types of PCT, but hepatic enzyme activity is reduced to less than about 20% of normal, suggesting the presence of an enzyme inhibitor. Phillips and colleagues identified this inhibitor as a uroporphomethene, probably derived from the partial oxidization of uroporphyrinogen"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver injury"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The hepatic UROD protein level remains at its genetically determined level in all types of PCT, but hepatic enzyme activity is reduced to less than about 20% of normal, suggesting the presence of an enzyme inhibitor. Phillips and colleagues identified this inhibitor as a uroporphomethene, probably derived from the partial oxidization of uroporphyrinogen"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "Uroporphomethene"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Uroporphomethene differs from uroporphyrinogen by a single oxidized bridge carbon, and although it is able to bind strongly to the active site of UROD, it is unable to serve as a sub strate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "Uroporphomethene"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrinogen III"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of PCT is thought to involve iron-generated free oxygen radicals that oxidize uroporphyrinogen, leading to the formation of a uroporphomethene inhibitor of UROD."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "Uroporphomethene"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrinogen III"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Proteasome inhibitors or chemical chaperones might stabilize abnormal UROS variants to increase its activity and reduce porphyrin accumulation and skin photosensitivity in patients with CEP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "Uroporphomethene"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A mild variant with low uroporphyrin I levels due to a missense mutation (A66V) encoding residual uroporphyrinogen III synthase activity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chlorophyll"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The patient also had a moderate hepatomegaly, and liver biopsy revealed a slight steatosis, a reticuloendothelial hemosiderin accumulation, and red fluorescence under Wood's light."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "fluorescence"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "Steatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^110 As many as 23 % of patients with EPP develop protoporphyrin-containing gallstones that emit red fluorescence under long-wave ultraviolet light."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "fluorescence"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Excess porphyrins in the skin interact with light of approximately 400 nm -wavelength and are activated and generate reactive oxygen species that cause skin damage and increased fragility (Grossman and Poh-Fitzpatrick, 1980; Lim, 1989)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "skin damage"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Sun exposure then activates these products facilitating an immune reaction and subsequent skin damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "skin damage"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "immune reaction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table: Classifications and principal clinical features"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blistering"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table: Classifications and principal clinical features"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-Aminolevulinic acid"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepatoerythropoietic porphyria (HEP) HEP is a rare form of cutaneous porphyria (Romeo and Levin, 1969), with approximately 40 cases were reported up to 2010 (Cantatore-Francis et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hepatoerythropoietic porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cutaneous porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Erythrocyte porphyrins are normal or mildly elevated in PCT but markedly elevated in HEP and congenital erythropoietic porphyria"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hepatoerythropoietic porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mild cases of HEP may resemble PCT but are readily differentiated by marked eleva tion in erythrocyte zinc protoporphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hepatoerythropoietic porphyria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In contrast, the need for erythroid heme synthesis is rather constant throughout life, although it, too, maybe stimulated under conditions of blood loss or hemolysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemolysis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hemolytic anemia is less frequent and severe than in CEP, but anemia due at least in part to hemolysis is common, and may be accompanied by hepatosplenomegaly ((Meguro et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemolysis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemolytic anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "secondary anemia due to hemolysis"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemolysis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mild to severe hemolysis is a feature of CEP and is accompanied by anisocytosis, poikilocytosis, polychromasia, basophilic stippling, reticulocytosis, increased circulating nucleated red cells, and absence of haptoglobin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemolysis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "reticulocytosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hemolytic anemia is less frequent and severe than in CEP, but anemia due at least in part to hemolysis is common, and may be accompanied by hepatosplenomegaly ((Meguro et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemolytic anemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "Hepatosplenomegaly"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mild anemia due at least in part to hemolysis is common, and may be accompanied by hepatosplenomegaly ((Meguro et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "anemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mild anemia due at least in part to hemolysis is common, and may be accompanied by hepatosplenomegaly ((Meguro et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "Hepatosplenomegaly"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Long-term compli cations of AHP include recurrent severe acute attacks, kidney failure, hypertension [5] and pri mary liver cancer (PLC)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with AHP had a higher risk of kidney cancer (0.8 % vs. 0.2 %, p<0.001), hypertension, and chronic kidney disease but no increase in risk for cardiovascular disease, except for cerebrovascular disease in patients with elevated U-PBG, (aHR =1.40 [95% CI:1.06-1.85])."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Long-term compli cations of AHP include recurrent severe acute attacks, kidney failure, hypertension [5] and pri mary liver cancer (PLC)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute Disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Based on the recorded causes of death, AHP patients had a higher risk of death related to renal disease ( n=12[1.0 %] vs. ref, n=37[0.3 %], p<0.001 ), PLC ( n=54[4.3 %] vs. ref, n=20[0.2 %], p<0.001 ) and porphyria ( n=10[0.8 %] vs. ref, n=0 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with AHP had a higher risk of kidney cancer (0.8 % vs. 0.2 %, p<0.001), hypertension, and chronic kidney disease but no increase in risk for cardiovascular disease, except for cerebrovascular disease in patients with elevated U-PBG, (aHR =1.40 [95% CI:1.06-1.85])."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our findings confirmed a substantially higher risk of PLC associated with AHP compared to the general population."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A strong association between AHP and PLC was f irst described by Swedish investigators in 1984"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Long-term compli cations of AHP include recurrent severe acute attacks, kidney failure, hypertension [5] and pri mary liver cancer (PLC)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Long-term compli cations of AHP include recurrent severe acute attacks, kidney failure, hypertension [5] and pri mary liver cancer (PLC)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The novel findings of a moderate to substantial association between AHP and kidney and endometrial cancers should be investigated further."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "endometrial cancers"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PLC risk was substantially higher for individuals with an AHP diagnosis compared to the reference population [adjusted hazard ratio (aHR) 108, 95% confidence interval (CI) 56207]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Based on the recorded causes of death, AHP patients had a higher risk of death related to renal disease ( n=12[1.0 %] vs. ref, n=37[0.3 %], p<0.001 ), PLC ( n=54[4.3 %] vs. ref, n=20[0.2 %], p<0.001 ) and porphyria ( n=10[0.8 %] vs. ref, n=0 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36028858.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Accumulation of ALA and PBG is thought to cause injury primarily to the nervous system, as well as to other organs, such as the liver and kidneys [2-4].Of the four subtypes of AHP, the most common is acute intermittent porphyria (AIP) [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria may be categorized clinically as acute hepatic, blistering cutaneous, or nonblistering cutaneous depending on clinical features."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Erythropoietic protoporphyria (EPP) is an inherited disorder of haem biosynthesis that results in the accumulation of protoporphyrin IX, a photosensitive molecule that causes severe cutaneous pain and, in a minority of patients, cholestatic liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cholestatic liver disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "coproporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^h Lead poisoning affects 3 enzymes involved in heme biosynthesis (ALAD, CPOX, and FECH)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most porphyriarelated drugs are thought to induce cytochrome P450 activity and thus increase the demand for hepatic heme biosynthesis, leading to increased porphyrin formation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias (APs) are inherited disorders caused by deficiencies in one of the enzymes involved in haem biosynthesis, leading to overproduction of potentially neurotoxic porphyrin precursors (delta-aminolaevulinic acid [ALA] and porphobilinogen [PBG]) in the liver when the rate-limiting enzyme, ALA synthase 1 (ALAS1), is activated."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias (APs) are inherited disorders caused by deficiencies in one of the enzymes involved in haem biosynthesis, leading to overproduction of potentially neurotoxic porphyrin precursors (delta-aminolaevulinic acid [ALA] and porphobilinogen [PBG]) in the liver when the rate-limiting enzyme, ALA synthase 1 (ALAS1), is activated."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two young adults, ages 21 and 23 years, with severe HEP developed generalized seizures and had neuroimaging evidence of cerebral cortical atrophy and calcifications in the frontal lobes, presumably related to hypoxic injury as in other porphyrias (Berenguer et al. 1997)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypoxic injury"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two young adults, ages 21 and 23 years, with severe HEP developed generalized seizures and had neuroimaging evidence of cerebral cortical atrophy and calcifications in the frontal lobes, presumably related to hypoxic injury as in other porphyrias (Berenguer et al. 1997)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypoxic injury"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "calcifications"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also review symptoms and pathologies of lead intoxication that affect enzymes that mediate heme synthesis and share features with porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lead intoxication"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heme therapy can relieve symptoms of lead intoxication and ALADP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lead intoxication"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other risk factors include aflatoxin B1 intake, alcohol consumption, and some hereditary diseases, among which are hereditary hemochromatosis, hereditary tyrosinemia, and \u00c3\u017d\u00c2\u00b1_1 anti-trypsin deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tyrosinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tyrosinemia"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Type 1 tyrosinemia is not a primary disorder of porphyrin metabolism but indirectly leads to similar biochemical changes and porphyria-like symptoms as in ALADP, caused by the accumulation of succinyl acetone, a potent inhibitor of ALAD."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tyrosinemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholism"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic renal insufficiency"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary tyrosinemia type 1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "coproporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Succinylacetone, a structural analogue of ALA and a potent inhibitor of ALAD (Sassa and Kappas, 1983), is increased in plasma and urine of patients with hereditary tyrosinemia type 1 (Lindblad, Lindstedt and Steen, 1977)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary tyrosinemia type 1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Succinylacetone"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other risk factors include aflatoxin B1 intake, alcohol consumption, and some hereditary diseases, among which are hereditary hemochromatosis, hereditary tyrosinemia, and \u00c3\u017d\u00c2\u00b1_1 anti-trypsin deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "aflatoxin B1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "One reason for iron accumulation is mutations of the HFE genes associated with hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron accumulation is more likely to occur in subjects with the common HFE mutations associated with hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": ", 2002), in 119 consecutive patients with chronic hepatitis C, the H F E mutations commonly associated with hereditary hemochromatosis were significantly more common in these patients in comparison with findings for control subjects ( 48 % vs. 37.9 %, P=.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of H F E, especially in C 282 Y^+1 s homozygotes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27, 1695-1699."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Indeed, recent study findings from Australia, summarized by Fletcher and Powell elsewhere in this volume, highlight the synergistic effects of alcohol and hereditary hemochromatosis in producing advanced degrees of hepatic fibrosis and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Indeed, recent study findings from Australia, summarized by Fletcher and Powell elsewhere in this volume, highlight the synergistic effects of alcohol and hereditary hemochromatosis in producing advanced degrees of hepatic fibrosis and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additional risk factors include myeloproliferative disorders, exposure to polyhalogenated compounds, estrogen therapy, diseases of iron overload like hereditary hemochromatosis (HH), and potentially, HIV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary hemochromatosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "myeloproliferative disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Succinylacetone, a structural analogue of ALA and a potent inhibitor of ALAD (Sassa and Kappas, 1983), is increased in plasma and urine of patients with hereditary tyrosinemia type 1 (Lindblad, Lindstedt and Steen, 1977)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Succinylacetone"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lead metal inhibits ALAD activity by displacing zinc from the enzyme (Bergdahl et al. 1997; Granick, Sassa and Kappas, 1978).Individuals with heterozygous ALAD deficiency may be more susceptible to lead poisoning (Doss, Laubenthal and Stoppler, 1984)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Specialized porphyria laboratories report levels of total erythrocyte, metal-free, and zinc-protoporphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "FECH also catalyzes the insertion of zinc, to form zinc protoporphyrin from any protoporphyrin that remains after completion of heme synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^113 The proportion of zinc-protoporphyrin to metal-free protoporphyrin is significantly higher in patients with XLP ( >25 % ) than in those with EPP (up to 15%).Notably, urinary porphyrins are normal in protoporphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^g In XLP, the ratio of zinc-bound protoporphyrin to metal-free protoporphyrin is >25 %."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Specialized porphyria laboratories report levels of total erythrocyte, metal-free, and zinc-protoporphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "EPP arises due to pathogenic variants in ferrochelatase (FECH), the last step in haem biosynthesis, which incorpo rates iron into protoporphyrin to form haem."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^h Lead poisoning affects 3 enzymes involved in heme biosynthesis (ALAD, CPOX, and FECH)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Lead"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^105,106 FECH deficiency increases levels of metalfree erythrocyte PPIX, in contrast to secondary elevations of zinc-bound erythrocyte protoporphyrin that are caused by iron deficiency, lead intoxication, or hemolytic anemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with erythropoietic protoporphyria have either a decreased activity of ferrochelatase (FECH) or a gain of function of aminolevulinic acid synthase 2 (ALAS2), leading to overproduction of protoporphyrin IX"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^105,106 FECH deficiency increases levels of metalfree erythrocyte PPIX, in contrast to secondary elevations of zinc-bound erythrocyte protoporphyrin that are caused by iron deficiency, lead intoxication, or hemolytic anemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "erythrocyte protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Etiology and pathogenesis of EPP and XLP\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009dEPP is caused by mutations in the gene encoding FECH, a mitochondrial enzyme that catalyzes the insertion of ferrous iron (Fe^2+) into protoporphyrin to form heme (Todd 1994; Poh-Fitzpatrick, 1995; Cox, 1997; Elder, 1999)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the 8th and final step of heme synthesis, the enzyme FECH inserts ferrous iron into PP to form heme."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Protoporphyrias ## Pathophysiology EPP is caused by a partial deficiency of FECH, which catalyzes the final step in heme synthesis (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "FECH also catalyzes the insertion of zinc, to form zinc protoporphyrin from any protoporphyrin that remains after completion of heme synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Because impaired FECH activity reduces formation of zinc protoporphyrin, more than 85 More than 130 FECH mutations have been identified in EPP (HGMD, 2014)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Because FECH is not deficient in XLP, some of the excess protopophryin measured in erythrocytes is zinc-chelated and only 50 \u00c3\u00a2\u00cb\u2020\u00c2\u00bc 85 % is metal-free."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The disease is characterized by overproduction and accumulation of protoporphyrin, the highly hydrophobic and photoactive substrate of the ferrochelatase enzyme."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Administration of an antisense oligonucleotide that prevents the abnormal splicing of the nascent mutant FECH mRNA in developing human erythroblasts of a patient with EPP increased the production of functional FECH and reduced the accumulation of PPIX.130 ## Case Report A 67-year-old female patient presented with pronounced photosensitivity (burning, stinging pain, swelling, and itching) on light-exposed skin areas (prominent in the face and on the back of the hands) since early childhood."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "splicing"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "EPO"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that protoporphyrin was significantly associated with platelet count (\u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, \u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.18, p = 0.029, Figure 1B), spleen length (\u00c3\u017d\u00c2\u00b2 = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, \u00c3\u017d\u00c2\u00b2 = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, \u00c3\u017d\u00c2\u00b2 = 0.22, p < 0.001, Figure 1D)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "extramedullary hematopoiesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Finally, spleen size, a potential marker for extramedullary haematopoiesis, has not been rigorously examined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "platelet count"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that protoporphyrin was significantly associated with platelet count (\u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, \u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.18, p = 0.029, Figure 1B), spleen length (\u00c3\u017d\u00c2\u00b2 = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, \u00c3\u017d\u00c2\u00b2 = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, \u00c3\u017d\u00c2\u00b2 = 0.22, p < 0.001, Figure 1D)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "platelet count"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, protoporphyrin was associated with platelet count, even when controlling for spleen size."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "platelet count"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This suggests that the relation ship between protoporphyrin and platelets could be related to a pathway that leads to an increase in spleen size, but there could also be a separate mechanism that does not involve the spleen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "mean corpuscular volume"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that protoporphyrin was significantly associated with platelet count (\u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, \u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.18, p = 0.029, Figure 1B), spleen length (\u00c3\u017d\u00c2\u00b2 = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, \u00c3\u017d\u00c2\u00b2 = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, \u00c3\u017d\u00c2\u00b2 = 0.22, p < 0.001, Figure 1D)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "mean corpuscular volume"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also found associations between protoporphyrin and MCV and between protoporphyrin and spleen length."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "splenomegaly"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that protoporphyrin was significantly associated with platelet count (\u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, \u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.18, p = 0.029, Figure 1B), spleen length (\u00c3\u017d\u00c2\u00b2 = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, \u00c3\u017d\u00c2\u00b2 = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, \u00c3\u017d\u00c2\u00b2 = 0.22, p < 0.001, Figure 1D)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "splenomegaly"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also found associations between protoporphyrin and MCV and between protoporphyrin and spleen length."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "splenomegaly"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For the first time, to our knowledge, we documented mild splenic enlargement in patients with EPP and found a direct relationship between protoporphyrin levels and spleen length."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "splenomegaly"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Therefore, we posit that the relationship between spleen size and protoporphyrin levels is an intriguing observation that deserves further investigation beyond this study."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Alanine Aminotransferase"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We found that protoporphyrin was significantly associated with platelet count (\u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, \u00c3\u017d\u00c2\u00b2 = \u00c3\u00a2\u00cb\u2020\u00e2\u20ac\u21220.18, p = 0.029, Figure 1B), spleen length (\u00c3\u017d\u00c2\u00b2 = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, \u00c3\u017d\u00c2\u00b2 = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, \u00c3\u017d\u00c2\u00b2 = 0.22, p < 0.001, Figure 1D)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^120,121 Erythrocyte concentrates that suppress erythropoiesis and plasma exchange that removes excess metal-free protoporphyrin have been used to treat liver failure or prevent further decompensation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "erythropoiesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "rythrocyte concentrates that suppress erythropoiesis and plasma exchange that removes excess metal-free protoporphyrin have been used to treat liver failure or prevent further decompensation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^f In EPP, the ratio of zinc-bound protoporphyrin to metal-free protoporphyrin is significantly lower ( <15 % ) than in XLP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The combination of two allelic variants reduces overall FECH activity to 35 % of normal or less, causing accumulation of protoporphyrin during hemoglobin synthesis (Gouya et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In this study of 152 patients with EPP followed at four specialized porphyria centres in the United States and Europe, we found a significant inverse linear association between protoporphyrin levels and platelet counts."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thrombocytopenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mild thrombocytopenia has also been observed in EPP, with an inverse relationship between protoporphyrin levels and platelet count."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The accumulation of protoporphyrin can cause liver damage when the hepatic load exceeds the canalicular excretion capacity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Photosensitivity Disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Protoporphyrin accumulation leads to painful sensitivity to sunlight in all patients and hepatobiliary dis ease in some patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Etiology and pathogenesis of EPP and XLP\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009dEPP is caused by mutations in the gene encoding FECH, a mitochondrial enzyme that catalyzes the insertion of ferrous iron (Fe^2+) into protoporphyrin to form heme (Todd 1994; Poh-Fitzpatrick, 1995; Cox, 1997; Elder, 1999)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Elevated levels of erythrocyte metal- free protoporphyrin IX (hereafter re ferred to as \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153protoporphyrin\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2) are diagnostic of EPP, with ge netic testing ruling out X- linked protoporphyria, a distinct protoporphyria caused by variants in ALAS2"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "severe disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On average, patients with XLP have more severe disease, with higher protoporphyrin levels and perhaps a greater risk of liver disease than do those with EPP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cholestasis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The liver damage is characterized by cholestasis due to protoporphyrin precipitation within hepatocytes and the intrahepatic biliary tree."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "hepatobillary disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Protoporphyrin accumulation leads to painful sensitivity to sunlight in all patients and hepatobiliary dis ease in some patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Gallstone Disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gallstone disease thought to result mainly from protoporphyrin precipitation in the gallbladder, may occur even in childhood"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "trichloroethylene"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The ALAD enzyme activity has also been shown to be reduced when rats were exposed to trichloroethylene (Fujita et al. 1984), styrene (Fujita et al. 1986), lead (Sassa, Granick, Kappas, 1975), and iron (Bonkovsky et al. 1987)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "styrene"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The ALAD enzyme activity has also been shown to be reduced when rats were exposed to trichloroethylene (Fujita et al. 1984), styrene (Fujita et al. 1986), lead (Sassa, Granick, Kappas, 1975), and iron (Bonkovsky et al. 1987)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hemoglobin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The excess zinc protoporphyrin in erythrocytes is probably formed from pathway intermediates that accumulate during hemoglobin synthesis and are later metabolized to protoporphyrin, and then complexed with zinc (Phillips et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "erythropoietic"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This is the basis for classification of porphyrias as either hepatic or erythropoietic."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS2"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "EPO"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In contrast to the liver, iron and erythropoietin, instead of heme, regulate the ratecontrolling bone marrow enzyme ALAS2."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS2"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is the most recently described porphyria, and results from gain of function mutations of the erythroid-specific form on \u00c3\u017d\u00c2\u00b4-aminolevulinic acid synthase (ALAS2), which catalyzes the first step in heme biosynthesis in marrow erythroid cells."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS2"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heterozygous females may have normal or elevated levels of protoporphyrin depending on the degree of inactivation of the X chromosome that carries the ALAS2 mutation (Whatley et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS2"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with erythropoietic protoporphyria have either a decreased activity of ferrochelatase (FECH) or a gain of function of aminolevulinic acid synthase 2 (ALAS2), leading to overproduction of protoporphyrin IX"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Photosensitivity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "EFO",
         "name": "hepatotoxicity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Abnormal liver enzyme level"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cholelithiasis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute Liver Failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "itching"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Swelling"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Swelling, burning, itching, and redness of the skin may appear during or after exposure to sunlight."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "redness of the skin"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "itching"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Swelling, burning, itching, and redness of the skin may appear during or after exposure to sunlight."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "redness of the skin"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Swelling"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Swelling, burning, itching, and redness of the skin may appear during or after exposure to sunlight."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Between 25% and 33% of patients with EPP display some degree of liver dam age."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Afamelanotide"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Afamelanotide for erythropoietic protoporphyria. Increasing skin pigmentation with afamelanotide, an \u00c3\u017d\u00c2\u00b1-melanocyte stimulating hormone analogue, can significantly increase sunlight tolerance"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALPL"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Alkaline phosphatase levels (strongly related to vitamin D deficiency) and low bone relevant physical activity are the most relevant predictors for osteoporosis in erythropoietic protoporphyria patients"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALPL"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin D"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Alkaline phosphatase levels (strongly related to vitamin D deficiency) and low bone relevant physical activity are the most relevant predictors for osteoporosis in erythropoietic protoporphyria patients"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin D"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cholestatic liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Among the cutaneous porphyrias, erythropoietic pro toporphyria (EPP) can lead to cholestatic liver failure where LT cures the liver disease but not the porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thrombocytopenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Therefore, splenic sequestration may be a more likely cause of the mild throm bocytopenia observed in EPP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron deficiency anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although some data suggest EPP cutaneous reactions may have some measurable inflammatory component,3,17,18 inflammation is expected to decrease haemoglobin but in crease ferritin and platelet count.19 Therefore, the laboratory values we observed seem more consistent with iron defi ciency anaemia than anaemia of inflammation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sideroblastic anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, erythropoietic protoporphyria patients have been reported to have small intestinal signs and have also been reported to develop eventually sideroblastic anemia (91)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Alkaline phosphatase levels (strongly related to vitamin D deficiency) and low bone relevant physical activity are the most relevant predictors for osteoporosis in erythropoietic protoporphyria patients"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition to a high prevalence of vitamin D deficiency, the prevalence of osteoporosis in erythropoietic protoporphyria patients is very high"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The aim of this study was to evaluate bone mineral density and known osteoporosis risk factors in erythropoietic protoporphyria patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "osteopenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The non-acute porphyrias are porphyria cutanea tarda, erythropoietic protoporphyria, X-linked protoporphyria, and the rare congenital erythropoietic porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On the contrary, Graziadei et al. observed that in 20 patients with EPP, sTfR levels were higher than those of the control patients, indicating decreased total body iron stores. In the present study, ferritin was lower in EPP patients than controls, which is both highly sensitive and specific for reduced total body iron stores."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "All patients had to have a confirmed diagnosis of erythropoietic protoporphyria, based on phototoxic symptoms with increased free protoporphyrin IX levels (> 4 times the upper limit of normal: 1.5 umol/ L in erythrocytes), and detection of known pathogenic mutations in the FECH gen, or a gain of function mutation in the ALAS2 gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "EPP arises due to pathogenic variants in ferrochelatase (FECH), the last step in haem biosynthesis, which incorpo rates iron into protoporphyrin to form haem."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "platelet count"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a case\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153control analysis, platelet count, haemoglobin, MCV and ferritin levels were all lower in EPP patients than in matched controls."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "mean corpuscular volume"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a case\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153control analysis, platelet count, haemoglobin, MCV and ferritin levels were all lower in EPP patients than in matched controls."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bone Density"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "large cohort of erythropoietic protoporphyria patients, clinically significant lower bone density was found in a high number of patients: osteopenia in 36% and osteoporosis in 23% of patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bone Density"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bone Density"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hemoglobin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a case\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153control analysis, platelet count, haemoglobin, MCV and ferritin levels were all lower in EPP patients than in matched controls."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "PFAM",
         "name": "Ferritin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a case\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153control analysis, platelet count, haemoglobin, MCV and ferritin levels were all lower in EPP patients than in matched controls."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "PFAM",
         "name": "Ferritin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On the contrary, Graziadei et al. observed that in 20 patients with EPP, sTfR levels were higher than those of the control patients, indicating decreased total body iron stores. In the present study, ferritin was lower in EPP patients than controls, which is both highly sensitive and specific for reduced total body iron stores."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ferrochelatase"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Autosomal recessive defects in ferrochetalase (FECH) causeery thropoieticprotoporphyria(EPP),whereaccumulationandphotoactiv ity of protoporphyrin mediate both skin and liver damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ferrochelatase"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The patient with EPP, Patient 5, was 18yearsold,withaconfirmedFECHdeletionandalowexpressionpre disposing single-nucleotide polymorphism(SNP)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with erythropoietic protoporphyria (EPP, OMIM 177000) suffer from extreme pain after (sun) light exposure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathophysiology is thought to involve the production of reactive oxygen species and complement after light activates protoporphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Protoporphyrin accumulation leads to painful sensitivity to sunlight in all patients and hepatobiliary dis ease in some patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS2"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "All patients had to have a confirmed diagnosis of erythropoietic protoporphyria, based on phototoxic symptoms with increased free protoporphyrin IX levels (> 4 times the upper limit of normal: 1.5 umol/ L in erythrocytes), and detection of known pathogenic mutations in the FECH gen, or a gain of function mutation in the ALAS2 gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Erythropoietic protoporphyria is a rare metabolic disease with painful photosensitivity due to protoporphyrin IX accumulation, resulting in lifelong light avoidance behaviour."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with erythropoietic protoporphyria have either a decreased activity of ferrochelatase (FECH) or a gain of function of aminolevulinic acid synthase 2 (ALAS2), leading to overproduction of protoporphyrin IX"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin IX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "All patients had to have a confirmed diagnosis of erythropoietic protoporphyria, based on phototoxic symptoms with increased free protoporphyrin IX levels (> 4 times the upper limit of normal: 1.5 umol/ L in erythrocytes), and detection of known pathogenic mutations in the FECH gen, or a gain of function mutation in the ALAS2 gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "large cohort of erythropoietic protoporphyria patients, clinically significant lower bone density was found in a high number of patients: osteopenia in 36% and osteoporosis in 23% of patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "osteopenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "large cohort of erythropoietic protoporphyria patients, clinically significant lower bone density was found in a high number of patients: osteopenia in 36% and osteoporosis in 23% of patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "osteopenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Photosensitivity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Erythropoietic protoporphyria is a rare metabolic disease with painful photosensitivity due to protoporphyrin IX accumulation, resulting in lifelong light avoidance behaviour."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Photosensitivity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with erythropoietic protoporphyria (EPP, OMIM 177000) suffer from extreme pain after (sun) light exposure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Lead"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Lead"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Lead"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Lead"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CPOX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "erythrocyte protoporphyrin"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "erythema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Sun-induced erythema and blistering occurred by age 2 years in 75% of reported cases of patients. Biochemical abnormalities resemble PCT, but with substantial elevations of erythrocyte protoporphyrin (predominantly zinc protoporphyrin) level."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "splenomegaly"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^135 Anemia and splenomegaly may develop later."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thrombocytopenia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Finally, spleen size, a potential marker for extramedullary haematopoiesis, has not been rigorously examined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thrombocytopenia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Yet, thrombocytopenia in EPP re mains poorly characterized, and levels of the megakaryocyte- stimulating hormone thrombopoietin (TPO) have not been reported."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thrombocytopenia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "extramedullary hematopoiesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Finally, spleen size, a potential marker for extramedullary haematopoiesis, has not been rigorously examined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bullae"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Skin biopsy was performed in these two patients revealing findings compatible with dermatological porphyria: subepidermal bullae with festooning of Table 1 Clinical characteristics of enrolled patients | Patients | Age | Ferritin (ng/mL) | HCV | Hormonal replacement therapy | Urinary porphyrin ( \u00c3\u017d\u00c2\u00bcg / Lt ) | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | | 1 | 34 | 902 | + | + | 7300 | | 2 | 29 | 540 | | + | 1185 | | 3 | 34 | 654 | | | 230 | | 4 | 33 | 4531 | | + | 203 | | 5 | 16 | 165 | | | 160 | | 6 | 38 | 3310 | + | | 142 | | 7 | 19 | 3410 | | | 76 | | 8 | 35 | 1919 | + | | 47 | | 9 | 21 | 5022 | | | 66 | | 10 | 27 | 264 | | | 95 | | 11 | 29 | 357 | | | 120 | | 12 | 41 | 293 | | + | 95 | | 13 | 32 | 2812 | + | + | 47 | | 14 | 24 | 164 | | | 57 | | 15 | 34 | 255 | | + | 95 | | 16 | 30 | 637 | | | 59 | | 17 | 48 | 592 | | | 33 | | 18 | 33 | 3041 | + | + | 52 | !"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bullae"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Figure 1 Patient with hypertrichosis of zygomatics, hyperpigmentation, scars and bullae of the face and hands."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bullae"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "IgG"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "al papillae into the bullae and in direct immunofluorescence deposition of IgG immunoglobulins around the blood vessels of the papillary dermis and dermoepidermal junction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "Exposure to light"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "swelling"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Continued light exposure can cause swelling, and redness, and systemic symptoms that can last for several days."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "Exposure to light"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "redness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Continued light exposure can cause swelling, and redness, and systemic symptoms that can last for several days."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron deficiency anemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "protoporphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mild iron deficiency anemia is a common feature of protoporphyria, and is poorly explained (Goerz et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CPOX"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^h Lead poisoning affects 3 enzymes involved in heme biosynthesis (ALAD, CPOX, and FECH)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CPOX"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lead poisoning"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CPOX"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Certain CPOX mutations release the substrate after one decarboxylation as harderoporphyrinogen, a tricarboxylate porphyrinogen that is then oxidized to the corresponding porphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CPOX"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "ovulation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "About 20% of those with an acute attack report photosensitivity although bullae and skin fragility are much less common than in VP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrinogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tricarboxylate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Certain CPOX mutations release the substrate after one decarboxylation as harderoporphyrinogen, a tricarboxylate porphyrinogen that is then oxidized to the corresponding porphyrin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vascular lesions"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "generalized seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Two young adults, ages 21 and 23 years, with severe HEP developed generalized seizures and had neuroimaging evidence of cerebral cortical atrophy and calcifications in the frontal lobes, presumably related to hypoxic injury as in other porphyrias (Berenguer et al. 1997)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vascular lesions"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "calcifications"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "osteolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Skeletal changes such as osteolysis and calcifications were frequent (Fritsch et al. 1997)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "myeloproliferative disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neurological impairment"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Another patient was a child with neurological impairment from birth, and the sixth was an adult and disease onset associated with a myeloproliferative disorder (Sassa, 1998; Maruno et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "spontaneous abortions"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This study suggested that most instances of compound heterozygosity in ALAD result in spontaneous abortions."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Clinical features of CEP\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009dThe phenotype can vary depending on the severity of the inherited UROS mutations and levels of porphyrins in plasma and erythrocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Metabolic Bone Disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "At the age of 20 he began to experience pain in the spine and sternum. He was investigated for metabolic bone disease at the age of 22."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Congenital erythropoietic heme biosynthesis, porphyria (CEP) is a rare disorder of resulting from reduced activity enzyme uroporphyrinogen (III) cosynthetase."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In patients with congenital erythropoietic porphyria (CEP), auto somal recessive deficiencies in uroporphyrinogen III synthase (UROS) lead to accumulation of the UROS substrate hydroxymethylbilane, which is converted to metabolites that accumulate in bone marrow erythroid precursors and are released into plasma by diffusion or hemolysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin D"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although tbe serum 250H vitamin D concentration was very low (because of light avoidance) there was no evidence that the bone disease was a consequence of this"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin D"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Privational vitamin D deficiency may also occur."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bone Density"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Spinal bone density (assessed by DPA) was reduced and at the hip bone density was at the lower limit of normal."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bone Density"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Biochemical and histological studies showed accelerated bone turnover."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Life Expectancy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The term PCT was first suggested by Waldenstr\u00c3\u0192\u00c2\u00b6m ^10 in 1937 to distinguish this form of porphyria from the rare photomutilating congenital erythropoetic porphyria (Gunther's Disease)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We conclude that CEP has a distinctive osteodystropby comprising osteolysis of light-exposed ex- tremities and a high turnover type of osteoporosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "osteopenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In this young man with CEP we have observed a form of generalised osteopenia affecting both the axial and peripheral skeleton and clinically characterised by bone pain and crush fractures of the spine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Metabolic Bone Disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Bone disease has been occasionally noted, but is not well characterised."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Bone pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On examination he had minimal bone tenderness, but no myopathy or kyphosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Bone pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In this young man with CEP we have observed a form of generalised osteopenia affecting both the axial and peripheral skeleton and clinically characterised by bone pain and crush fractures of the spine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Bone pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We describe a man with CEP who developed bone pain and spinal crush fractures at the age of 22."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Compression Fractures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We describe a man with CEP who developed bone pain and spinal crush fractures at the age of 22."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "osteodystrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We conclude that CEP has a distinctive osteodystropby comprising osteolysis of light-exposed ex- tremities and a high turnover type of osteoporosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "osteodystrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This report describes the osteodystrophy of CEP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acro-Osteolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We conclude that CEP has a distinctive osteodystropby comprising osteolysis of light-exposed ex- tremities and a high turnover type of osteoporosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bone Demineralization"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although bone demineralization and fractures have been described in patients with CEP (Piomelli et al. 1986), bone disease has not been generally recognized as a complication of this disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Fractures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although bone demineralization and fractures have been described in patients with CEP (Piomelli et al. 1986), bone disease has not been generally recognized as a complication of this disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neonatal Jaundice"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "CEP was diagnosed at the age of two months in an infant presenting with persistent neonatal jaundice and hemolysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "CEP was diagnosed at the age of two months in an infant presenting with persistent neonatal jaundice and hemolysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Photosensitivity Disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Upon absorption of light, these highly photoreactive com pounds cause oxidative damage to the cell membrane and organelles"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Congenital erytbropoietic porphyria (CEP) is a rare disorder of heme biosynthesis that results in the production of large quantities of photoactive porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemolytic anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical syndrome is dominated by extreme photosensitivity with mutilation of light exposed extremities and bemolytic anemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemolytic anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Skeletal radiographs revealed features typical of other severe hemolytic anemias, but in addition there was loss of the terminal phalanges of the hand as a result of photomutilation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemolytic anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxymethylbilane"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In patients with congenital erythropoietic porphyria (CEP), auto somal recessive deficiencies in uroporphyrinogen III synthase (UROS) lead to accumulation of the UROS substrate hydroxymethylbilane, which is converted to metabolites that accumulate in bone marrow erythroid precursors and are released into plasma by diffusion or hemolysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Photosensitivity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical syndrome is dominated by extreme photosensitivity with mutilation of light exposed extremities and bemolytic anemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "photomutilation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Skeletal radiographs revealed features typical of other severe hemolytic anemias, but in addition there was loss of the terminal phalanges of the hand as a result of photomutilation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "photomutilation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "photomutilation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There was extensive photomutilation of the face and hands with scarring alopecia and shortening of the digits."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SNOMED",
         "name": "Hepatosplenomegaly"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "erythrodontia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alopecia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There was extensive photomutilation of the face and hands with scarring alopecia and shortening of the digits."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Upon absorption of light, these highly photoreactive com pounds cause oxidative damage to the cell membrane and organelles"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "mutations"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Clinical features of CEP\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009dThe phenotype can vary depending on the severity of the inherited UROS mutations and levels of porphyrins in plasma and erythrocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxymethylbilane"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Examinations revealed positivity for porphobilinogen (PBG) in urine and a mutation in the hydroxymethylbilane synthetase (HMBS) gene: c. 806 C>G (p.Thr269Arg) (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxymethylbilane"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "coproporphyrinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^133,134 This leads to accumulation of hydroxymethylbilane, spontaneously (non-enzymatically) forming uroporphyrinogen I, that is further metabolized to the non-functional end product coproporphyrinogen I. Spontaneous oxidation of the porphyrinogens generates porphyrins that accumulate in tissues."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxymethylbilane"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "UROS catalyzes the conversion of hydroxymethylbilane, a linear tetrapyrrole, to the cyclic tetrapyrrole uroporphyrinogen III."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hydrops"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Biochemical diagnosis of a fatal case of Gunther's disease in a newborn with hydrops foetalis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Gunther's disease"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Compared to PCT, the cutaneous features of HEP typically have earlier onset, increased severity leading to disfigurement, and closer resemblance to those in CEP (G\u00fcnther disease)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "EPX"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is not known why in families with two disabling FECH mutations, EPP is associated with palmar keratoderma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "carcinogenesis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In general, VP and HCP are less clinically active and have lower levels of ALA, which is regarded as the most likely porphyrin precursor to be involved in carcinogenesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antidiuretic hormone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter may be due to hyponatremia, resulting from hypothalamic involvement and inappropriately high levels of antidiuretic hormone."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antidiuretic hormone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "An inappropriately high secretion of antidiuretic hormone (Schwartz-Bartter syndrome) leads to a potentially lifethreatening severe hyponatremia, another diagnostic feature of acute porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "progesterone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The reproductive steroids progesterone, medroxyprogesterone and testosterone are particularly potent inducers of hepatic ALAS1 (Kappas, Sassa and Anderson, 1983; Thunell, Pomp and Brun, 2007)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "progesterone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogens"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Some women have cyclic menstrual attacks, progesterone increases heme catabolism, and synthetic estrogens and progesterones induce porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "progesterone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "luteal phase"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Some women have attacks during the luteal phase of the cycle when levels of progesterone are increased."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sideroblastic anemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | porphyria ('ALASm')/ sideroblastic anemia | 5-aminolevulinate synthase ( A L A S 2, Gene ID: 212, E.C. 2.3.1.37)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HHcy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HHcy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HHcy"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "Deep venous thrombosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "After exclusion of factors showing a high collinearity, at multivariate analysis, only disease status (i.e. being in APBP/APSP groups) was shown to be an independent predictor of HHcy [OR = 25 (95 Three patients had a history of deep vein thrombosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HHcy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The link between AP, HHcy and vitamin deficiency is also intriguing if considering that the clinic of peripheral neuropathy resulting from a deficiency in PLP shows striking resemblances to that observed in acute porphyrias [45-47].When considering the high prevalence of vitamin deficiencies in the general population [18,48,49], and in porphyria patients [50], it is likely that depletion of vitamin cofactors in multiple tissues promoted by a deficiency in heme biosynthesis may contribute to worsen other underlying deficiencies."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "testosterone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The reproductive steroids progesterone, medroxyprogesterone and testosterone are particularly potent inducers of hepatic ALAS1 (Kappas, Sassa and Anderson, 1983; Thunell, Pomp and Brun, 2007)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "testosterone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "medroxyprogesterone"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The reproductive steroids progesterone, medroxyprogesterone and testosterone are particularly potent inducers of hepatic ALAS1 (Kappas, Sassa and Anderson, 1983; Thunell, Pomp and Brun, 2007)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "medroxyprogesterone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The reproductive steroids progesterone, medroxyprogesterone and testosterone are particularly potent inducers of hepatic ALAS1 (Kappas, Sassa and Anderson, 1983; Thunell, Pomp and Brun, 2007)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "diets"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PPARGC1A"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Fasting and low calorie diets can cause attacks due to ALAS induction, and this effect is mediated by PGC-1 \u00c3\u017d\u00c2\u00b1 (Phillips and Kushner, 2005)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "serum cholesterol"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperthyroidism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Increased serum T4 and thyroxine binding globulin in the absence of hyperthyroidism, and elevated serum cholesterol and low-density lipoprotein (LDL), are sometimes seen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "NASH"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "NASH"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "NASH"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "An Australian study showed that the major HFE mutation (C282Y) associated with HH is correlated with iron abnormalities found in patients with NASH."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "NASH"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Serum iron indices and hepatic iron staining were higher in our NASH patients who carried HFE mutations than in those who did not, but there was no difference in HIC or HII between the NASH patients with and without HFE mutations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "quadriplegia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "VP can cause acute attacks identical to those in AIP, with abdominal pain, vomiting, constipation, hypertension, tachycardia, and neuromuscular weakness that can progress to quadriplegia and respiratory weakness (Chemmanur and Bonkovsky, 2004)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "quadriplegia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tachycardia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "VP can cause acute attacks identical to those in AIP, with abdominal pain, vomiting, constipation, hypertension, tachycardia, and neuromuscular weakness that can progress to quadriplegia and respiratory weakness (Chemmanur and Bonkovsky, 2004)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "quadriplegia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "VP can cause acute attacks identical to those in AIP, with abdominal pain, vomiting, constipation, hypertension, tachycardia, and neuromuscular weakness that can progress to quadriplegia and respiratory weakness (Chemmanur and Bonkovsky, 2004)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "quadriplegia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "neuromuscular weakness"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "VP can cause acute attacks identical to those in AIP, with abdominal pain, vomiting, constipation, hypertension, tachycardia, and neuromuscular weakness that can progress to quadriplegia and respiratory weakness (Chemmanur and Bonkovsky, 2004)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "respiratory paralysis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "respiratory paralysis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "constipation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "quadriparesis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31374307.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition to a mutation in the gene coding for UROD, several factors are known to reduce enzyme activity and thus facilitate porphyrin accumulation: high alcohol intake, smoking, iron overload, hepatitis C, human immundeficiency virus (HIV), and estrogen use in women."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Five of these women had prominent hepatic steatosis; 1 had estrogen-induced hepatic adenomas, but the porphyrin content of a biopsy specimen taken from the adenoma did not differ from a sample from a normal portion of the liver (data not shown)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SERPINA7"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other abnormalities include increased serum T4, thyroxine binding globulin (but AIP patients are usually euthyroid, only rarely frankly thyrotoxic), and elevated cholesterol and low-density lipoprotein (LDL), simulating an exaggerated estrogen effect."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic steatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Five of these women had prominent hepatic steatosis; 1 had estrogen-induced hepatic adenomas, but the porphyrin content of a biopsy specimen taken from the adenoma did not differ from a sample from a normal portion of the liver (data not shown)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "estrogen"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic adenomas"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Five of these women had prominent hepatic steatosis; 1 had estrogen-induced hepatic adenomas, but the porphyrin content of a biopsy specimen taken from the adenoma did not differ from a sample from a normal portion of the liver (data not shown)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic adenomas"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Estrogens"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methylprednisolone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, the key drugs used in systemic therapy, such as methylprednisolone and cyclophosphamide, can induce the acute onset of AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "infectious"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On the other hand, a PCT diagnosis, black and other race compared to white race, and Hispanic ethnicity were associated with a decreased risk of cellulitis.- PCT showed no significant association with blisters, although tobacco use and hepatitis C were associated with increased risk of Table 3 Descriptive statistics by infectious outcomes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "infectious"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although disease-causing CPOX mutations occur equally in males and females, acute attacks are much more frequent in women, mainly between ages 16 and 45 years (the years of active ovulation)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Hydroxychloroquine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatotoxicity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hydroxychloroquine (and chloroquine) in the amounts used for other diseases cause hepatotoxicity in PCT, and this adverse effect is largely avoided with the low-dose regimen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "UROD deficiency"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrinogens"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This UROD deficiency is sufficient to lead to accumulation of highly carboxylated porphyrinogens and porphyrins in liver and possibly other tissues."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ulcerations"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a study using 130 cases of CEP, dermal deposits of uroporphyrin frequently induced dramatic phototoxic oxygen-dependent skin damage with extensive ulcerations and mutilations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Splenomegaly"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemolytic anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Splenomegaly and hemolytic anemia were typical internal symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemolytic anemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zinc"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^105,106 FECH deficiency increases levels of metalfree erythrocyte PPIX, in contrast to secondary elevations of zinc-bound erythrocyte protoporphyrin that are caused by iron deficiency, lead intoxication, or hemolytic anemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HP"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mild to severe hemolysis is a feature of CEP and is accompanied by anisocytosis, poikilocytosis, polychromasia, basophilic stippling, reticulocytosis, increased circulating nucleated red cells, and absence of haptoglobin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Afamelanotide"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Photosensitivity Disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Afamelanotide was approved in 2019 as a photosensitivity reducing treatment for EPP, but requires regular visits to providers trained on the implant and is not widely available; there are no similar therapies for CEP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "GBP* | OXC, TPM, VPA | CBZ, PB, PHT, PRM | | Osteoporosis | BZD, LEV, LTG, PGB, ZNS."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bone Density"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Osteoporosis increases the risk of fragility fractures"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bone Density"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Bone fragility"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "large cohort of erythropoietic protoporphyria patients, clinically significant lower bone density was found in a high number of patients: osteopenia in 36% and osteoporosis in 23% of patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Osteoporosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "Bone fragility"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hemoglobin"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also demonstrated that hepcidin levels were positively associated with ferritin and haemoglobin levels, suggesting normal physiologic iron regulation in patients with EPP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hemoglobin"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FTH1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We also demonstrated that hepcidin levels were positively associated with ferritin and haemoglobin levels, suggesting normal physiologic iron regulation in patients with EPP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hepatoerythropoietic porphyria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepatoerythropoietic porphyria: A variant of childhood-onset porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "excretion"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The metabolic (and clinical) activity of the acute porphyrias and the efficacy of therapy can be monitored by assessing metabolite excretion."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "excretion"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The diagnosis of PCT was based on typical clinical features and was confirmed by increased urine excretion of uroporphyrin (quantified spectrophotometrically) and skin biopsy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "excretion"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26132003.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Metal-free protoporphyrin enters the plasma from the bone marrow and circulating erythrocytes and is then transported to the skin, causing photosensitivity, and to the liver for excretion into bile (Bloomer et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "enterohepatic circulation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26494868.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Some protoporphyrin may subsequently be reabsorbed and undergo enterohepatic circulation (Ibrahim and Watson, 1968)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute intermittent porphyria (AIP) is an autosomal dominant inherited error of metabolism resulting from a partial deficiency in haem biosynthetic enzymes, caused by mutations in the PBGD gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a prolonged attack, acute peripheral neuropathy (PNP) and signs of central nervous system (CNS) involvement may occur. The prevalence of acute intermittent porphyria (AIP) has been estimated at 1:2000 based on likely pathogenic variations identified in the HMBS (hydroxymethylbilane synthase) gene in Caucasians, but the estimated risk of clinical symptoms in them is low, ~1%."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Nanoparticular PBGD RNA was recently shown to target hepatocytes, restore deficient enzyme activity, and protect from induced porphyria attacks in mice."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "If urine analysis identifies an acute (hepatic) porphyria, it is necessary to measure the activity of PBGD in erythrocytes and perform genetic analyses, to confirm a diagnosis of AIP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Examinations revealed positivity for porphobilinogen (PBG) in urine and a mutation in the hydroxymethylbilane synthetase (HMBS) gene: c. 806 C>G (p.Thr269Arg) (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A mutation in the HMBS gene was detected in the patient and her cousin, but the patient had more severe AIP and more severe symptoms (such as epilepsy and a limp), which may be related to the co-morbidity of PSS."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PLCD1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It has been speculated that the high incidence of AP\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090associated PLC found in Swedish studies might be related to the presence of the dominating HMBS founder gene variant (c.593G>A), found in approximately 2 / 3 of Swedish patients with AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Detection of a mutation in the HMBS gene causing porphyria: c. 806 C>G : p."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^21,22 ## Acute Hepatic porphyrias ## Pathophysiology AIP, HCP, and VP are caused by defects in enzyme (PBGD, CPOX, and protoporphyrinogen oxidase, respectively) and are promoted by excess activity of the first enzyme in hepatic heme synthesis, ALAS1 (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxymethylbilane"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Examinations revealed positivity for porphobilinogen (PBG) in urine and a mutation in the hydroxymethylbilane synthetase (HMBS) gene: c. 806 C>G (p.Thr269Arg) (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "missense mutation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Whole exon sequencing revealed a heterozygous missense mutation HMBS:NM_000190:exon12:c.806C>G (p.Thr269Arg) in the woman and her cousin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tetrapyrrole"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "tryptophan metabolic pathway"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This makes sense as ALA accumulation in the brain is one of the most significant findings involved in psychiatric manifestations of porphyria, specifically accountable for psychomotor agitation, hallucinations, anxiety, and depressive behaviors [25] (Table 2).ALA acts as an agonist of GABA autoreceptors [31], decreasing release of GABA."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "tryptophan metabolic pathway"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Current thinking is that decreased GABAergic neurons' activity in conjunction with increased glutamate release [25], increased oxidative stress [26\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2], and increased metabolites of kynurenine pathway [27] leads to disease pathology."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "tryptophan metabolic pathway"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Manifestation of psychiatric behaviors in a mouse model of griseofulvin-induced hepatic porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ammonia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Sunitinib"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SNOMED",
         "name": "Pseudoporphyria (disorder)"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Sanz-Motilva V, Martorell-Calatayud A, Llombart B, Requena C, Serra-Guill\u00c3\u0192\u00c2\u00a9n C, Nagore E, Guill\u00c3\u0192\u00c2\u00a9n C, Traves V, Sanmartin O (2015) Sunitinib-induced pseudoporphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrin metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chloroquine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Goerz G, Bolsen K, Merk H (1985) Influence of chloroquine on the porphyrin metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GPT"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Ribavirin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ribavirin monotherapy failed as a potential cure for HCV liver disease because it only improved alanine aminotransferase (ALT) without achieving sustained viral clearance."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GPT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "erythema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GPT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "pruritus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GPT"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GOT1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There were no significant differences in ALT, aspartate transaminase or total bilirubin between the EPP cases and controls (Figure S2A-C)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "glucose intolerance"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cirrhosis, on the other hand, was strongly associated with glucose intolerance."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": ", 2002), in 119 consecutive patients with chronic hepatitis C, the H F E mutations commonly associated with hereditary hemochromatosis were significantly more common in these patients in comparison with findings for control subjects ( 48 % vs. 37.9 %, P=.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of H F E, especially in C 282 Y^+1 s homozygotes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The HFE mutations were significantly more common in these patients in comparison with findings for control subjects ( 48 % versus 37.9 %, p=0.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of HFE, especially in C282Y homozygotes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A recent study of 36 patients showed that mRNA of hepcidin correlated with albumin synthesis and HIC and inversely correlated with the degree of hepatic fibrosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALB"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A recent study of 36 patients showed that mRNA of hepcidin correlated with albumin synthesis and HIC and inversely correlated with the degree of hepatic fibrosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "mRNA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A recent study of 36 patients showed that mRNA of hepcidin correlated with albumin synthesis and HIC and inversely correlated with the degree of hepatic fibrosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "type 3 PCT. HFE mutations or shared environmental factors may be present in such families"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Inherited factors may include UROD and HFE pathogenic variants."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In human beings with PCT, the presence of HFE gene mutations is the major reason for increased hepatic iron, with alcohol perhaps playing a secondary role, as has just been described for the mouse model of human hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In human beings with PCT, the presence of HFE gene mutations is the major reason for increased hepatic iron, with alcohol perhaps playing a secondary role, as has just been described for the mouse model of human hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mahon C, Purvis D, Laughton S, Bradbeer P, Teague L (2014) Imatinib mesylate-induced pseudoporphyria in two children."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Imatinib mesylate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SNOMED",
         "name": "Pseudoporphyria (disorder)"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Merk H, Bolsen K, Lissner R, Goerz G (1986) Hexachlorobenzene alteration of benzo[a]pyrene metabolism in porphyric and non-porphyric rats."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "benzo[a]pyrene"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Hexachlorobenzene"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26743054.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Eine vermehrte UV-Licht-unabh\u00c3\u0192\u00c2\u00a4ngige Kollagensynthese durch Porphyrine lie\u00c3\u0192\u00c5\u00b8 sich experimentell nachweisen [22]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "UV"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methotrexate"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "After she received 100 mg of methotrexate, drug eruptions were observed starting on day 3 and grew progressively worse."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "drug eruptions"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methotrexate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "After five uneventful cycles of actinomycin D, our patient achieved and maintained a normal serum human chorionic gonadotropin level for 3 years."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "human chorionic gonadotropin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "actinomycin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "actinomycin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Conclusions: Methotrexate and actinomycin D did not induce acute porphyric attacks in this patient with acute intermittent porphyria; however, severe adverse effects were noted with methotrexate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "actinomycin"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Methotrexate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On day 8, the erythema became brown (*upper panel*); bullous lesions were observed on her hands (*middle panel*), and mucosal erosion of her mouth continued (*lower panel*)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bullous"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "erythema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In cases not involving potentially porphyrinogenic chemotherapeutic agents, stresses such as sepsis from neutropenia and long fasting related to gastrointestinal toxicity or pain [6] could also induce acute attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neutropenia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sepsis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hematologic growth factors, including G-CSF, have been reported to be safe for porphyria patients [12], and this was true in our experience."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CSF3"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, as she was unable to recover from neutropenia (ANC remained at 12 / \u00c3\u017d\u00c2\u00bcL on day 13), additional subcutaneous G-CSF at 150 \u00c3\u017d\u00c2\u00bc g / day was administered for 2 days beginning on day 13, and her neutropenia finally resolved on day 15 (ANC, 1598 / \u00c3\u017d\u00c2\u00bcL ).During that time, her skin lesions and stomatitis also began to improve, and the prednisolone dose was reduced to 40 mg / day."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CSF3"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neutropenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our results thus indicate that G-CSF can help to prevent acute attacks resulting from sepsis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CSF3"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sepsis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Among commonly prescribed antiemetics, the 5-hydroxytryptamine receptor antagonist ondansetron and glucocorticoid are also considered safe for patients with porphyria [4, 5]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ondansetron"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Central antiemetics such as ondansetron or metoclopramide may be used for severe attacks of nausea in AP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ondansetron"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Among commonly prescribed antiemetics, the 5-hydroxytryptamine receptor antagonist ondansetron and glucocorticoid are also considered safe for patients with porphyria [4, 5]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucocorticoid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Average daily alcohol consumption was estimated in all 108 patients as follows: grade 0 (consumed no alcohol): 11 (10%) patients, including 3 children; grade 1 (drank only occasionally): 24 (22%) patients ( 5 men and 19 women); grade 2 (consumed between 20 and 70 g of alcohol daily): 23 (21%) patients ( 17 men and 6 women); and grade 3 (consumed more than 70 g of alcohol daily): 40 (46%) patients ( 42 men and 8 women)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "alcohol consumption"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Alcohol"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Such acute attacks are the most concerning manifestation of porphyria and are known to be induced by certain drugs, infection, alcohol consumption, smoking, fasting, and stress."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "alcohol consumption"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALAS1 is induced via induction of cytochrome P450 (CyP450), such as by xenobiotics, smoking, excess alcohol consumption, fasting, and female sex hormones."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "alcohol consumption"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Such acute attacks are the most concerning manifestation of porphyria and are known to be induced by certain drugs, infection, alcohol consumption, smoking, fasting, and stress."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "alcohol consumption"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "acute"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other risk factors include aflatoxin B1 intake, alcohol consumption, and some hereditary diseases, among which are hereditary hemochromatosis, hereditary tyrosinemia, and \u00c3\u017d\u00c2\u00b1_1 anti-trypsin deficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "alcohol consumption"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tyrosinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In various conditions associated with PCT, such as chronic HCV and alcohol use, hepcidin levels are low compared with controls."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Alcohol consumption decreases hepcidin expression and thereby increases iron absorption, which is mostly carried out by duodenal enterocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Contributing environmental factors include alcohol use and hepatitis C virus (HCV) infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In hepatocytes, alcohol and iron are believed to act synergistically to generate free radicals, which contribute to the forma tion of the uroporphomethene that inhibits hepatic UROD, as well as cause cellular damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "free radical"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The folic acid antagonist MTX is most frequently used to treat gestational trophoblastic disease (GTD) [2], as well as leukemia and other cancers [^0]such as breast cancer and urothelial carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid antagonist"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gestational trophoblastic disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The folic acid antagonist MTX is most frequently used to treat gestational trophoblastic disease (GTD) [2], as well as leukemia and other cancers [^0]such as breast cancer and urothelial carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid antagonist"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "leukemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The folic acid antagonist MTX is most frequently used to treat gestational trophoblastic disease (GTD) [2], as well as leukemia and other cancers [^0]such as breast cancer and urothelial carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid antagonist"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "breast cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The folic acid antagonist MTX is most frequently used to treat gestational trophoblastic disease (GTD) [2], as well as leukemia and other cancers [^0]such as breast cancer and urothelial carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid antagonist"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "urothelial carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition to GTD treatment, ACT-D is used to treat Wilms' tumor, Ewing sarcoma, and rhabdomyosarcoma; however, this agent has been reported to induce hepatic vein obstruction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "rhabdomyosarcoma"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "GTD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "She received intravenous prednisolone at 60 mg / day beginning on day 5 to treat the drug eruption."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "prednisolone"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "drug eruption"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | CBZ | | PB | | PHT | | VPA | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | | Anthracyclines | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | Cyclophosphamide | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | Cisplatin | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153\u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Corticosteroids | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153\u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | Etoposides | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | Fluorpyrimidines | | | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | Irinotecan topotecan | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | Methotrexate | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | Nitrosureas | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc| | Taxoides | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | Vincristine | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | The arrows on the left hand side of the boxes indicate the effect of interaction on the plasma levels of the cytotoxic and corticosteroid drugs and the ones on the right hand side indicate the effect on plasma levels of AEDs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Cyclophosphamide"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Anthracyclines"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the cause of this pain. Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Cyclophosphamide"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Cyclophosphamide"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "azathioprine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-fluorouracil"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "busulfan"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "procarbazine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hexamethylmelamine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Dacarbazine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chlorambucil"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "melphalan"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Mitomycin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cyclophosphamide"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, the key drugs used in systemic therapy, such as methylprednisolone and cyclophosphamide, can induce the acute onset of AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cyclophosphamide"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "mitoxantrone"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cytosine arabinoside"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "doxorubicin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "6-thioguanine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "vincristine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cisplatin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "26781485.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The doctors at Saitama Medical Center told me that methotrexate (MTX) was most commonly used to treat my disease (invasive mole with lung metastasis) but had not been implicated as either porphyrinogenic or nonporphyrinogenic, and therefore, they carefully treated me with MTX."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "lung metastasis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methotrexate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA is associated with oxidative stress and DNA damage, is cytotoxic in vitro, and is elevated in tyrosinemia type 1 , which has also been associated with a high risk of liver cancer."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "liver cancer"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALA is associated with oxidative stress and DNA damage, is cytotoxic in vitro, and is elevated in tyrosinemia type 1 , which has also been associated with a high risk of liver cancer."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "liver cancer"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "DNA damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is yet unclear whether the pathology of liver disease in patients with HCV is influenced by iron overload or limited to the direct cell damage from replication of the virus and subsequent inflammation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As a result, the main triggers for chronic encephalopathy and neuropathy in AP may be the constant excess of ALA and low\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090grade inflammation of hepatic origin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "encephalopathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^32 The overexpression of heme oxygenase-1 under conditions of inflammation, fasting, or physical or oxidative stress increases heme degradation and thereby removes feedback inhibition of ALAS1, promoting disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMOX1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As a result, the main triggers for chronic encephalopathy and neuropathy in AP may be the constant excess of ALA and low\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090grade inflammation of hepatic origin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Four types of diagnosis-specific non-PLC malignancies with more than two cases were identified as follows: kidney (n=3), endometrial (n=3), breast (n=3) and prostate cancers (n=4).The exposed were at a sevenfold increased risk of kidney cancer compared with the reference population and a sixfold increased risk of endometrial cancer (Table 3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "prostate cancers"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PLCD1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Kidney cancer is more common in patients with kidney failure, although the cause of this association is not well understood [27]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney failure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "kidney cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal impairment is a known cause of morbidity in those with acute intermittent porphyria [28]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Renal impairment"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28730628.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AEDs and obesity Some AEDs are associated with weight gain (CBZ, CLB, GBP, PGB and VPA) and others with weight loss (TPM and ZNS).The majority have a neutral effect in this respect."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "obesity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | CBZ | | PB | | PHT | | VPA | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | | Anthracyclines | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | Cyclophosphamide | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | Cisplatin | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153\u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Corticosteroids | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153\u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | Etoposides | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | Fluorpyrimidines | | | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | Irinotecan topotecan | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | Methotrexate | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | Nitrosureas | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc| | Taxoides | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | Vincristine | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | The arrows on the left hand side of the boxes indicate the effect of interaction on the plasma levels of the cytotoxic and corticosteroid drugs and the ones on the right hand side indicate the effect on plasma levels of AEDs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Anthracyclines"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "GBP* | BZD, CBZ, ESM, PB, PHT, PRM, TGB, ZNS | LTG, VPA | | Renal impairment | BZD, CBZ, ESM, PHT, TGB, VPA | GBP, LEV, LTG, OXC, PB, PGB, PRM, TPM, ZNS | - | | porphyria | LEV, OXC, PGB."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Renal impairment"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "VPA only causes a minimal reduction of cyclosporine and tacrolimus levels."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cyclosporine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^32,33 The most recommended AEDs in renal impairment and haemodialysis are those that are mainly eliminated by the liver, such as BZD, CBZ, ESM, PHT, TGB and VPA."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal impairment"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Antiplatelets | Salicylates increase the free fraction of VPA."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Antiplatelets"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Response to conventional AEDs seems to be variable, with 70 % of patients with brain tumours treated with CBZ, 51 % of those treated with PHT, and 44 % of those treated with VPA having persistent seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Their study showed that CBZ, VPA, and clonazepam (CZP) increased the production of porphyrin to the same level as was found before for phenobarbital (PB) and PHT (8)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Some studies with small sample size found that patients on VPA treatment who gained weight showed insulin resistance that was reversible on withdrawal of VPA."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "insulin resistance"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Some studies suggest that VPA might stimulate the viral replication of latent HIV in vitro, but more recent results are negative and there is thus no evidence against it."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "viral replication"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | | VPA increases levels of nimodipine by 50 %."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "nimodipine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Likewise, VPA can cause a subclinical, reversible increase in TSH."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "TSH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Vitamin D deficiency is a risk factor for lower bone mineral density and osteoporosis"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Vitamin D Deficiency"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bone Density"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "28815553.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Afamelanotide, an agonistic analogue of \u00c3\u017d\u00c2\u00b1-melanocyte-stimulating hormone, received marketing authorization and been released for treatment in the EU. This drug has been shown in double blind placebo controlled trials to increase the amount of time erythropoietic protoporphyria patients can be exposed to light and to reduce the severity of phototoxic symptoms"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEMBL",
         "name": "Afamelanotide"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Photosensitivity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyrias are a group of rare metabolic disorders most commonly attributed to a hereditary mutation that alters enzymatic activity in the heme biosynthesis pathway [1 \u00c3\u201a\u00c2\u00b7 \u00c3\u201a\u00c2\u00b7"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Catatonia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Depressive disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bipolar and related disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Antipsychotics"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "quetiapine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbohydrate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The treatment strategy for our patient, including intravenous hemin administration, discontinuation of so dium valproate (a known AIP exacerbant), and initiation of a high-carbohydrate diet, is consistent with the recom mendations in the Chinese Expert Consensus on Diagnosis and Treatment of AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbohydrate"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The total carbohydrate content in the diet was converted to starch and dextrin uptake, since polysaccharides are most abundant carbohydrate component present in our diet (1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbohydrate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "starch"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Antipsychotics, are safe for use in individuals with porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral motor neuropathy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Diagnosis should be suspected when there is prolonged and recurrent episodes of unexplained abdominal pain-particularly when it is associated with neurological complications such as peripheral motor neuropathy, convulsions, coma or bulbar paralysis, hyponatremia or prompted by fasting, diets, or exposure to certain medications [5]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bulbar paralysis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Summary Broad psychiatric symptoms have been associated to acute porphyria (AP) and correspond to a spectrum of heterogeneous manifestations such as anxiety, affective alterations, behavioral changes, personality, and psychotic symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "adjustment disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "psychiatric conditions"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Summary Broad psychiatric symptoms have been associated to acute porphyria (AP) and correspond to a spectrum of heterogeneous manifestations such as anxiety, affective alterations, behavioral changes, personality, and psychotic symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "substance use disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "adjustment disorder"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Somatic symptom disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Sleep-wake disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "conduct disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Neurocognitive disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Personality disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Chronic fatigue"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Personality traits | Not specified | Emotional lability, Borderline personality disorder considered | Not specified | Not specified | Not specified | Not specified | Not specified | | Classical symptoms | Sharp Teeth ^b | Abdominal pain | Abdominal pain, dark urine | Not specified | Dark urine | None | Abdominal pain, nausea, vomiting."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cramping"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Olanzapine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Consistent with what was previously described, when reviewing what is available in the medical literature, there are no studies with sufficient methodological strength offering guidance as to how one should approach and manage of a patient with porphyria and associated neuropsychiatric symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tryptophan metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias typically present with unspecific neurovisceral symptoms such as abdominal pain ( 90 % ), bloating, nausea, vomiting, and tachycardia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "attention deficit hyperactivity disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepatic alteration of tryptophan metabolism in an acute porphyria model its relation with gluconeogenic blockage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "attention deficit hyperactivity disorder"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary coproporphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Regarding the type of AP, most assessments of PLC risk are based on cohorts with a predominance of patients with AIP. Sporadic cases of PLC in patients with VP and HCP have been published,11,15,74\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u015377 but large VP or HCP cohort studies exploring PLC risk are lacking and specific risk estimates for these forms of AP are scarce."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary coproporphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, little is known concerning antiepileptic drug (AED) treatment in patients with hereditary coproporphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary coproporphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antiepileptic drug"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with variegate porphyria and hereditary coproporphyria can present with skin photosensitivity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary coproporphyria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "VP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Inherited or acquired defects in CPOX may thus give rise to increased accumulation of copro'gen 3, such as occurs in hereditary coproporphyria (hereditary coproporphyria) or heavy alcohol use or exposure to heavy metals, which inhibit CPOX activity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary coproporphyria"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CPOX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Three porphyrias; acute intermittent porphyria (AIP), hereditary coproporphyria (HCP) and variegate porphyria (VP) are commonly labelled acute porphyrias (AP) since they can all present with episodic acute neurovisceral attacks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary coproporphyria"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "F female, M male, A I P acute intermittent porphyria, H C P hereditary coproporphyria, A D H D attention deficit hyperactivity disorder, B I D bis in die, T I D ter in die ^a Diagnosis not confirmed ^b Although not a core symptom in porphyria, it was the reason that triggered the porphyria workup ^c Doses given daily unless stated otherwise."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "griseofulvin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In summary, in both alcoholic and nonalcoholic steatohepatitis and fatty liver disease, there is both experimental and clinical evidence that increased oxidative stress plays an important role."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatty liver disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In summary, in both alcoholic and nonalcoholic steatohepatitis and fatty liver disease, there is experimental and clinical evidence that increased oxidative stress plays an important role."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fatty liver disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The predicted reduced urea secretion flux (Fig. 4) in the porphyria models was due to a reduced urea cycle, indicating ammonia toxicity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ammonia"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "urea cycle"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Synthesis of urea | Elimination of ammonia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ammonia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "Synthesis of urea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Current thinking is that decreased GABAergic neurons' activity in conjunction with increased glutamate release [25], increased oxidative stress [26\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u00a2], and increased metabolites of kynurenine pathway [27] leads to disease pathology."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hallucinations"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hallucinations"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The kynurenine pathway was recently introduced as relevant in the development of schizophrenia and bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Kynurenic acid"
        }
       ]
      ]
     },
     {
      "relation": "regulates"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29392446.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The kynurenine pathway was recently introduced as relevant in the development of schizophrenia and bipolar disorder."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Kynurenic acid"
        }
       ]
      ]
     },
     {
      "relation": "regulates"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "dopamine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron and chronic viral hepatitis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic viral hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HCV patients with cirrhosis and DM have high insulin levels, consistent with the insulin resistance seen in cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "insulin"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## porphyria Cutanea Tarda and Diabetes Mellitus Knowledge about an association between PCT and altered glucose metabolism arose in the 1950s, ^15 and since then several cohort studies have shown a relatively high prevalence, 15 24 %, of diabetes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "glucose metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For example, cirrhosis has been associated with abnormal glucose metabolism for more than 20 years."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "glucose metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## porphyria Cutanea Tarda and Diabetes Mellitus Knowledge about an association between PCT and altered glucose metabolism arose in the 1950s, ^15 and since then several cohort studies have shown a relatively high prevalence, 15 24 %, of diabetes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "glucose metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Diabetes Mellitus - Definition and Clinical Course DM is a serious metabolic disease defined by hyperglycemia and complicated by micro- and macrovascular abnormalities."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "metabolic disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Methods to Detect the Level of Glycemia for the Diagnosis and Monitoring of Diabetes Mellitus The definition of diabetes is based on the presence of hyperglycemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Glycemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "29516487.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## Methods to Detect the Level of Glycemia for the Diagnosis and Monitoring of Diabetes Mellitus The definition of diabetes is based on the presence of hyperglycemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Glycemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperglycemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | | Carbonic anhydrase activity | For availability of bicarbonate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "bicarbonate"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CA1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There is no doubt that alcohol plays a major role in increasing liver damage in HH, and heterozygosity for the H F E mutations associated with HH likely play some role in increasing iron loading and liver injury."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Synergistic effects of alcohol and HH in producing advanced degrees of hepatic fibrosis and cirrhosis have been well described."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Synergistic effects of alcohol and HH in producing advanced degrees of hepatic fibrosis and cirrhosis have been well described."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "insulin resistance"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "insulin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Thyroid disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepatitis C and C282Y heterozygosity can decrease UROD activity and therefore decrease conversion of uroporphyrinogen to coproporphyrinogen, which in turn, can be oxidized in the presence of P450 1A2."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepatitis C and C282Y heterozygosity can decrease UROD activity and therefore decrease conversion of uroporphyrinogen to coproporphyrinogen, which in turn, can be oxidized in the presence of P450 1A2."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "coproporphyrinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepatitis B , on the other hand, causes less than 5 % of MC."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "MC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Also, iron overload may increase oxidative stress (ROS) which can induce ALA synthase and increase the production of ALA, which in turn, may increase uroporphyrinogen production."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ROS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a small proportion of patients, the cutaneous symptoms are associated with abdominal pain, about one-quarter display abnormal liver enzyme activities and rarely develop severe hepatobiliary injury, including jaundice and liver cirrhosis, can occur."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "jaundice"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "At that time, he had an acute HCV infection and jaundice that required a prolonged hospitalization."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "jaundice"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^21 Multiple studies have shown that the heterozygosity for HFE is significantly linked to the risk of cardiovascular events, including the fact that heterozygosity for C282Y has been shown to be a risk factor for myocardial infarction in men and cerebrovascular death in women."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular events"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^21 Multiple studies have shown that the heterozygosity for HFE is significantly linked to the risk of cardiovascular events, including the fact that heterozygosity for C282Y has been shown to be a risk factor for myocardial infarction in men and cerebrovascular death in women."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cerebrovascular"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other skin manifestations include hyperpigmentation, hypertrichosis, alopecia due to scaring and purplish heliotrope suffusion of periorbital areas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alopecia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertrichosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other skin manifestations include hyperpigmentation, hypertrichosis, alopecia due to scaring and purplish heliotrope suffusion of periorbital areas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "alopecia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperpigmentation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additional manifestations of HH include hyperpigmentation, cardiomyopathy, diabetes mellitus, hypogonadism, hypothyroidism, and arthropathy due to pseudogout."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypogonadism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additional manifestations of HH include hyperpigmentation, cardiomyopathy, diabetes mellitus, hypogonadism, hypothyroidism, and arthropathy due to pseudogout."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "arthropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes mellitus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is yet unclear whether the pathology of liver disease in patients with HCV is influenced by iron overload or limited to the direct cell damage from replication of the virus and subsequent inflammation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "replication"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cytochrome"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cytochrome"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Yet, as described elsewhere in this issue, excessive iron is toxic to all types of cells because it increases oxidative stress and reactive oxygen species, which in turn cause the oxidation of lipids, proteins, and nucleic acids."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Yet, as described elsewhere in this issue, excessive iron is toxic to all types of cells because it increases oxidative stress and reactive oxygen species, which in turn cause the oxidation of lipids, proteins, and nucleic acids."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In hepatocytes, alcohol and iron are believed to act synergistically to generate free radicals, which contribute to the forma tion of the uroporphomethene that inhibits hepatic UROD, as well as cause cellular damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "free radical"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "Uroporphomethene"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron overload can impact disease progression and treatment options for patients with comorbid conditions, such as porphyria cutanea tarda, hepatitis C virus, and coronary artery disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "coronary artery disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32269472.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron overload can impact disease progression and treatment options for patients with comorbid conditions, such as porphyria cutanea tarda, hepatitis C virus, and coronary artery disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "coronary artery disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron overload"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Estrogens"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic steatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Estrogens"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "intrahepatic cholestasis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "intrahepatic cholestasis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic steatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peliosis hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Estrogens"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE genotyping DNA was available from 87 patients with PCT ( 64 with S-PCT and 23 with F-PCT) and from 56 clinically normal subjects married to members of well-characterized hemochromatosis pedigrees."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "DNA"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE genotyping DNA was available from 87 patients with PCT ( 64 with S-PCT and 23 with F-PCT) and from 56 clinically normal subjects married to members of well-characterized hemochromatosis pedigrees."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "DNA"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The highest 24 -hour urine porphyrin excretion, 26921 \u00c3\u017d\u00c2\u00bc g, was found in a 65 -year-old woman who was receiving chemotherapy for metastatic lung cancer."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "metastatic lung cancer"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interaction between iron metabolism and 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice with variants of the Ahr gene: a hepatic oxidative mechanism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tetrachlorodibenzo-p-dioxin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is characterized clinically by a photosensitive dermatosis associated with skin fragility and blistering."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dermatosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most anticonvulsants can aggravate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "anticonvulsants"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Many anticonvulsants can cause exacerbation of clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-5)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "anticonvulsants"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most anticonvulsants can aggravate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "anticonvulsants"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Many anticonvulsants can cause exacerbation of clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-5)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "anticonvulsants"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Use of propofol anesthesia and adjunctive treatment with levetiracetam and gabapentin in managing status epilepticus in a patient of acute intermittent porphyria A 12-year-old boy presented to us in the emergency with a 3-day history of progressive drowsiness and intermittent generalized seizures followed by status epilepticus of 1 day duration."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "gabapentin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "status epilepticus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "reported one patient with complex partial and secondarily generalized seizures and PCT with phenytoin (PHT; 300 mg / day), who was then safely treated with gabapentin (GBP), an AED with no influence on hepatic enzymes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "gabapentin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phenytoin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Actually, only gabapentin (GBP), an AED without any hepatic metabolism, is known as a potential therapy for partial seizures in patients having hepatic forms of porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "gabapentin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "He was diagnosed as having porphyria during an episode of status epilepticus 1 year previously based on a positive urinary test for porphobilinogen and had been receiving gabapentin and levetiracetam ever since."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "gabapentin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 6"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "gabapentin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "arrhythmias"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epileptic seizure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "arrhythmias"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypotension"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epileptic seizure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypotension"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epileptic seizure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HT was more common among patients with AHP ( n=253,20 % ), and particularly in the U-PBG-positive AIP subgroup ( n=148,30 % ) than among the comparators (n=1834,15 %; Table 5, Figure 2A,B)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseases"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AHP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Oxcarbazepine appeared to be safe when used in a patient with focal seizures and hepatic porphyria, however, that patient had porphyria cutanea tarda which is not one of the inducible porphyrias and is not drug sensitive (Elder, 1998; Gaida-Hommernick et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Oxcarbazepine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 6"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Oxcarbazepine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Oxcarbazepine (OCBZ), a new AED for treating focal epilepsies, presents a low level of hepatic induction for certain microsomal enzymes (6) and might therefore be suitable for treating patients with hepatic forms of porphyria The patient is a 28 -year-old man who has had complex partial and secondarily generalized seizures since childhood, with a seizure frequency of at least five to six per month."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Oxcarbazepine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsies"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "OXC has been used successfully in an isolated case of porphyria cutanea tarda and alsoin anothercaseof intermittent acute porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Oxcarbazepine"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "OXC has been used successfully in an isolated case of porphyria cutanea tarda and also in another case of intermittent acute porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Oxcarbazepine"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In chronic antiepileptic treatment, carbamazepine (CBZ), oxcarbazepine (OXC) and PHT should be used with caution in patients with heart disease, and they should be avoided in the event of atrioventricular conduction dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "heart disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antiepileptic"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The patient also had a moderate hepatomegaly, and liver biopsy revealed a slight steatosis, a reticuloendothelial hemosiderin accumulation, and red fluorescence under Wood's light."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "Steatosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatomegaly"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Eventually, her seizure condition became much better controlled with one to two convulsive seizures per year using a combination of CBZ, clobazam and levetiracetam (age 29 to 32 years)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "levetiracetam"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "After 4 hours, the hyponatremia worsened ( 110 mEq / L ) and generalized convulsions necessitated the administration of levetiracetam, intubation, stepwise careful compensation of hyponatremia with intravenous sodium chloride (3%), and mechanical ventilation for 2 days."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "levetiracetam"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intravenous hemin administration (4mg/kg once daily for 7 consecutive days) to inhibit \u00c3\u017d\u00c2\u00b4-ALA synthase (ALAS) activity and reduce porphyrin precursor accumulation; discontinuation of sodium valproate (which may exacerbate AIP) and replacement with levetiracetam (500mgtwicedaily) for seizure control; and maintenance of acid-base balance, correction of electrolyte disturbances, and a high-carbohydrate diet (daily intake \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a5 300g) to stabilize metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "levetiracetam"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition, the replacement of sodium valproate with levetiracetam aligns with the consensus\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u201e\u00a2s warning against porphyrogenic anti epileptics, demonstrating the practical value of adhering to guideline-based treatment in improving patient outcomes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "levetiracetam"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Liver histology of explanted livers from patients with AIP who had undergone liver transplantation revealed hemosiderosis associated with years of regular haematin infusions."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Hematin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemosiderosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Haematin infusions have reduced the activity of hepatic ALAS1 and subsequently lowered plasma and urinary ALA levels for 7\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u015310 days. This was sufficient for a patient to recover from an acute attack."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Hematin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Low\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090grade inflammation has been found in the livers of AP patients with recurrent attacks and chronic symptoms. The authors hypothesise that recurrent haematin infusions may have led to chronic liver inflammation, but that chronic AP may also have induced it."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Hematin"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For the im- mediate treatment of seizures, diazepam (DZP) is recommended, but its effectiveness is lost the longer the patient takes the drug."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "diazepam"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Bromides have been recommended for long-term management in case of acute intermittent porphyria and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Bromides"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Bromides have been recommended for long-term management in case of acute intermittent porphyria and seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Bromides"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Actually, only gabapentin (GBP), an AED without any hepatic metabolism, is known as a potential therapy for partial seizures in patients having hepatic forms of porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "partial seizures"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "gabapentin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# Eslicarbazepine for focal epilepsy and acute intermittent porphyria* Tamara Herrera-Fortin, Raluca Pana, Ewa Wesolowska, Josiane Bourr\u00c3\u0192\u00c2\u00a9-Tessier, Dang K. Nguyen University of Montreal Hospital Center, Montreal, Quebec, Canada Received January 6, 2020; Accepted March 12, 2020 #### Abstract porphyrias are rare genetic disorders which cause a deficiency in the enzymes involved in the biosynthesis of heme."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "focal epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Eslicarbazepine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We report a patient with focal epilepsy and la tent hereditary coproporphyria who had exacerbation of clini cal symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without ex acerbation of clinically latent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "focal epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary coproporphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It should be emphasized that our case report presents a patient with partial and secondarily generalized seizures within the scope of a cryptogenic focal epilepsy since childhood, and that no porphyria-induced generalized seizures as seen in a porphyric crisis were reported."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "focal epilepsy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "generalized seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Their study showed that CBZ, VPA, and clonazepam (CZP) increased the production of porphyrin to the same level as was found before for phenobarbital (PB) and PHT (8)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "clonazepam"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of \u00c3\u017d\u00c2\u00b4-aminolevulinic acid synthase."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "vigabatrin"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "\u00c3\u017d\u00c2\u00b4-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GOT1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "erythema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "11422339.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GOT1"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "pruritus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The natural history of hepatocellular carcinoma is heterogeneous and is influenced by nodule dimension, the mono- or plurifocality of lesions at diagnosis, the growth rate of the tumor, and the stage of the underlying cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tumor"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Little is known about the carcinogenic mechanisms involved in the development of HCC in AP, but the features mentioned above indicate an AP\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090specific tumour development process."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tumor"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In most cases hepatocellular carcinoma develops in cirrhotic livers, where the persistent proliferation of liver cells represents the key factor of progression to hepatocellular carcinoma independent of the etiology."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "proliferation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a small proportion of patients, the cutaneous symptoms are associated with abdominal pain, about one-quarter display abnormal liver enzyme activities and rarely develop severe hepatobiliary injury, including jaundice and liver cirrhosis, can occur."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most patients with AP and PLC do not have other chronic liver diseases or liver cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Primary Liver Cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In almost all cases, neoplastic degeneration occurs in patients with liver cirrhosis, whereas only a few cases of HCV-associated HCC have been reported in the noncirrhotic liver, indicating that this virus possibly has a mutagenic effect."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Nevertheless, it is a frequent etiologic agent of liver cirrhosis, through which it can favor the development of HCC."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most HCCs develop in the setting of long\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090standing inflammation associated with an underlying chronic liver disease that leads to liver cirrhosis or advanced fibrosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCC"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12095924.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AFB1 has recently been redimensioned as an etiologic factor in HCC, because although its consumption is high in those countries, such as Africa and Asia, where the incidence of HCC is high, it seems to be only a cofactor of neoplastic degeneration."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neoplastic"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "aflatoxin B1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Corneal ulcers"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lichen planus"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Pulmonary fibrosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Although only 10 % of HCV-infected persons will have symptomatic xerophthalmia or xerostomia, \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a4 77 % will have evidence of Sj\u00c3\u0192\u00c2\u00b6gren syndrome if it is sought with diagnostic tests (Table 6)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "xerophthalmia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "xerostomia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Among the woman's family members, a cousin had similar attacks of abdominal pain, but the symptoms were mild, and there were no symptoms such as a dry mouth and dry eyes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry eyes"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | Sj\u00c3\u0192\u00c2\u00b6gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Fibromyalgia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On B cells, CD81 is associated with CD19 and CR2 and also with MCH class II (Figure 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD81"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD19"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On B cells, CD81 is associated with CD19 and CR2 and also with MCH class II (Figure 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CD81"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CR2"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "MC-associated neuropathy is usually a moderate axonal sensory polyneuropathy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sensory polyneuropathy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a well-documented case, progression from MC to accelerated malignant lymphoma occurred at the time of a second mutation of the myc oncogene to the \u00c3\u017d\u00c2\u00bb light-chain locus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "MYC"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "malignant lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In a well-documented case, progression from MC to accelerated malignant lymphoma occurred at the time of a second mutation of the myc oncogene to the \u00c3\u017d\u00c2\u00bb light-chain locus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "malignant lymphoma"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Recognizing that HCV infection alone may account for autoantibodies that were previously thought to be specific for autoimmune hepatitis may prevent the erroneous diagnosis of autoimmune hepatitis in association with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "autoimmune hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "peripheral neuropathies"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Another site reported not infrequently is the stomach, and HCV has been associated with gastric lymphoproliferation and has been proposed to be a potential cause, in addition to Helicobacter pylori, for mucosa-associated lymphoid tissue lymphomas."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoproliferation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The preponderance of data indicates that HCV-associated lymphomas arise out of B cell proliferation that is driven by the same process that drives cryoglobulinemia production."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "cell proliferation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The preponderance of data indicates that HCV-associated lymphomas arise out of B cell proliferation that is driven by the same process that drives cryoglobulinemia production."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "cell proliferation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "lymphoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Antiviral therapy is efficacious for extrahepatic manifestations, although mostly features related to cryoglobulinemia have been studied in trials."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Antiviral therapy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "hyperinsulinemia"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "insulin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "No data has been published regarding the effects of combined pegylated interferon and ribavirin, which is now the state-of-the-art therapy for active liver disease caused by HCV."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ribavirin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The management of chronic hepatitis C has been improved with the demonstration that the combination of interferon and ribavirin is superior to interferon alone for cure of hepatitis C. Further improvements have been possible with the use of long-acting, pegylated interferons plus ribavirin, such that apparent cures are now possible in about 50 % of patients who are able to afford and to tolerate such combination therapy for 1 year (Fried et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ribavirin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The management of CHC has been improved with the demonstration that the combination of interferon and ribavirin is superior to interferon alone for cure of hepatitis C.Further improvements have been possible with the use of long-acting, pegylated interferons plus ribavirin, such that apparent cures are now possible in \u00c3\u00a2\u00cb\u2020\u00c2\u00bc 50 to 60 % of patients who are able to afford and to tolerate such combination therapy for 1 year."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ribavirin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most frequent cutaneous manifestation of the MC syndrome is palpable purpura of the lower extremities, although upper extremities, abdomen, and/or buttocks are sometimes also involved."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "palpable purpura"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Cutaneous Vasculitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most frequent cutaneous manifestation of the MC syndrome is palpable purpura of the lower extremities, although upper extremities, abdomen, and/or buttocks are sometimes also involved."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Cutaneous Vasculitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The symptoms of MC syndrome are caused by vascular deposition of the cryoprecipitate, which contains HCV RNA, low-density lipoprotein, IgG, and a highly restricted monoclonal IgM that has RF activity (Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "RNA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "IgG"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, almost all patients who do not achieve clearance of HCV RNA will relapse shortly after treatment is stopped."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "RNA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "relapse"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most common are acute symptomatic generalized seizures occurring in the context of AIP in relapse (Winkler et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "relapse"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "generalized seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The process begins as a lymphocytic capillaritis of the glands, which progresses to a lymphocytic sialadenitis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "Capillaritis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sialadenitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The triad of purpura, arthralgias, and weakness has been used to define patients with MC syndrome since 1966, but this definition is no longer adequate because additional symptoms are now known to be related to MC (Table 3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "arthralgias"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "purpura"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Arthralgias are relatively common in HCV, but arthritis not related to MC is Table 2.Reported Prevalences of Cryoglobulinemia in Persons Infected with Hepatitis C | Country | HCV (n) | Cryo+ (%) | RF+(%) | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | | Sweden ^7 | 21 | 0 | ND | | Israel ^8 | 90 | 11 | 44 % | | Germany ^9 | 132 | 28 | 42 % | | France ^10 | 58 | 36 | 70 % | | France ^11 | 321 | 56 | 38 % | | Korea ^12 | 49 | 59 | 14 % | Cryo, cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cryoglobulinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Arthralgias are relatively common in HCV, but arthritis not related to MC is Table 2.Reported Prevalences of Cryoglobulinemia in Persons Infected with Hepatitis C | Country | HCV (n) | Cryo+ (%) | RF+(%) | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153: | | Sweden ^7 | 21 | 0 | ND | | Israel ^8 | 90 | 11 | 44 % | | Germany ^9 | 132 | 28 | 42 % | | France ^10 | 58 | 36 | 70 % | | France ^11 | 321 | 56 | 38 % | | Korea ^12 | 49 | 59 | 14 % | Cryo, cryoglobulinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Cryoglobulinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Arthralgias"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Over time, pigmentation, depigmentation, hirsutism, and sclerodermoid appearance can develop."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hirsutism"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "pigmentation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Compared with patients with non-HCV-related cryoglobulinemia, HCV patients have the same frequency of cutaneous involvement, renal involvement, and peripheral neuropathy, but they less frequently manifest fever, lymphadenopathy, articular involvement, or Raynaud phenomenon."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SCTID",
         "name": "Raynaud's phenomenon"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cryoglobulinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The current case involved a 30-year-old woman who had episodic abdominal pain for six years and a dry mouth and eyes for three and a half years."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry mouth"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Among the woman's family members, a cousin had similar attacks of abdominal pain, but the symptoms were mild, and there were no symptoms such as a dry mouth and dry eyes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry mouth"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The patient also had cutaneous purpura, renal damage, hypothyroidism, and other extra-glandular lesions with dry mouth and eyes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry mouth"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "purpura"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On the other hand, there were typical clinical manifestations of PSS such as dry eyes and a dry mouth, the elevation of immunoglobulins (IgG and IgA) and the results of Schirmer's test, an anti-SS-A antibody test, an anti-SS-B antibody test, and a labial gland biopsy were all positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry mouth"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry eyes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the United States, 10 to 20 % of MPGN is associated with HCV infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "MPGN"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "They often ( 72 % ) have serum albumin <3 g / dL with mild renal insufficiency."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal insufficiency"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALB"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A recent study of 36 patients showed that mRNA of hepcidin correlated with albumin synthesis and HIC and inversely correlated with the degree of hepatic fibrosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALB"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, 88 % will have abnormal liver biopsy consistent with chronic active hepatitis, often with cirrhosis (50 %) .^35 Complement levels are also depressed in the majority."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic active hepatitis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, combined antiviral and immunosuppressive therapy may be treatment of choice in patients with severe renal disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antiviral"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A case control study performed in Italy found that HCV infection increased the risk for NHL of the liver or salivary glands by 50 -fold, which was greater than the relative risk of hepatocellular carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "NHL"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HCV infection"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12640289.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Almost all patients with pre-existing DM or hypertension (80-100%) develop an interferon-associated retinopathy that may be permanent."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "retinopathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Once endocytosed, the small interfering RNA is cleaved from the conjugate to potently reduce levels of ALAS1 mRNA and protein."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "mRNA"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^31 Heme is not a direct inhibitor of ALAS1 at physiologically achievable concentrations, but rather decreases stability of ALAS1 messenger RNA (mRNA) and therefore its protein expression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "mRNA"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Administration of an antisense oligonucleotide that prevents the abnormal splicing of the nascent mutant FECH mRNA in developing human erythroblasts of a patient with EPP increased the production of functional FECH and reduced the accumulation of PPIX.130 ## Case Report A 67-year-old female patient presented with pronounced photosensitivity (burning, stinging pain, swelling, and itching) on light-exposed skin areas (prominent in the face and on the back of the hands) since early childhood."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "mRNA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter change may well occur due to downregulation by ethanol (actually, its proximate oxidation product, acetaldehyde) of hepatic production of hepcidin, ^11 which, in turn, appears to be the key regulator of expression of ferroportin on the basolateral membrane of duodenal enterocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "acetaldehyde"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In addition to increased duodenal absorption, other mechanisms have been postulated as causes of portosystemic shuntrelated iron overload, including relative hepatic hypoxia, and associated pancreatic insufficiency with decreased bicarbonate secretion (Grace & Powell, 1974)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "pancreatic insufficiency"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "bicarbonate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron, HFE gene mutations, and end-stage liver disease Serum iron indices and hepatic iron concentrations are often increased in patients with end-stage liver disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "end-stage liver disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Iron storage disorders of the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "storage disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Spur cell anaemia acid hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "anaemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hemochromatosis gene modifies course of hepatis C viral infection."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "viral infection"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hemochromatosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver fibrosis and cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver fibrosis and cirrhosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "12957298.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In summary, in both alcoholic and nonalcoholic steatohepatitis and fatty liver disease, there is both experimental and clinical evidence that increased oxidative stress plays an important role."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "alcoholic liver disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "oxidative stress"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We report a patient with focal epilepsy and la tent hereditary coproporphyria who had exacerbation of clini cal symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without ex acerbation of clinically latent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Valproate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We report a patient with focal epilepsy and la tent hereditary coproporphyria who had exacerbation of clini cal symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without ex acerbation of clinically latent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Primidone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Primidone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 6"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Levetiracetam"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Levetiracetam (LEV) might be suitable for treating patients with hereditary coproporphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Levetiracetam"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hereditary coproporphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "15101839.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We report a patient with focal epilepsy and la tent hereditary coproporphyria who had exacerbation of clini cal symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without ex acerbation of clinically latent porphyria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Levetiracetam"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The major recognized risk factors for disease development are chronic hepatitis C(CHC), heavy alcohol use, iron overload (which is generally only mild or moderate), and estrogen use."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CHC"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mortality associated with CHC virus infection is mainly attributable to progression of hepatic fibrosis and subsequent occurrence of cirrhosis with its complications of portal hypertension and hepatocellular carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "virus infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatocellular carcinoma"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mortality associated with CHC virus infection is mainly attributable to progression of hepatic fibrosis and subsequent occurrence of cirrhosis with its complications of portal hypertension and hepatocellular carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "virus infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mortality associated with CHC virus infection is mainly attributable to progression of hepatic fibrosis and subsequent occurrence of cirrhosis with its complications of portal hypertension and hepatocellular carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "virus infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mortality associated with CHC virus infection is mainly attributable to progression of hepatic fibrosis and subsequent occurrence of cirrhosis with its complications of portal hypertension and hepatocellular carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "virus infection"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "portal hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In summary, hepcidin appears to be a key liverderived peptide important in iron homeostasis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "peptide"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "An Australian study showed that the major HFE mutation (C282Y) associated with HH is correlated with iron abnormalities found in patients with NASH."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abnormalities"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "MDA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "malondialdehyde"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "4-hydroxynonenal"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "malondialdehyde"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "4HNE"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "malondialdehyde"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "lipid peroxidation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "malondialdehyde"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrogenic"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "malondialdehyde"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Use of propofol anesthesia and adjunctive treatment with levetiracetam and gabapentin in managing status epilepticus in a patient of acute intermittent porphyria A 12-year-old boy presented to us in the emergency with a 3-day history of progressive drowsiness and intermittent generalized seizures followed by status epilepticus of 1 day duration."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "propofol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "status epilepticus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The porphyrias are a group of uncommonly inherited metabolic disorders in which there is disturbance of haem synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A recessive form of PNH due to *ARGEF2* gene mutations has also been reported in children with microcephaly, severe delay and early-onset seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SNOMED",
         "name": "PNH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lissencephaly-pachygyria and subcortical band heterotopia (SBH) result from mutations of either the *LIS1* or *XLIS* gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PAFAH1B1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lissencephaly"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lissencephaly-pachygyria and subcortical band heterotopia (SBH) result from mutations of either the *LIS1* or *XLIS* gene."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PAFAH1B1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "pachygyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "18454784.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "List of drugs to be avoided in porphyria | Common drugs | Antiepileptic drugs | | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | :\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153 | | I. Sulfonamides | I. Carbamazepine | | 2."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Sulfonamides"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A possible explanation of our finding is that in our patient population, coexistence of various concomitant precipitat ing factors such as iron overload, oestrogen replacement therapy and HCV infection, seems to facilitate cumulatively the manifesta tion of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hepacivirus"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "amenorrhoea"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "viral hepatitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "amenorrhoea"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oestrogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The two women with the substantially elevated urinary porphyrin levels had a combination of predisposing factors: they were receiving oestrogen replacement therapy because of amenorrhoea, had markedly elevated plasma ferritin concentration, while one of them was HCV positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "amenorrhoea"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oestrogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Prior treatment with oestrogen replacement therapy was determined and toxicological tests from hair samples were performed to exclude exposure to polychlorinated hydrocarbons."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydrocarbons"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oestrogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20236192.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Twenty-four hour urine specimens revealed substantially high level of urinary porphyrins in the two patients presenting with dermatological lesions, while a mild elevation was demonstrated in three other patients, one amongst them being with pseudoscleroderma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "pseudoscleroderma"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phenobarbital"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "topiramate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "zonisamide"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 6"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Pregabalin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pregabalin (PGB) should be used with care in cases of heart failure due to left ventricular systolic dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Pregabalin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "heart failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pregabalin (PGB) should be used with care in cases of heart failure due to left ventricular systolic dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Pregabalin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "left ventricular systolic dysfunction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The risk of other cardiovascular conditions commonly associated with HT such as heart failure, atrial fibrillation, ischemic heart disease, and peripheral artery disease did not differ between the AHP groups and comparators."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "heart failure"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular conditions"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 6"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "benzodiazepine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intravenous magnesium sulphate and BZDs have also been used in isolated cases of status epilepticus, although in theory BZDs can worsen porphyria symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "magnesium sulphate"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "status epilepticus"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intravenous magnesium sulphate and BZDs have also been used in isolated cases of status epilepticus, although in theory BZDs can worsen porphyria symptoms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "magnesium sulphate"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "GBP* | - | CBZ, OXC, PB, PRM, VPA | | Hypothyroidism | BZD, LEV, LTG, PGB, ZNS."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hypothyroidism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "GBP* | VPA | CBZ, PB, PHT, PRM | | Obesity | TPM, ZNS | CBZ, CLB | GBP, PGB, VPA | | HIV | LEV, PGB, TPM."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Obesity"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "GBP* | CBZ, OXC, PHT, TPM, VPA | BZD, PB, PRM | | Brain tumour | LEV, VPA."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Brain tumour"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Lung disease Parenteral use of barbiturates, BZD and PHT can cause respiratory depression."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "respiratory depression"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Lung disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^20 ## 5.Liver disease In the case of hepatic dysfunction, the hepatic metabolism of some AEDs is impaired, and there may be associated hypoalbuminaemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic dysfunction"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | CBZ | | LTG | | PB | | PHT | | VPA | | | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | \u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u009d | | Albendazole | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | = | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | = | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | = | | | | Carbapenems | | | | | | | | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | Ciprofloxacin | | | | | | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | Clarithromycin | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | | | | | | | | Doxycycline | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | | Erythromycin | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | | | | | | | | Fluconazole | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | NRTI | = | = | = | = | = | | = | = | = | = | | NNRTI | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | = | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | = | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | PI | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | = | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | = | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Isoniazid | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Ketoconazole | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | | | | | | | | Metronidazole | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | | | | Praziquantel | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | = | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | = | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | = | | | | Rifampicin | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | Sulphonamides | | | | | | | | \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | | The arrows on the left hand side of the boxes indicate the effect of interaction on the plasma levels of the antibiotics and the ones on the right hand side indicate the effect on plasma levels of AEDs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Albendazole"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Azathioprine, mycophenolate and muromonab-CD3 (OKT3) are not significantly affected by AEDs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "mycophenolate"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Azathioprine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Azathioprine can not be used together with febuxostat (9), and has potent myelosuppressive action (10)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Azathioprine"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MEDDRA",
         "name": "Myelosuppression"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, the use of Diazepam (oral or rectal route) or Midazolam (buccal or intranasal route) is recommended for acute treatment of prolonged and cluster seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Diazepam"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, the use of Diazepam (oral or rectal route) or Midazolam (buccal or intranasal route) is recommended for acute treatment of prolonged and cluster seizures."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Midazolam"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizures"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Conclusions: In this review we make recommendations based on the best scientific evidence available for treating epilepsy in patients with other comorbidities, including the treatment of epileptic seizures in acute situations as well as chronic antiepileptic treatment."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antiepileptic"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The use of intravenous PHT or fosphenytoin is contraindicated in patients with severe heart disease and second or third degree atrioventricular block."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fosphenytoin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "heart disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The use of intravenous PHT or fosphenytoin is contraindicated in patients with severe heart disease and second or third degree atrioventricular block."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fosphenytoin"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrioventricular block"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In our case, ESL was chosen over oxcarbazepine given that it has fewer interactions with the CYP450s system (Peltola et al."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oxcarbazepine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In chronic antiepileptic treatment, carbamazepine (CBZ), oxcarbazepine (OXC) and PHT should be used with caution in patients with heart disease, and they should be avoided in the event of atrioventricular conduction dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "oxcarbazepine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "heart disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Antiplatelets | Salicylates increase the free fraction of VPA."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Salicylates"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Antiarrhythmics | Enzyme-inducing AEDs increase the metabolism of antiarrhythmics and so it may be necessary to increase the doses of the latter."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Antiarrhythmics"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Antihypertensives | Enzyme-inducing AEDs increase the metabolism of beta-blockers and dihydropyridine calcium antagonists | | | PHT reduces the active metabolite of losartan by up to 63 %."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "losartan"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AEDs and obesity Some AEDs are associated with weight gain (CBZ, CLB, GBP, PGB and VPA) and others with weight loss (TPM and ZNS).The majority have a neutral effect in this respect."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "weight loss"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "obesity"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the treatment of neurocysticercosis, enzyme-inducing AEDs reduce the concentration of praziquantel and albendazole by over 50 %."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "praziquantel"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neurocysticercosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the treatment of neurocysticercosis, enzyme-inducing AEDs reduce the concentration of praziquantel and albendazole by over 50 %."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "albendazole"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neurocysticercosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the treatment of tuberculosis, isoniazid inhibits the metabolism of CBZ, PHT and VPA, and can cause toxicity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "isoniazid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "metabolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In the treatment of tuberculosis, isoniazid inhibits the metabolism of CBZ, PHT and VPA, and can cause toxicity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "isoniazid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The interaction between VPA and amitriptyline or nortriptyline can cause an increase of up to 60 % in the plasma levels of these drugs, causing intoxication."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "amitriptyline"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The interaction between VPA and amitriptyline or nortriptyline can cause an increase of up to 60 % in the plasma levels of these drugs, causing intoxication."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "nortriptyline"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "VPA"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "SSRIs can cause hyponatraemia and so they must be used with caution when combined with CBZ or OXC."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatraemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "SSRIs"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "amoxapine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "maprotiline"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "bupropion"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "clozapine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "20554455.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chlorpromazine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Tachycardia, hypertension, and sweating are often present."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Tachycardia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Tachycardia coupled with hypertension and a reddish dark urine are further diagnostic signs (Figure 2A)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Tachycardia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hyponatremia may be due to the syndrome of inappropriate antidiuretic hormone secretion, but gastrointestinal or renal sodium losses are sometimes important (until dehydration) [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dehydration"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sodium"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other clinical signs include vomiting, failure to thrive, dehydration, disacchariduria including lactosuria, renal tubular acidosis and amino aciduria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dehydration"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hypertension, sphincter dysfunction, and severe gastroparesis impeding enteral feeding were initially ascribed to dysautonomia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dysautonomia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hypertension, sphincter dysfunction, and severe gastroparesis impeding enteral feeding were initially ascribed to dysautonomia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastroparesis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dysautonomia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "pyruvate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "lactate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "pyruvate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "alanine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "pyruvate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "alanine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "pyruvate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "pyruvate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "lactate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "alanine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Another noteworthy observation was the failure to synthesize alanine from glutamine in the absence of glucose, which we observed for both diets (when glucose was removed under this particular simulation condition)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "alanine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "alanine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "gluconeogenesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "gluconeogenesis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "pyruvate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "gluconeogenesis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "alanine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "When simulating the average American diet, glucose-galactose malabsorption (OMIM: 606 824) affected in silico the highest number of metabolic tasks (i.e. 22 out of 50) (Fig. 3), including reduced fluxes through gluconeogenesis from glutamine and the synthesis of gamma-aminobutyric-acid, i.e. GABA from putrescine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "gluconeogenesis"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "glucose-galactose malabsorption"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| In one case, trans-mural infarction of distal ileum and the existence of sickle cell anemia caused death (49)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sickle cell anemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "infarction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hypocortisolism, factors related to erythropoiesis and celiac disease, should be excluded."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "celiac disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hypocortisolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Coincidental existence of porphyrias and celiac disease also exists, villous atrophy has been seen (50)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "celiac disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "citrullinemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "citrullinemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ornithine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "When comparing the results for the maximal possible flux values of the different metabolic tasks, we found an increased flux for the synthesis of important products, such as glucose, ornithine and citrulline, from glutamine in the average American diet compared with the balanced diet (Table 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ammonia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to lactate conversion | Utilization of glutamine, sparing glucose."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "lactate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | | Synthesis of alanine from glutamine | To be sent to the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "alanine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "When comparing the results for the maximal possible flux values of the different metabolic tasks, we found an increased flux for the synthesis of important products, such as glucose, ornithine and citrulline, from glutamine in the average American diet compared with the balanced diet (Table 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to glucose conversion | Endogenous glucose production."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "When comparing the results for the maximal possible flux values of the different metabolic tasks, we found an increased flux for the synthesis of important products, such as glucose, ornithine and citrulline, from glutamine in the average American diet compared with the balanced diet (Table 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ornithine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | | Glutamine to carbon dioxide conversion | Utilization of glutamine, sparing glucose."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbon dioxide"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Simultaneously, the glutamine oxidation flux to carbon dioxide was higher under the average American dietary regime, reflecting the higher glutamine availability in this diet."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbon dioxide"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to proline conversion | Delivery to the liver."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "proline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to citrulline conversion | For arginine synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "arginine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ornithine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to ornithine conversion | For spermine synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ornithine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ornithine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "urea cycle"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "secretion"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "citrullinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thus, there likely can be competition for succinylCoA between heme synthesis and the formation of succinate, fumarate, malate, and other tricarboxylic acid cycle intermediates."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fumarate"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fumarate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "citrullinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "citrullinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FH"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fumarate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "These predictions were consistent with the reported build-up of citrulline in patients (37).Moreover, the model predicted an increased flux through the luminal uptake reactions of two amino acid transporters, ASCT2 (SLC1A5, GeneID: 6510) and B(0)AT1 (SLC6A19, GeneID: 340024 ), and through the alanine transaminase (E.C.2.6.1.2."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC1A5"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "These predictions were consistent with the reported build-up of citrulline in patients (37).Moreover, the model predicted an increased flux through the luminal uptake reactions of two amino acid transporters, ASCT2 (SLC1A5, GeneID: 6510) and B(0)AT1 (SLC6A19, GeneID: 340024 ), and through the alanine transaminase (E.C.2.6.1.2."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC6A19"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "urea cycle"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The predicted reduced urea secretion flux (Fig. 4) in the porphyria models was due to a reduced urea cycle, indicating ammonia toxicity."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "urea cycle"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gyrate atrophy (OMIM: 258 870) and ornithine translocase deficiency (OMIM: 238 970) are caused by mutations in ornithine aminotransferase (OAT, GeneID: 4942, E.C. 2.6.1.13) and mitochondrial ornithine transporter (SLC25A15, GeneID: 10 166), respectively."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "OAT"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Gyrate atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gyrate atrophy (OMIM: 258 870) and ornithine translocase deficiency (OMIM: 238 970) are caused by mutations in ornithine aminotransferase (OAT, GeneID: 4942, E.C. 2.6.1.13) and mitochondrial ornithine transporter (SLC25A15, GeneID: 10 166), respectively."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "OAT"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Gyrate atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "While gyrate atrophy patients usually have vision loss (OMIM: 258 870), ornithine translocase deficiency is associated with neurocognitive deficits, liver dysfunctions and lethargy (56)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ornithine translocase deficiency"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Gyrate atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gyrate atrophy patients have degenerative changes in the white matter and brain atrophy (57), whereas for ornithine translocase deficiency patients usually show developmental delay, ataxia, spasticity and learning disabilities (56)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "brain atrophy"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Gyrate atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gyrate atrophy patients have degenerative changes in the white matter and brain atrophy (57), whereas for ornithine translocase deficiency patients usually show developmental delay, ataxia, spasticity and learning disabilities (56)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ataxia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "brain atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gyrate atrophy patients have degenerative changes in the white matter and brain atrophy (57), whereas for ornithine translocase deficiency patients usually show developmental delay, ataxia, spasticity and learning disabilities (56)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "spasticity"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "brain atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gyrate atrophy patients have degenerative changes in the white matter and brain atrophy (57), whereas for ornithine translocase deficiency patients usually show developmental delay, ataxia, spasticity and learning disabilities (56)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cholesterol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cholesterol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The liver synthesizes bile acids from cholesterol, which are then delivered to the intestinal lumen to aid in the digestion and absorption of fat with their emulsifying properties."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cholesterol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "bile acids"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The liver synthesizes bile acids from cholesterol, which are then delivered to the intestinal lumen to aid in the digestion and absorption of fat with their emulsifying properties."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "digestion"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cholesterol"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The liver synthesizes bile acids from cholesterol, which are then delivered to the intestinal lumen to aid in the digestion and absorption of fat with their emulsifying properties."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "digestion"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "bile acids"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, these two IEMs showed the highest reduction in flux through the synthesis of GABA, an inhibitory neurotransmitter (59)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "GABA"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "synthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u0153 | | Putrescine to GABA conversion | Exerts protective effect in small intestine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "GABA"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Putrescine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | | Putrescine to methionine conversion | Regeneration of methionine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Putrescine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methionine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, MMA and propionic acidemia share common clinical features with respect to movement disorders, gastroenteritis and neurologic abnormalities (particularly vulnerable basal ganglia) (65)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "movement disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "propionic acidemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Methylmalonic aciduria III | Methylmalonyl-CoA epimerase (MCEE, Gene ID: 84693 , E.C. 5.1.99.1) | Nervous system (OMIM: 251 120) | Co-occurrence of methylmalonic and propionic acidemia has been reported in patients, who also had gastroenteritis (65)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "propionic acidemia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Methylmalonic aciduria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Methylmalonic aciduria III | Methylmalonyl-CoA epimerase (MCEE, Gene ID: 84693 , E.C. 5.1.99.1) | Nervous system (OMIM: 251 120) | Co-occurrence of methylmalonic and propionic acidemia has been reported in patients, who also had gastroenteritis (65)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Methylmalonic aciduria"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "MCEE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, MMA and propionic acidemia share common clinical features with respect to movement disorders, gastroenteritis and neurologic abnormalities (particularly vulnerable basal ganglia) (65)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastroenteritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "movement disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, MMA and propionic acidemia share common clinical features with respect to movement disorders, gastroenteritis and neurologic abnormalities (particularly vulnerable basal ganglia) (65)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastroenteritis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "propionic acidemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Glycerol kinase deficiency | Glycerol kinase (GK, GeneID: 2710, E.C. 2.7.1.30) | Digestive system, nervous system | GI symptoms (including gastroenteritis and decreased oral intake) are the initial features of this disease (OMIM: 307 030), (119)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastroenteritis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GK"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Glycerol kinase deficiency | Glycerol kinase (GK, GeneID: 2710, E.C. 2.7.1.30) | Digestive system, nervous system | GI symptoms (including gastroenteritis and decreased oral intake) are the initial features of this disease (OMIM: 307 030), (119)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GK"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Glycerol kinase deficiency"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Our in silico analysis also predicted a failure to synthesize phosphatidylcholine from phosphatidylethanolamine in the latter two IEMs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phosphatidylethanolamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phosphatidylcholine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This inability may also contribute to their similar clinical features, since phosphatidylcholine is an important membrane constituent and has been shown to exert anti-inflammatory roles, most highly beneficial in ulcerative colitis (66)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phosphatidylcholine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ulcerative colitis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This inability may also contribute to their similar clinical features, since phosphatidylcholine is an important membrane constituent and has been shown to exert anti-inflammatory roles, most highly beneficial in ulcerative colitis (66)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "anti-inflammatory"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phosphatidylcholine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The high consumption of fructose from added sugars has been linked to hypertension (42) and its increased levels in serum and urine have also been found in patients with diabetes type 2 (43)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fructose"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "diabetes type 2"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fructose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fructose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The conversion of fructose to glucose was not possible in the balanced diet due to the absence of fructose in this diet (1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fructose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fructose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cholesterol"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "triglyceride"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Mevalonic aciduria | Mevalonate kinase (MVK, Gene ID: 4598, E.C. 2.7.1.36) | Nervous system, liver, spleen, muscles (OMIM: 251 170) | One case reported complete jejunal and ileal obstruction and failure to thrive in mevalonic aciduria (114)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Mevalonic aciduria"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "MVK"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Mevalonic aciduria | Mevalonate kinase (MVK, Gene ID: 4598, E.C. 2.7.1.36) | Nervous system, liver, spleen, muscles (OMIM: 251 170) | One case reported complete jejunal and ileal obstruction and failure to thrive in mevalonic aciduria (114)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Mevalonic aciduria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "obstruction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Mevalonic aciduria | Mevalonate kinase (MVK, Gene ID: 4598, E.C. 2.7.1.36) | Nervous system, liver, spleen, muscles (OMIM: 251 170) | One case reported complete jejunal and ileal obstruction and failure to thrive in mevalonic aciduria (114)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Mevalonic aciduria"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "failure to thrive"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | SLOS | 7-Dehydrocholesterol reductase (DHCR7, Gene ID: 1717, E.C. 1.3.1.21) | Nervous system, muscles (OMIM: 270400) | Infants with SLOS usually present GI problems that include dysmotility, hypomotility, GI reflux, constipation, formula intolerance and developmental delay (38)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "DHCR7"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "SLOS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methyl"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-methyltetrahydrofolate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-methyltetrahydrofolate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-methyltetrahydrofolate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "amino acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Main Hcy determinants (MTHFR C677T status, vitamin B6, B12 and folate status) were also assessed."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folate"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "MTHFR"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methyl"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "THF"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methyl"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "THF"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-methyltetrahydrofolate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 2 summarizes homocysteine-related vitamin status and C677T polymorphism status for MTHFR gene in the studied groups."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "MTHFR"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "purine metabolism"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-methyltetrahydrofolate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| Fatigue, dizziness, a rapid heartbeat, pale skin, and an enlarged liver and spleen (OMIM: 300751 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "pale skin"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Fatigue"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This compound has potential antioxidant activity, comparable with that of beta-carotene and tocopherol, under low oxygen conditions (51) and, at very low concentrations, bilirubin tends to exert protective effects on the small intestine (52)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tocopherol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "bilirubin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The porphyria models were not able to secrete carbon monoxide (Fig. 4), which has various roles in the GI tract, including regulation of GI motility, activation of guanylate cyclase (suggested role in inflammation), function as a neurotransmitter, contribution to the membrane potential gradient and exerting protective role during GI injury (53,54)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbon monoxide"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The porphyria models were not able to secrete carbon monoxide (Fig. 4), which has various roles in the GI tract, including regulation of GI motility, activation of guanylate cyclase (suggested role in inflammation), function as a neurotransmitter, contribution to the membrane potential gradient and exerting protective role during GI injury (53,54)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbon monoxide"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GUCY2C"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Particularly, the latter role suggests that this compound may contribute to the GI inflammation observed in chronic inflammatory bowel disease (IBD)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammatory bowel disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "inflammation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, IBD patients are prone to develop acute intermittent porphyria, i.e. AIP (55)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "IBD"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Atrophy patients, acting through the gut\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153brain axis and (v) identification of known and novel co-morbidities."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "gut brain axis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, the reactions of the HMP were utilized to generate NADP, which was channeled into proline synthesis, and 5-phospho-alpha-D-ribose-1-diphosphate, which was used for the purine salvage pathway."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "NADP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "proline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, the reactions of the HMP were utilized to generate NADP, which was channeled into proline synthesis, and 5-phospho-alpha-D-ribose-1-diphosphate, which was used for the purine salvage pathway."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "NADP"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "D-ribose"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Ornithine transcarbamylase deficiency | Ornithine carbamoyltransferase, mitochondrial (OTC, Gene ID: 5009, E.C. 2.1.3.3) | Nervous system, liver, skin, hair (OMIM: 311250) | Intestinal ornithine transcarbamylase /lactase ratio indicates degree of mucosal damage and atrophy (110)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "OTC"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Ornithine transcarbamylase deficiency"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Pyrimidine synthesis | Maintenance of the purine level and important byproduct release."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "purine"
        }
       ]
      ]
     },
     {
      "relation": "regulates"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "Pyrimidine synthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc || Fructose to glucose conversion | Fructose utilization"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "fructose"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, the synthesis of phosphatidylethanolamine from phosphatidylserine in rat small intestine has been suggested (78).Deoxy-nucleotides have been also removed from the Recon 1 biomass reactions as sIECs cannot replicate (79)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phosphatidylserine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "phosphatidylethanolamine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Numerous metabolites, including bilirubin, nitric oxide and cholesterol, are also secreted into the lumen."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "nitric oxide"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "bilirubin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "An exception is the GLUT-2 transporter, which is usually present at the basolateral side, but which can also migrate onto the luminal side to aid in glucose absorption under fully fed state (29)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC2A2"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, we analyzed the in silico effect of cystinuria (OMIM: 220 100), which is caused by mutation in either solute carrier family 3 (SLC3A1, GeneID: 6519) or solute carrier family 7 (SLC7A9, GeneID: 11 136).Cystinuria was included in the analysis as the intestinal dibasic amino acid transport system is defective in these patients (35), and thus evidence of the expression of both the genes in human sIECs exists."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC3A1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cystinuria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, blocked flux through HMP, reduced fluxes through reactions involved in pyrimidine synthesis, in the conversion of glutamine to carbon dioxide, and in the purine catabolism pathway contributed to a block in the biomass reaction for cystinuria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cystinuria"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, blocked flux through HMP, reduced fluxes through reactions involved in pyrimidine synthesis, in the conversion of glutamine to carbon dioxide, and in the purine catabolism pathway contributed to a block in the biomass reaction for cystinuria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cystinuria"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "carbon dioxide"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, blocked flux through HMP, reduced fluxes through reactions involved in pyrimidine synthesis, in the conversion of glutamine to carbon dioxide, and in the purine catabolism pathway contributed to a block in the biomass reaction for cystinuria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cystinuria"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "purine catabolism"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Additionally, we analyzed the in silico effect of cystinuria (OMIM: 220 100), which is caused by mutation in either solute carrier family 3 (SLC3A1, GeneID: 6519) or solute carrier family 7 (SLC7A9, GeneID: 11 136).Cystinuria was included in the analysis as the intestinal dibasic amino acid transport system is defective in these patients (35), and thus evidence of the expression of both the genes in human sIECs exists."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC7A9"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cystinuria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "There is disordered intestinal function in both (102), while untreated type 1 b can lead to intestinal mucosal ulcers (103)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "type 1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ulcers"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Microvillus inclusion disease (MVID) is a rare congenital enteropathy associated with brush border atrophy and reduced expression of enzymes at the enterocyte's apical surface."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Microvillus inclusion disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Microvillus inclusion disease (MVID) is a rare congenital enteropathy associated with brush border atrophy and reduced expression of enzymes at the enterocyte's apical surface."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Microvillus inclusion disease"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "enteropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Congenital sucrase-isomaltase deficiency (CSI) | Sucrase-isomaltase (SI, Gene ID:6476, E.C. 3.2.1.48 and 3.2.1.10) | Digestive system | CSI is caused by a deficiency in sucraseisomaltase, an integral brush border membrane protein of the small intestine (OMIM:222 900).It is charaterized by fermentative diarrhea, abdominal pain and cramps (106)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SI"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Congenital sucrase-isomaltase deficiency"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | Propionic acidemia | Propionyl-CoA carboxylase (PCCA or PCCB, Gene ID: 5095, Gene ID: 5096, E.C. 6.4.1.3) | Nervous system, muscle, heart (OMIM: 606054) | Co-occurrence of methylmalonic and propionic acidemia has been reported in patients, who also had gastroenteritis (65)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PCCA"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Propionic acidemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Uptake and secretion of cholic acid | Enterohepatic circulation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "Enterohepatic circulation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cholic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Uptake and secretion of glyco-cholic acid | Enterohepatic circulation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "Enterohepatic circulation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cholic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Uptake and secretion of tauro-cholic acid | Enterohepatic circulation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "Enterohepatic circulation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cholic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Cysteine to pyruvate conversion | Maintenance of cytosolic pyruvate pool."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cysteine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "pyruvate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Methionine to cysteine conversion | Synthesis of cysteine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cysteine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Methionine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | | Synthesis of FMN | Conversion of riboflavin to active form."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "FMN"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "riboflavin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tetrahydrofolate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methyl"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Causes of HHcy include defects of its catabolism, due to inherited enzymatic and/ or vitamin deficiencies (B6, folic acid, or vitamin B12 are important enzymatic cofactors), and conditions responsible for renal or liver failure [9,10,18-22]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methyl"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tetrahydrofolate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "carbon metabolism"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "folic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "carbon metabolism"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tetrahydrofolate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Analysis of the model's metabolic capability revealed that this reduced cysteine secretion flux is due to the model's inability to convert methionine to cysteine."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "methionine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cysteine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | TCA cycle flux | Energy generation, anaplerosis, and amphibolic role."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "anaplerosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "TCA cycle"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Also, the cofactor requirement and sub-cellular localization of reactions included in the cholesterol synthesis pathway, which are catalyzed by the desmosterol reductase (E.C. 1.3.1.72) and HMG-CoA reductase (E.C. 2.3.3.10) reactions, were updated in accordance with the current literature evidence (76)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "desmosterol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "cholesterol synthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to citrulline conversion | For arginine synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "arginine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "citrulline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to ornithine conversion | For spermine synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "spermine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to ornithine conversion | For spermine synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "spermine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ornithine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| | | Glutamine to aspartate conversion | For nucleotide synthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "aspartate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GLS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glutamate"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "| \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u02dc | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GLS"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ammonia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Megaloblastic anemia leads to GI disturbances like malabsorption and diarrhea (118)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "malabsorption"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Megaloblastic anemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Consequently, one of the intestinal amino acid transporters (ATB0, SLC6A14, GeneID: 11254), which has a broad substrate specificity for both neutral and cationic amino acids (39) and requires the presence of sodium and chloride for its activity, could not be used in this diet."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC6A14"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sodium"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Consequently, one of the intestinal amino acid transporters (ATB0, SLC6A14, GeneID: 11254), which has a broad substrate specificity for both neutral and cationic amino acids (39) and requires the presence of sodium and chloride for its activity, could not be used in this diet."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "chloride"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC6A14"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other clinical signs include vomiting, failure to thrive, dehydration, disacchariduria including lactosuria, renal tubular acidosis and amino aciduria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal tubular acidosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other clinical signs include vomiting, failure to thrive, dehydration, disacchariduria including lactosuria, renal tubular acidosis and amino aciduria."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal tubular acidosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dehydration"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "23492669.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "GSD type 1 a is casued due to mutations in G6PC and type 1 b due to defect in SLC37A. | Liver, kidney, digestive system, respiratory system, skeletal system (OMIM:232 200) | In both of these disorders, there is frequently occurring chronic diarrhea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "G6PC1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "type 1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Moreover, PLP is in important co-factor for Glutamate decarboxylase (GAD) activity, the sole enzyme able to synthesize \u00c3\u017d\u00c2\u00b3-aminobutyric acid (GABA), a major inhibitory neurotransmitter, whose reduced effect or availability has also been observed during AP exacerbations [60-61]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "GAD"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "4-aminobutyric acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In fact, in our survey all patients undergoing chronic Heme-arginate who developed venous thrombosis showed moderate to severe HHcy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "venous thrombosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In fact, in our survey all patients undergoing chronic Heme-arginate who developed venous thrombosis showed moderate to severe HHcy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "arginate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "venous thrombosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine \u00c3\u017d\u00c2\u00b2 synthase (CBS) and cystathionine \u00c3\u017d\u00c2\u00b3-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine \u00c3\u017d\u00c2\u00b2 synthase (CBS) and cystathionine \u00c3\u017d\u00c2\u00b3-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cystathionine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine \u00c3\u017d\u00c2\u00b2 synthase (CBS) and cystathionine \u00c3\u017d\u00c2\u00b3-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sulphur"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Causes of HHcy include defects of its catabolism, due to inherited enzymatic and/ or vitamin deficiencies (B6, folic acid, or vitamin B12 are important enzymatic cofactors), and conditions responsible for renal or liver failure [9,10,18-22]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Overall, the Hcy/Cys ratio showed a significant inverse correlation with plasma B6 levels (r = -.567, p = .000)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin B6"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cysteine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Discussion Hyperhomocysteinemia, a condition defined by serum levels of homocysteine above 15 \u00c3\u201a\u00c2\u00b5mol/L, has been claimed as an independent risk factor for the development of a wide range of diseases, including thrombosis, atherosclerosis, endothelial damage, osteoporosis and neuropsychiatric illness."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "thrombosis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Discussion Hyperhomocysteinemia, a condition defined by serum levels of homocysteine above 15 \u00c3\u201a\u00c2\u00b5mol/L, has been claimed as an independent risk factor for the development of a wide range of diseases, including thrombosis, atherosclerosis, endothelial damage, osteoporosis and neuropsychiatric illness."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atherosclerosis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hyperhomocysteinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Blood samples were collected in EDTA tubes and immediately centrifuged in order to prevent Hcy and Cys efflux from erythrocytes to plasma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "EDTA"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cysteine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine \u00c3\u017d\u00c2\u00b2 synthase (CBS) and cystathionine \u00c3\u017d\u00c2\u00b3-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cystathionine"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine \u00c3\u017d\u00c2\u00b2 synthase (CBS) and cystathionine \u00c3\u017d\u00c2\u00b3-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "cystathionine"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sulphur"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Homocysteine (Hcy) is a metabolic intermediate of sulphur amino acid metabolism (Fig. 2) [8-10]: its elevation in plasma, a condition referred as hyperhomocysteinemia (HHcy), has been related to neurological and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis) [11-17]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sulphur"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Homocysteine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Homocysteine-related vitamin status in AP studied groups."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Homocysteine"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Homocysteine (Hcy) is a metabolic intermediate of sulphur amino acid metabolism (Fig. 2) [8-10]: its elevation in plasma, a condition referred as hyperhomocysteinemia (HHcy), has been related to neurological and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis) [11-17]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Homocysteine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "venous thrombosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Homocysteine (Hcy) is a metabolic intermediate of sulphur amino acid metabolism (Fig. 2) [8-10]: its elevation in plasma, a condition referred as hyperhomocysteinemia (HHcy), has been related to neurological and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis) [11-17]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Homocysteine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperhomocysteinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Table 2 summarizes homocysteine-related vitamin status and C677T polymorphism status for MTHFR gene in the studied groups."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "homocysteine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In order to evaluate the possible mechanisms underlying the observed HHcy in AP patients, we considered different well-known Hcy determinants, such as the vitamin status."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamin"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HHcy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The link between AP, HHcy and vitamin deficiency is also intriguing if considering that the clinic of peripheral neuropathy resulting from a deficiency in PLP shows striking resemblances to that observed in acute porphyrias [45-47].When considering the high prevalence of vitamin deficiencies in the general population [18,48,49], and in porphyria patients [50], it is likely that depletion of vitamin cofactors in multiple tissues promoted by a deficiency in heme biosynthesis may contribute to worsen other underlying deficiencies."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Vitamin deficiency"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "HHcy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "We measured plasma homocysteine in a group of patients with Acute porphyrias (AIP and VP), in order to determine whether these diseases are associated with a derangement of Hcy catabolism responsible for HHcy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Vitamins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "homocysteine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32554360.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Eventually, her seizure condition became much better controlled with one to two convulsive seizures per year using a combination of CBZ, clobazam and levetiracetam (age 29 to 32 years)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "clobazam"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "seizure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cyclosporine-A mainly inhibits T cell proliferation and is nephrotoxic (7,8)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Cyclosporine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "cell proliferation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Azathioprine can not be used together with febuxostat (9), and has potent myelosuppressive action (10)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "febuxostat"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Azathioprine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The patient and her cousin underwent exon gene sequencing, and genes related to AIP and immunodeficiency disorders were analyzed."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "immunodeficiency disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Since the patient was given artificial tears to relieve dry eyes, she was given mycophenolate mofetil to delay the progression of the primary disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MAXO",
         "name": "artificial tears therapy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry eyes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Since the patient was given artificial tears to relieve dry eyes, she was given mycophenolate mofetil to delay the progression of the primary disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "mycophenolate mofetil"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dry eyes"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The woman had severe abdominal pain after a cold, flaccid paralysis of the limbs, and muscle atrophy in the left hand."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "muscle atrophy"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Each attack was treated with high concentration of glucose, heme arginate, an analgesic, and a beta blocker to lower blood pressure; the condition was relieved for one-three weeks."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "analgesic"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glucose"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Test results (Table 1) indicated that serum immunoglobulins (IgG and IgA) were elevated, and serum anti-SS-A antibody, serum anti-SS-B antibody, Schirmer's test were positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "IGHD"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "IgG"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On the other hand, there were typical clinical manifestations of PSS such as dry eyes and a dry mouth, the elevation of immunoglobulins (IgG and IgA) and the results of Schirmer's test, an anti-SS-A antibody test, an anti-SS-B antibody test, and a labial gland biopsy were all positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "IGHD"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "IgG"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Serum immunoglobulin continued to rise (IgG: 16.70 \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 28.00 g / L, IgA: 5.23 \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 6.24 g / L )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "IGHD"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "IgG"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Test results (Table 1) indicated that serum immunoglobulins (IgG and IgA) were elevated, and serum anti-SS-A antibody, serum anti-SS-B antibody, Schirmer's test were positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SSB"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "GO",
         "name": "IgG"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Test results (Table 1) indicated that serum immunoglobulins (IgG and IgA) were elevated, and serum anti-SS-A antibody, serum anti-SS-B antibody, Schirmer's test were positive."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SSB"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "IGHD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "# The challenge of managing comorbidities: a case report of primary Sjogren's syndrome in a patient with acute intermittent porphyria Qing Teng ^1, Liyan Ma^2, Yuelin Ma^1, Yiran Zhang ^3, Ninglin Kang ^4, Yuanxiang Hu^5, Songyun Zhang ^1, * ^1 Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; ^2 Department of Rheumatology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; ^3 School of First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China; ^4 Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, Hebei, China; ^5 Geriatrics, First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjogren's syndrome"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Primary Sjogren's syndrome (PSS) is a common autoimmune disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Sjogren's syndrome"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "autoimmune disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The woman developed mumps 3 times, and rampant dental caries and tooth loss gradually appeared."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dental caries"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mumps"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The woman developed mumps 3 times, and rampant dental caries and tooth loss gradually appeared."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mumps"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tooth loss"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The woman developed mumps 3 times, and rampant dental caries and tooth loss gradually appeared."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tooth loss"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dental caries"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Five years ago, the woman was diagnosed with Hashimoto's thyroiditis (subclinical hypothyroidism), and she was given Euthyrox 50 ug / d. Three years ago, intermittent purpura developed on the skin of the lower limbs after physical activity, though this was not treated."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Hashimoto's thyroiditis"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "purpura"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Some studies have reported increased risks of schizophrenia and bipolar disease in AHP cohorts, and an increased prevalence of AHP in psychiatric patient cohorts."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "bipolar disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "schizophrenia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The difference in cardiovascular disease between porphyria patients and the general population was not significant ( 41.73 % vs. 36.79 % p=.150 ).All diseases except renal diseases were more frequent in the reference group with fibromyalgia compared to the porphyria patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Except for deaths due to PLC and porphyria per se, a higher risk of death due to renal diseases was also detected, confirming previous results from a regional single center cohort."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with AHP had a nonsignificant trend towards lower rates of two cancer forms that are related to smoking, lung cancer, and bladder cancer (Table 3), compared to the matched comparators."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "bladder cancer"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "lung cancer"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The rate of cerebrovascular disease was increased in U-PBG positive AIP ( aHR=1.40[95 %CI=1.06-1.85] ), mainly related to an increased rate of hemorrhagic stroke ( aHR=1.91 [95 %CI=1.11-3.31] ), but not in AHP in general."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cerebrovascular disease"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemorrhagic stroke"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The risk of cerebrovascular disease in U-PBG positive patients with AIP was mainly associated to an increased risk of hemorrhagic stroke ( aHR=1.91 [ 95 % CI=1.11-3.31] ), which might be related to the high frequency of HT in these patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemorrhagic stroke"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cerebrovascular disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The risk of other cardiovascular conditions commonly associated with HT such as heart failure, atrial fibrillation, ischemic heart disease, and peripheral artery disease did not differ between the AHP groups and comparators."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ischemic heart disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrial fibrillation"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The risk of other cardiovascular conditions commonly associated with HT such as heart failure, atrial fibrillation, ischemic heart disease, and peripheral artery disease did not differ between the AHP groups and comparators."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ischemic heart disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "heart failure"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Similarly, risks of specified forms of psychiatric disorders such as mood disorders, psychosis, and addiction were not different from the matched reference population."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mood disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "psychiatric disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "36546345.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Furthermore, studies have proposed that the disease-associated gene in AIP, H M B S (hydroxymethylbilane synthase), has a tumor suppressor function."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "tumor suppressor"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "erythropoietic protoporphyrias (EPP and XLEPP) can develop a severe cholestatic liver disease that is often fatal without a liver transplantation. In AP, some patients have severe recurrent attacks that do not respond to treatment and LT is a curative treatment option. Hence, the treatment aims for LT in porphyrias can be quite different."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "NCIT",
         "name": "curative treatment"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cholestatic liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Four frequent problems have been identified in LT for EPPassociated liver disease: disease recurrence in the graft, phototoxic tissue injuries from surgical lights, high frequencies of postoperative neuropathies and biliary tract complications."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathies"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyperplasia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Histological findings suggest that renal arterioles may be permanently injured, leading to chronic vasculopathy with narrowed lumen and tissue ischaemia contributing to CKD. Human peptide transporter 2 (PEPT2) has been suggested to have an impact on PAKD"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ischaemia"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vasculopathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Histological findings suggest that renal arterioles may be permanently injured, leading to chronic vasculopathy with narrowed lumen and tissue ischaemia contributing to CKD. Human peptide transporter 2 (PEPT2) has been suggested to have an impact on PAKD in French patients with AP. ALA, which is highly hydrophilic, is freely filtered in the urine and reabsorbed by PEPT2 in the proximal tubule."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vasculopathy"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "ischaemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "If the levels of porphyrin precursors are close to normal (<2\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090fold increase), the association between chronic pain and AP is unlikely."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic pain"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most studies are descriptive and lack biochemical porphyria markers and criteria for chronic pain and specific categorisation of chronic pain types."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic pain"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic pain mainly represents the neuropathic type based on burning and tingling sensations, poor response to painkillers and numbness. In some cases, it is diffuse, affecting the whole abdomen or \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153whole body'. Overlap with signs of sensory (19%) Overlap with signs of sensory (19%) and motor (22%) neuropathy and chronic pain (25%-40%) was common. The frequency and proportion of pain types have varied in different series (Table 1) due to variability in the severity of AP and the methodological issues mentioned above."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic pain"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathic"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic pain occurs in patients with recurrent attacks, combined with chronic fatigue and nausea, leading to poor quality of life."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic pain"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic pain itself can cause nausea."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic pain"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "On neurophysiological assessment, classic nerve conduction studies are usually normal or show sequelae of previous acute PNP. Quantitative thermal sensation testing and skin punch biopsy may help to confirm the diagnosis of small fibre neuropathy in chronic neuropathic pain, but these studies are lacking in AP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic neuropathic pain"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropathy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This could include mirtazapine for patients with a low BMI, or escitalopram or trazodone for severe insomnia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "escitalopram"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "severe insomnia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Considering the clinical severity of AIP in these patients, surprisingly few histopathological findings could be detected. Based on the 25 explanted livers, none of the AP patients had cirrhosis and only one subject had stage III fibrosis due to advanced hemosiderosis. Histological studies of peritumoral liver samples resected from patients with AP\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090associated PLC showed cirrhosis or advanced fibrosis in several patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemosiderosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Considering the clinical severity of AIP in these patients, surprisingly few histopatho- logical findings could be detected. Based on the 25 explanted livers, none of the AP patients had cirrhosis and only one subject had stage III fibrosis due to advanced hemosiderosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hemosiderosis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Of note, CYP450\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090related drug interactions should be checked if givosiran is used.45 The use of antidepressants is justified as 67 also reported in AP9, 10, 11 (Table 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "drug interactions"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYP450"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Of the 251 AP patients in the Norwegian porphyria Register, three cases (1.2%) were identi fied compared to 6868 cases out of 4 398 546 individuals (.1%) in the reference population, resulting in the HR of 7.6.75 The Swedish registry- based cohort study with 1244 AP and 12 362 individuals in the reference population identified 10 (.8%) cases versus 27 (.2%) in the comparators, giving the HR = 3.92.48 Four of the tumours were clear cell renal cell carcinoma and two were chromophobe renal cell carcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "clear cell renal cell carcinoma"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The role of haem depletion or mitochondrial dysfunction is also possible in chronic fatigue syndrome associated with AP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic fatigue syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mitochondrial dysfunction"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As chronic fatigue and depression often overlap, the use of cognitive behavioural therapy and/or antidepressants may have some effect. As with myalgic encephalomyelitis or chronic fatigue syndrome, an energy coping strategy of finding individual limits to mental and physical activity and following this balance may be recommended."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "antidepressants"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic fatigue"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Proton pump inhibitors are worth trying to rule out gastro\u00c3\u00a2\u00e2\u201a\u00ac\u00c2\u0090oesophageal reflux disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastro oesophageal reflux disease"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Proton pump inhibitors"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Central antiemetics such as ondansetron or metoclopramide may be used for severe attacks of nausea in AP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "metoclopramide"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "nausea"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic pain mainly represents the neuropathic type based on burning and tingling sensations, poor response to painkillers and numbness. In some cases, it is diffuse, affecting the whole abdomen or \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153whole body'. Overlap with signs of sensory (19%) Overlap with signs of sensory (19%) and motor (22%) neuropathy and chronic pain (25%-40%) was common. The frequency and proportion of pain types have varied in different series (Table 1) due to variability in the severity of AP and the methodological issues mentioned above."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tingling sensations"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic pain mainly represents the neuropathic type based on burning and tingling sensations, poor response to painkillers and numbness. In some cases, it is diffuse, affecting the whole abdomen or \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153whole body'. Overlap with signs of sensory (19%) Overlap with signs of sensory (19%) and motor (22%) neuropathy and chronic pain (25%-40%) was common. The frequency and proportion of pain types have varied in different series (Table 1) due to variability in the severity of AP and the methodological issues mentioned above."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "numbness"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Chronic pain mainly represents the neuropathic type based on burning and tingling sensations, poor response to painkillers and numbness. In some cases, it is diffuse, affecting the whole abdomen or \u00c3\u00a2\u00e2\u201a\u00ac\u00cb\u0153whole body'. Overlap with signs of sensory (19%) Overlap with signs of sensory (19%) and motor (22%) neuropathy and chronic pain (25%-40%) was common. The frequency and proportion of pain types have varied in different series (Table 1) due to variability in the severity of AP and the methodological issues mentioned above."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "diffuse"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "chronic pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tubulointerstitial"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Fourteen kidney biopsies from PAKD patients revealed chronic tubulointerstitial disease, characterised by interstitial fibrosis and tubular atrophy"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tubulointerstitial"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "atrophy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypovolemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hypertension"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Stacked bar chart showing the proportion of total physician visits among acute porphyria patients, stratified by specialist group and compared to the general population and fibromyalgia patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibromyalgia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In particular, the difference between porphyria patients and those diagnosed with fibromyalgia was statistically significant (p = .013)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibromyalgia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A closer look at the subgroups of porphyria patients compared to fibromyalgia patients showed that the mean number of sick days of active porphyria patients with <2 attacks was 25.0 (IQR: 14.1\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u015328.5), which is comparable to that of fibromyalgia patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibromyalgia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The dynamics of hospitalization in porphyria patients show an evolution, with an increase from 27.4 % to 33.8 % between the 4th and the 1st year before the index (Figure 3).Among fibromyalgia patients, 35.8 % experienced at least one hospitalization in the first-year pre-index, compared with 19.3 % of the general population, the latter difference being significant when compared with the porphyria study population ( p<.001 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibromyalgia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, similar to the porphyria patients, the fibromyalgia patients also had a high visit rate of 99.8 %."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibromyalgia"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In patients with active porphyria, patients had similar median sickness days than patients with fibromyalgia (20 vs. 23.5 days, p = .736)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sickness"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Cardiovascular diseases were diagnosed in 41.7 % of the porphyria patients 1 year before the index, with a higher incidence in active patients with at least 2 attacks ( 56.7 % ), and in active porphyria patients with fewer than 2 attacks compared to the porphyria patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "cardiovascular diseasess"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Looking more closely at the health challenges faced by acute porphyria patients, it was found that these patients were more likely to suffer from nervous system disorders, pain, and mental disorders in the first year before the index compared to the general population."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "mental disorders"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In patients with fibromyalgia, 31.6 % received opioids."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "opioids"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "fibromyalgia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Gastrointestinal diseases include abdominal pain, appendicitis, nausea and vomiting, constipation, diarrhoea and ileus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "appendicitis"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "gastrointestinal disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Nervous system disorders cover e.g. epilepsy, polyneuropathy, convulsions, paranesthesia, and motor weakness."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "polyneuropathy"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Nervous system disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Nervous system disorders cover e.g. epilepsy, polyneuropathy, convulsions, paranesthesia, and motor weakness."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "motor weakness"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "epilepsy"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39016183.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Nervous system disorders cover e.g. epilepsy, polyneuropathy, convulsions, paranesthesia, and motor weakness."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "motor weakness"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "Nervous system disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39463915.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Notably, the use of trimethoprim, an antibiotic contraindicated in AIP due to its potential to disrupt heme biosynthesis, was identified as a trigger for her acute crisis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "trimethoprim"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heme synthesis requires condensation of glycine and succinyl-CoA into 5-aminolevulinic acid (5-ALA) and the subsequent enzymatic conversion of 5-ALA into heme."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "glycine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Heme synthesis requires condensation of glycine and succinyl-CoA into 5-aminolevulinic acid (5-ALA) and the subsequent enzymatic conversion of 5-ALA into heme."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "succinyl-CoA"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "electromagnetic radiation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "sunlight"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "photosynthesis"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Phlebotomy is first-line treatment and mitigates the presence of iron overload, and hydroxychloroquine serves to inhibit porphyrin formation and promote urinary excretion of the porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxychloroquine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Treatment includes therapeutic phlebotomy to decrease total body iron levels and low-dose hydroxychloroquine, which reduces hepatic porphyrin content."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxychloroquine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients with porphyria cutanea tarda benefit from iron depletion, hydroxychloroquine therapy, and, if applicable, elimination of the hepatitis C virus."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxychloroquine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Identify effective treatments for PCT, including phlebotomy and hydroxychloroquine"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxychloroquine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Low-dose hydroxychloroquine (100 mg orally twice weekly) is an alternative option for patients with PCT who do not have access to or cannot tolerate therapeutic phlebotomy, and who do not have marked iron overload. Chloroquine can be used as well, but hydroxychloroquine is preferred because of its superior safety pro file. These 4-aminoquinolines are taken up in hepatocyte lysosomes, which then release large amounts of accumu lated porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxychloroquine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydroxychloroquine"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However, studies have shown that the use of dialysis machines with higher specifications, and with more modern, high-flux dialysis membranes combined with higher blood flow rates during dialysis may lead to increased porphyrin clearance within the dialysate."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "blood flow"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vascular diseases"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "urinary tract obstruction"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "dysfunction"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "kidney disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As with most compounds transported by MRP2, CP1, and CP3 are also transported by the basolateral efflux transporter MRP3 ( A B C C 3 )."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ABCC2"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PCBP1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Normally, Urine CP1/ Urine CP1+CP 3 is less than 33 %, but in the absence of MRP2, this ratio is increased, often to greater than 80 %.Urinary CP1 fraction greater than 80 % has close to 100 % specificity and sensitivity for Dubin-Johnson syndrome."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ABCC2"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PCBP1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "However when MRP2 function is impaired (eg, in Dubin-Johnson syndrome), MRP3 levels increase to provide a compensatory pathway for hepatic efflux."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Dubin-Johnson syndrome"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ABCC2"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "As in Dubin-Johnson syndrome, the proportion of urinary CP1 exceeds that of CP3 in a ratio of about 2-3/1."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Dubin-Johnson syndrome"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "PCBP1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thus, there likely can be competition for succinylCoA between heme synthesis and the formation of succinate, fumarate, malate, and other tricarboxylic acid cycle intermediates."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "succinate"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thus, there likely can be competition for succinylCoA between heme synthesis and the formation of succinate, fumarate, malate, and other tricarboxylic acid cycle intermediates."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "malate"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In Rotor syndrome total urinary CP excretion is markedly increased."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SNOMED",
         "name": "Rotor syndrome"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "excretion"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In contrast, the need for erythroid heme synthesis is rather constant throughout life, although it, too, maybe stimulated under conditions of blood loss or hemolysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blood loss"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Xenobiotics inhibit the activities of multidrug resistance-associated proteins and/or OATPs and affect the metabolism and disposition of CPs."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "multidrug resistance-associated proteins"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Xenobiotics"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ethanol decreases activities of ALAD, UROD, CPOX, and FECH."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Ethanol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ethanol decreases activities of ALAD, UROD, CPOX, and FECH."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Ethanol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ethanol decreases activities of ALAD, UROD, CPOX, and FECH."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Ethanol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ethanol decreases activities of ALAD, UROD, CPOX, and FECH."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Ethanol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CPOX"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ethanol leads to modest increases in ALA synthase- 1^66,67 and to CYPs, especially CYP2E1."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Ethanol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "CYPs"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ethanol leads to modest increases in ALA synthase- 1^66,67 and to CYPs, especially CYP2E1."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Ethanol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "CYP2E1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## MRP2 and Dubin-Johnson Syndrome (Mendelian Inheritance in Man 237500) The Dubin-Johnson syndrome is characterized by chronic conjugated hyperbilirubinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Dubin-Johnson Syndrome"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ABCC2"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "## MRP2 and Dubin-Johnson Syndrome (Mendelian Inheritance in Man 237500) The Dubin-Johnson syndrome is characterized by chronic conjugated hyperbilirubinemia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hyperbilirubinemia"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ABCC2"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Coproporphyrins (CPs) are tetrapyrroles, formed by nearly all organisms."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "tetrapyrroles"
        }
       ]
      ]
     },
     {
      "relation": "is_a"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Coproporphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "or in hereditary tyrosinemia type 1 , in which 4,6-dioxoheptanoic acid (also known as succinyl acetone), a potent inhibitor of ALAD, accumulates."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "succinyl acetone"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAD"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Type 1 tyrosinemia is not a primary disorder of porphyrin metabolism but indirectly leads to similar biochemical changes and porphyria-like symptoms as in ALADP, caused by the accumulation of succinyl acetone, a potent inhibitor of ALAD."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "succinyl acetone"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "tyrosinemia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "TPO, a hormone constitutively produced by the liver, is responsible for the growth and maturation of megakaryocytes in the bone marrow."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hormone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "TPO"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "All TPO values in our cohort were within the normal range, suggesting that there is no global alteration in platelet production in patients with EPP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "TPO"
        }
       ]
      ]
     },
     {
      "relation": "causes_no_change"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "GOBP",
         "name": "platelet production"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mild microcytic anaemia and iron deficiency have long been recognized as features of EPP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "anemias"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Mild microcytic anaemia and iron deficiency have long been recognized as features of EPP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "iron deficiency"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Finally, spleen size, a potential marker for extra medullary haematopoiesis, has not been rigorously exam ined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Spleen"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For the first time, to our knowledge, we documented mild splenic enlargement in patients with EPP and found a direct relationship between protoporphyrin levels and spleen length."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Spleen"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Finally, spleen size, a potential marker for extra medullary haematopoiesis, has not been rigorously exam ined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Spleen"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "extramedullary hematopoiesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This study, comprising 108 patients with PCT, was intended to define the role of hemochro matosis gene (HFE) mutations in the expression of PCT and to determine the contribution of acquired factors includ ing alcohol, hepatitis C virus (HCV), and estrogen. The 2 known HFE mutations, cysteine 282 tyrosine (Cys282Tyr) and histidine 63 asparagine (His63Asp), were detected by polymerase chain reaction, and anti-HCV immunoglobulin G was detected serologically."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.Cys282Tyr"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.Cys282Tyr"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatic fibrosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.Cys282Tyr"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver cirrhosis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For instance, in 1 study of 108 patients with PCT, 19% were homozygous for the HFE C282Y pathogenic variant."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.Cys282Tyr"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "For instance, in 1 study of 108 patients with PCT, 19% were homozygous for the HFE C282Y pathogenic variant."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.Cys282Tyr"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Chronic hepatitis C"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.Cys282Tyr"
           }
          ]
         ]
        ]
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Alcohol further contributes by down-regulating hepcidin and enhancing oxidative stress."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The results were interpreted to indicate that the effect of ethanol to produce a PCT phenotype is mediated by effects of alcohol on iron metabolism, specifically an effect to increase iron within hepatocytes."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "16315139.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Results from early work showed that relatively large doses of alcohol given to rodents were capable of increasing activity of 5-aminolevulinate synthase, the first and rate-controlling enzyme of heme synthesis. However, levels of activity of 5-aminolevulinate synthase in human beings with PCT have not been shown to be increased. Thus, the relevance of this finding to clinical PCT has remained uncertain."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "Alcohol"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Treatment for one year with clodronate and a high transfusion regime was associated with small reductions in serum alkaline phosphatase and urine hydroxy- proline excretion, but there was no improvement in bone mineral density."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEMBL",
         "name": "clodronate"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALPL"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Treatment for one year with clodronate and a high transfusion regime was associated with small reductions in serum alkaline phosphatase and urine hydroxy- proline excretion, but there was no improvement in bone mineral density."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEMBL",
         "name": "clodronate"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEMBL",
         "name": "hydroxyproline"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "22273750.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Tracking infections and providing prompt therapy is important because they are often the cause of AIP exacerbations."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Infections"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Tachycardia coupled with hypertension and a reddish dark urine are further diagnostic signs (Figure 2A)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "reddish"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Tachycardia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intravenous heme (Normosang; Orphan Europe, Puteaux, France, in Europe and some other regions, and Panhematin; Recordati Rare Diseases, Lebanon, NJ, in the United States, Mexico, and elsewhere) acts as a transcription factor that reduces expression of the ratelimiting hepatic enzyme ALAS1."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Rare Diseases"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Increased plasma levels of porphyrins, especially zinc protoporphyrin and coproporphyrin, are found in patients with diseases other than porphyrias, such as in colorectal adenocarcinoma."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "DO",
         "name": "colorectal adenocarcinoma"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Most of the porphyrins emit red fluorescence when exposed to long-wave ( 366 nm ) ultraviolet light, as exemplified by brown, high protoporphyrin-containing chicken eggshells (Supplementary Figure 1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "ultraviolet light"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "If liver biopsies are exposed to long-wave ultraviolet light, those from PCT produce red fluorescence."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "ultraviolet light"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "fluorescence"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^110 As many as 23 % of patients with EPP develop protoporphyrin-containing gallstones that emit red fluorescence under long-wave ultraviolet light."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHPP",
         "name": "ultraviolet light"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Uncontrolled observations suggest successful treatment with ursodeoxycholic acid that may increase hepatic clearance, and with cholestyramine that may bind protoporphyrin and interrupt its enterohepatic circulation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "ursodeoxycholic acid"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "protoporphyrin"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "An inappropriately high secretion of antidiuretic hormone (Schwartz-Bartter syndrome) leads to a potentially lifethreatening severe hyponatremia, another diagnostic feature of acute porphyrias."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Bartter syndrome"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^38 PEPT2*1 is also found in the choroid plexus and may be important in pumping variable amounts of toxic ALA into the brain, which could explain the variable susceptibility to neuropsychiatric symptoms in patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC15A2"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "neuropsychiatric symptoms"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A variant of kidney peptide transporter 2 (PEPT2*1*) has high affinity for ALA and promotes its reabsorption, likely contributing to renal damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC15A2"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "renal damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Laboratory analysis again showed severe hyponatremia (112 mEq/L) with a urine sodium level of 114 mEq / L. Careful substitution with 3 % sodium chloride was started, with intensive monitoring and hourly controls of serum sodium to prevent pontine myelinolysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sodium chloride"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hyponatremia"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Laboratory analysis again showed severe hyponatremia (112 mEq/L) with a urine sodium level of 114 mEq / L. Careful substitution with 3 % sodium chloride was started, with intensive monitoring and hourly controls of serum sodium to prevent pontine myelinolysis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sodium chloride"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "pontine myelinolysis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eating disorder"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "abdominal pain"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eating disorder"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "vomiting"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eating disorder"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "eating disorder"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "worsening"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^6,95,96 During the first 3 months after patients begin receiving 4-aminoquinolines, urinary porphyrin excretion usually increases more than 2-fold and skin photosensitivity can worsen, but thereafter decreases, resulting in clinical remission and improved liver enzyme activities in 95 % of patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Remission"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "After subcutaneous injection, Givosiran is directed to and endocytosed by hepatocytes that carry the N -acetylgalactosamine binding asialoglycoprotein receptor."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "acetylgalactosamine"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "After subcutaneous injection, Givosiran is directed to and endocytosed by hepatocytes that carry the N -acetylgalactosamine binding asialoglycoprotein receptor."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ASGR1"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Givosiran"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^131,132 GATA1, encoded by a gene on the X chromosome, is a transcription factor that regulates heme biosynthesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "GATA1"
        }
       ]
      ]
     },
     {
      "relation": "regulates"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "heme biosynthesis"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "ALAS1 is induced via induction of cytochrome P450 (CyP450), such as by xenobiotics, smoking, excess alcohol consumption, fasting, and female sex hormones."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "xenobiotics"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^23,25 Moreover, a drug-responsive sequence in the ALAS1 gene mediates a direct transcriptional activation via drugs such as barbiturates, hydantoins, and metyrapone."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydantoins"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^23,25 Moreover, a drug-responsive sequence in the ALAS1 gene mediates a direct transcriptional activation via drugs such as barbiturates, hydantoins, and metyrapone."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "metyrapone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^23,25 Moreover, a drug-responsive sequence in the ALAS1 gene mediates a direct transcriptional activation via drugs such as barbiturates, hydantoins, and metyrapone."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "metyrapone"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "hydantoins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^26-29 Glucose activation of peroxisome proliferator-activated receptor \u00c3\u017d\u00c2\u00b3-coactivator 1 \u00c3\u017d\u00c2\u00b1 prevents transcription of ALAS1."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "Glucose"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "^12 The lipophilic PPIX, which is eliminated via bile, is hepatotoxic at high concentrations, causing varying degrees of liver damage."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "PPIX"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "liver damage"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients have symptoms of burning, itching, pain, erythema, and edema on sun-exposed skin areas, sometimes but not always resembling sunburn."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sunburn"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "erythema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "31085196.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patients have symptoms of burning, itching, pain, erythema, and edema on sun-exposed skin areas, sometimes but not always resembling sunburn."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "sunburn"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "edema"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In order to better define the association between HHcy and AP, patients were assessed in respect to heme arginate prophylactic therapy. Surprisingly, patients under heme arginate prophylactic therapy showed significantly higher serum Hcy mean levels."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "Heme arginate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "homocysteine"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Total plasma (TPP), erythrocyte (TEP), and urine por phyrin levels (TUP) measured at follow-up were significantly reduced from pretransplant levels"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematopoietic Stem Cell Transplantation"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "plasma porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Total plasma (TPP), erythrocyte (TEP), and urine por phyrin levels (TUP) measured at follow-up were significantly reduced from pretransplant levels"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematopoietic Stem Cell Transplantation"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "PKG",
         "name": "erythrocyte porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Total plasma (TPP), erythrocyte (TEP), and urine por phyrin levels (TUP) measured at follow-up were significantly reduced from pretransplant levels"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematopoietic Stem Cell Transplantation"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "34245225.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Patient 1, who had pretransplant liver biopsy with iron of 6466 \u00c3\u201a\u00c2\u00b5g/g tissue dry weight and an iron index of 5.8 \u00c3\u201a\u00c2\u00b5mol/g/year, developed veno-occlusive disease (VOD),"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hematopoietic Stem Cell Transplantation"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Hepatic Veno-Occlusive Disease"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Understand that PCT arises from decreased UROD activ ity in the liver"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda (PCT) occurs due to inhibition of the fifth enzyme of heme biosynthesis, uroporphyrinogen decarboxylase (UROD)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT usually occurs in the absence of a UROD pathogenic variant, and a heterozygous UROD pathogenic variant alone is not sufficient to cause the disease."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The decreased activity of UROD, the fifth step in the pathway, leads to porphyria cutanea tarda."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Inherited factors may include UROD and HFE pathogenic variants."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT is a hepatic porphyria that arises due to the acquired inhibition of hepatic UROD."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda is the result of absent or defective uropor phyrinogen III decarboxylase (UROD), the enzyme responsible for the conversion of uroporphyrinogen III into coproporphyrinogen III."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "35193623.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "porphyria cutanea tarda (PCT) is a skin disorder caused by a defect in the liver enzyme uroporphyrino gen decarboxylase and is associated with hepatitis C virus infection, high alcohol intake, smoking and iron overload."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "35193623.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "In susceptible individuals, impaired UROD activity causes accumulation of porphyrins in the liver"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Treatment includes therapeutic phlebotomy to decrease total body iron levels and low-dose hydroxychloroquine, which reduces hepatic porphyrin content."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Phlebotomy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Identify effective treatments for PCT, including phlebotomy and hydroxychloroquine"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Phlebotomy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Phlebotomy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A reduction in hepatic iron stores via therapeutic phlebotomy is an effective and well-tolerated therapy in the majority of patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Phlebotomy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Treatment includes therapeutic phlebotomy to decrease total body iron levels and low-dose hydroxychloroquine, which reduces hepatic porphyrin content."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Phlebotomy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A reduction in hepatic iron stores via therapeutic phlebotomy is an effective and well-tolerated therapy in the majority of patients."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "biological_process"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Phlebotomy"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "iron"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pseudoporphyria is a dermatologic condition with blistering skin lesions identical to those observed in PCT, but without alterations in heme biosynthesis or evi dence of porphyrin accumulation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SNOMED",
         "name": "Pseudoporphyria (disorder)"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pseudoporphyria is a dermatologic condition with blistering skin lesions identical to those observed in PCT, but without alterations in heme biosynthesis or evi dence of porphyrin accumulation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SNOMED",
         "name": "Pseudoporphyria (disorder)"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Pseudoporphyria is a dermatologic condition with blistering skin lesions identical to those observed in PCT, but without alterations in heme biosynthesis or evi dence of porphyrin accumulation."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "SNOMED",
         "name": "Pseudoporphyria (disorder)"
        }
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "UROD deficiency re sults in the accumulation of uroporphyrinogen III in skin tissues, and upon sun exposure, uroporphyrinogen III generates reactive oxygen species, resulting in a high susceptibility to sun-damaged skin amongst this patient population."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrinogen III"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The predominant clinical manifestations of PCT are skin fragility and blistering skin lesions."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrinogen III"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Skin Diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "UROD deficiency re sults in the accumulation of uroporphyrinogen III in skin tissues, and upon sun exposure, uroporphyrinogen III generates reactive oxygen species, resulting in a high susceptibility to sun-damaged skin amongst this patient population."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrinogen III"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Photosensitivity Disorders"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "UROD deficiency re sults in the accumulation of uroporphyrinogen III in skin tissues, and upon sun exposure, uroporphyrinogen III generates reactive oxygen species, resulting in a high susceptibility to sun-damaged skin amongst this patient population."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrinogen III"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "reactive oxygen species"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The predominant clinical manifestations of PCT are skin fragility and blistering skin lesions."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "uroporphyrinogen III"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "blisters"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "10688809.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This study, comprising 108 patients with PCT, was intended to define the role of hemochro matosis gene (HFE) mutations in the expression of PCT and to determine the contribution of acquired factors includ ing alcohol, hepatitis C virus (HCV), and estrogen. The 2 known HFE mutations, cysteine 282 tyrosine (Cys282Tyr) and histidine 63 asparagine (His63Asp), were detected by polymerase chain reaction, and anti-HCV immunoglobulin G was detected serologically."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.His63Asp"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other HFE genotypes are reported to occur at higher frequencies in patients with PCT as compared with controls, including compound heterozygous C282Y/H63D."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.His63Asp"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Other HFE genotypes are reported to occur at higher frequencies in patients with PCT as compared with controls, including compound heterozygous C282Y/H63D."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.His63Asp"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HFE"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepcidin, a peptide hormone produced by the liver that serves as a master regulator of iron homeostasis, is thought to be involved in PCT pathogenesis."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Ajioka et al found that hepatic expression of HAMP, the gene that encodes hepcidin, is significantly reduced in patients with PCT with out ESKD and that hepcidin would also be expected to be reduced."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HAMP"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "negative_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Smoking"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Low-dose hydroxychloroquine (100 mg orally twice weekly) is an alternative option for patients with PCT who do not have access to or cannot tolerate therapeutic phlebotomy, and who do not have marked iron overload. Chloroquine can be used as well, but hydroxychloroquine is preferred because of its superior safety pro file. These 4-aminoquinolines are taken up in hepatocyte lysosomes, which then release large amounts of accumu lated porphyrins."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "DB",
         "name": "4-aminoquinoline"
        }
       ]
      ]
     },
     {
      "relation": "decreases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "figure 4"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Tobacco Products"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40097071.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "Tobacco Use"
        }
       ]
      ]
     },
     {
      "relation": "association"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid [\u00c3\u017d\u00c2\u00b4-ALA]) in the body [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "HP",
         "name": "abnormal enzyme activity"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid [\u00c3\u017d\u00c2\u00b4-ALA]) in the body [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The mutations associated with AIP have been observed only in the HMBS gene, which encodes HMBS (PBGD)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "This mutation is a splicing mutation, which leads to a functional defect in HMBS (PBGD) and thereby induces AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "AIP is caused by a mutation in the HMBS gene (also known as PBGD) and is involved in the synthesis of porphyrinogen in the porphyrin bio synthesis pathway, with a prevalence rate of 50 cases per 1 million people [2\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u01534]"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid [\u00c3\u017d\u00c2\u00b4-ALA]) in the body [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphobilinogen"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid [\u00c3\u017d\u00c2\u00b4-ALA]) in the body [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "5-aminolevulinic acid"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid [\u00c3\u017d\u00c2\u00b4-ALA]) in the body [1]."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "porphyrins"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Intravenous hemin administration (4mg/kg once daily for 7 consecutive days) to inhibit \u00c3\u017d\u00c2\u00b4-ALA synthase (ALAS) activity and reduce porphyrin precursor accumulation; discontinuation of sodium valproate (which may exacerbate AIP) and replacement with levetiracetam (500mgtwicedaily) for seizure control; and maintenance of acid-base balance, correction of electrolyte disturbances, and a high-carbohydrate diet (daily intake \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a5 300g) to stabilize metabolism."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sodium valproate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The treatment strategy for our patient, including intravenous hemin administration, discontinuation of so dium valproate (a known AIP exacerbant), and initiation of a high-carbohydrate diet, is consistent with the recom mendations in the Chinese Expert Consensus on Diagnosis and Treatment of AIP."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "abundance"
        }
       },
       [
        {
         "namespace": "CHEBI",
         "name": "sodium valproate"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the renin\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153angiotensin system, increased blood pressure, water\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153sodium retention, metabolite accumulation, and damage to the blood\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153brain barrier."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Renin-Angiotensin System"
        }
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "41180247.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the renin\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153angiotensin system, increased blood pressure, water\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153sodium retention, metabolite accumulation, and damage to the blood\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u0153brain barrier."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Water-Electrolyte Balance"
        }
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PRES"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38456621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It has been speculated that the high incidence of AP- associated PLC found in Swedish studies might be related to the presence of the dominating HMBS founder gene variant (c.593G>A), found in approximately 2/3 of Swedish patients with AIP"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.R26H"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40495387.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "EPP arises due to pathogenic variants in ferrochelatase (FECH), the last step in haem biosynthesis, which incorpo rates iron into protoporphyrin to form haem."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "FECH"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.?"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "EPP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "PCT can be classified based on the presence or absence of UROD pathogenic variants and family his tory. Most cases (~80%) are sporadic (type 1), with no UROD pathogenic variants. A heterozygous UROD pathogenic variant is found in familial (type 2), which is an autosomal dominant condition with low penetrance, such that there is usually no family history of PCT."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.G281E"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "PCT"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "39644053.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Hepatoerythropoietic por phyria (HEP) is an ultra rare form of por phyria caused by homo zy gous path o genic UROD var i ants that usu ally pres ents in early child hood with blis ter ing skin lesions, ane mia, and hepato splenomegaly and resem bles con gen i tal eryth ro poi etic por"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROD"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "c.[404T>G];[404T>G]"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "positive_correlation"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "hepatoerythropoietic porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "33953217.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "One such example is congenital erythropoietic porphyria (CEP), most commonly caused by loss of function mutation in uroporphyrinogen III synthase (UROS; Fig.S1), the enzyme that catalyzes the third step of the heme biosyn thetic pathway"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "c.217T>C"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Congenital erythropoietic heme biosynthesis, porphyria (CEP) is a rare disorder of resulting from reduced activity enzyme uroporphyrinogen (III) cosynthetase."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "c.217T>C"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "2064845.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "It is autosomal recessive, and associated with reduced UROS activity (5% of normal) and consequent accumulation of uro/coproporphyrin-I (uro/copro-I) in bone marrow, erythrocytes, plasma, and increased uro/copro-I excretion in urine and stool"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "UROS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "c.217T>C"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "CEP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Acute porphyrias (AP) are characterized by heme deficiency and induction of hepatic 5-aminole vulinate synthase (ALAS1)."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "c.604C>T"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32487371.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and \u00c3\u017d\u00c2\u00b4-aminolevulinic acid (ALA)]"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "c.604C>T"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "40228600.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Thus, relative deficiency of heme, such as may occur in the hepatic porphy rias, in which there are defects in enzymes distal to ALA synthase-1, leads to marked up-regulation of ALA syn thase-1, whereas sufficiency of heme, which may be sup plied to hepatocytes from other cells or from the blood, such as when patients are treated with intravenous heme for acute porphyric attacks, leads to rapid down-regulation of ALA synthase-1"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "ALAS1"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "c.604C>T"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "AIP"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Detection of a mutation in the HMBS gene causing porphyria: c. 806C>G: p.T269R."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.Thr269Arg"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "Whole exon sequencing revealed a heterozygous missense mutation HMBS:NM_000190:exon12:c.806C>G (p.Thr269Arg) in the woman and her cousin."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.Thr269Arg"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "32844069.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "NM_000190.4(HMBS):c.806C>T (p.Thr269Ile)"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "HMBS"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "p.Thr269Ile"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "process",
         "name": "pathology"
        }
       },
       [
        {
         "namespace": "MESHD",
         "name": "Acute porphyria"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "A variant of the gene encoding PEPT2, PEPT2*2, reduces the transporter's affinity for ALA and has been associated with reduced severity and slower progression of PAKD, supporting the hypothesis of ALA in tubular injury."
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC15A2"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "hPEPT2*1|*2"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "kidney diseases"
        }
       ]
      ]
     }
    ]
   },
   {
    "sets": [
     {
      "citation": {
       "type": "PubMed",
       "title": "",
       "ref": "38819621.0",
       "pub_date": "",
       "author_list": "",
       "comment": ""
      }
     },
     {
      "set": {
       "DataSource": [
        "SHERPA-manual-curation"
       ]
      }
     },
     {
      "evidence": "nan"
     }
    ]
   },
   {
    "statement": [
     {
      "subject": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "HGNC",
         "name": "SLC15A3"
        },
        [
         [
          {
           "function": {
            "type": "modifier",
            "name": "variant"
           }
          },
          [
           {
            "hgvs": "rs12345"
           }
          ]
         ]
        ]
       ]
      ]
     },
     {
      "relation": "increases"
     },
     {
      "object": [
       {
        "function": {
         "type": "abundance",
         "name": "protein"
        }
       },
       [
        {
         "namespace": "MESH",
         "name": "kidney diseases"
        }
       ]
      ]
     }
    ]
   }
  ]
 }
]